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Many individuals with impaired vision experience a decrease3d quality of life. Quality of life is 
defined as “the degree to which an individual enjoys the important possibilities of their life.” Vision 
rehabilitation outcomes primarily focus on the functional impacts of interventions, with less attention 
being paid to any associated psychosocial impacts. This study examines the relationship between 
measures of visual function status and psychosocial status in individuals acquiring low vision 
assistive devices for the first time. One hundred and twenty subjects were evaluated after purchasing 
their first low vision device from a University-based low vision clinic. The measures used were the 
National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) and the Psychosocial Impact of 
Assistive Devices Scales (PIADS). The NEI-VFQ 25 measures the status of visual function, while 
PIADS is a device impact measure, which explores the psychosocial impact of devices on three 
domains: competence, adaptability, and self-esteem. This study determines the strength of 
association between these two measures at initial and follow-up administrations, and between each 
subsequent measure as a result of the time interval between administrations, in addition to assessing 
whether or not a change in stability for the measures occurred over time. Modest strengths of 
associations were anticipated and the short time interval was not expected to be a factor in change in 
stability of the measures. The expectation was that subjective reports of functional changes should 
have a moderate correlation with psychosocial impact. 
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1.1 Low Vision 
Low vision describes any condition of functional vision loss that cannot be corrected by spectacles, 
contact lenses, or medical interventions such as surgery
1-3
. The International Classification of 
Functioning, Disability and Health (ICF), a classification of health and health related domains that 
describe body functions and structures, is published by the World Health Organization, which 
provides a useful context for understanding health outcomes. According to ICF, disorders of the eye 
and other organs of the visual system result in impairments in “seeing functions”, which are sub 
classified as visual acuity function, visual field functions, and quality of vision functions
4
. Low 
vision may result from many different ocular and neurological disorders. Visual impairments affect 
about 10% of people aged 65-75, and 20% of those aged 75 or older
1
. Disorders of the visual system 
include any diseases, injuries, or abnormal development affecting the eyes or their neural 
connections. The ensuing visual impairments may interfere with an individual’s ability to perform 
work and their ability to participate in activities of daily living and leisure activities
1
. This deficit 
vision performance is described as a visual impairment 
5
. The prevalence of low vision in North 
America is increasing dramatically as the baby boomer population ages and becomes more 
vulnerable to sight-limiting conditions associated with aging. In Canada, the number people over the 
age of 65 are expected to increase from about 5 million people by 2021, increasing the number of 
visually impaired individuals
1
. The most common causes of blindness in North America are age-
related macular degeneration (AMD), glaucoma, and cataracts 
1, 2
.  Many individuals with impaired 
vision fail to obtain vision rehabilitation services because they are unaware of the potential benefits 




Vision loss is not dichotomous, but occurs as a continuum that ranges from modest low vision to 
total blindness 
1
.  While the functional consequences (disabilities) of vision loss are generally 
dependant on the severity of the impairment, this is not always the case 
7
. Assistive devices are 
available to provide functional solutions for these seeing problems.  
 
2 
There is a broad range of definitions for “quality of life” in the professional literature, making it a 
highly variable and unstable construct that is difficult to measure
14
. Quality of life has been defined 
as the ‘degree to which an individual enjoys the important possibilities of their life’ 
12, 13
.  It is 
assumed to be a complex and multidimensional construct. It is dynamic and changes over time and 
over a person’s life. It arises from a person’s interaction with their environment and is experienced 




The primary role of vision rehabilitation is to help people maximize functional independence, 
maintain quality of life, and adapt to the psychosocial aspects of their vision loss 
1, 2
. Low vision 
rehabilitation allows people with visual impairments to use their limited residual vision as optimally 
as possible, with the use of assistive devices and technologies, and to make adaptations to activities 
of daily living in order to maintain functionality and independence
1, 8
. The intention is to restore lost 
function and to limit or minimize any related disabilities 
5, 9
. The level of difficulty of any desired 
seeing task is determined by the individual’s functional reserve, which is the difference between the 
person’s seeing abilities and the seeing requirements of the seeing task 
9
. Successful low vision 
rehabilitation alters the impact of visual impairments on functional performance, thereby reducing 
the level of disability 
10
. Rehabilitation services are intended to achieve positive outcomes in one or 
more of the following domains: cognition, communication, functional independence, mobility, 
occupational performance, perception, physical function, psychological well being, quality of life, 
social skills and socialization 
11
. Vision rehabilitation can be very successful at reducing costs and 





Low vision rehabilitation is a very reliable and successful intervention for many young patients 
8
. 
However, the majority of people with low vision are elderly. It may be more difficult to counsel and 
rehabilitate older people because they may be more set in their ways.  Many older people become 
fixated on finding a cure for their vision problems, and defer seeking rehabilitation solutions.  There 
is a higher prevalence of depression in older people with age related vision loss 
16
. In these instances, 
rehabilitation must include counselor support that helps people accept and adapt to their vision loss. 
Successful low vision rehabilitation is often subjective and its success may be determined by 
whether the individual feels their assistive device has helped or not 
8
. Rehabilitation should be 
ongoing rather than short term since generally with the progression of a condition or disease, an 
3 
individual’s general health and mental status may tend to also deteriorate
8
. Repeated outcome 
administrations are necessary to help track such changes.  
 
Low vision rehabilitation can only be successful if it is accessible to low vision patients. The WHO 
estimates that there are 140 million people worldwide with low vision, with the leading cause being 
Cataracts followed by Age-Related Macular Degeneration, 35 million of which require services 
because their vision loss is untreatable 
17
. Some of the issues that individuals face when attempting to 
access services are: lack of awareness of services, transportation, ineffective communication between 





The rationale for obtaining low vision devices is to restore an individual’s capability to perform 
desired seeing tasks that are difficult or impossible due to the presence of a low vision condition. It is 
generally assumed that restoring an individual’s lost ability to perform seeing activities of 
importance, such as the ability to read or watch television, will translate into a verifiable 
improvement in the individual’s quality of life. Outcome measures have primarily focused on 
functional impacts of assistive technology 
18
. Research has focused less on the psychosocial impacts 
of these interventions. Assuming that the measures represent different aspects of quality of life, we 
predict that measures using both types will be moderately correlated. We further predict that the two 
measures are not redundant and will collectively provide broader insights than might otherwise be 
captured using a single outcomes administration tool. Such outcomes research is generally concerned 
with verifying that interventions are causally responsible for observed changes in targeted 
individuals or populations and developing an improved understanding of such causal relationships
19
. 
Two administration tools were used in an attempt to unravel a moderate strength of association. The 
administration tools were the PIADS (Psychosocial Impact of Assistive Devices Scale) and the NEI-
VFQ 25 (National Eye Institute Visual Function Questionnaire), which will described later in this 
review. NEI-VFQ 25 is a functional status measure in this study, whereas PIADS is measuring the 
change in impact.  
The study aimed to answer the following questions:  
1. How do each of the PIADS and NEI-VFQ 25 correlate with clinical measures (Visual acuity 
and contrast sensitivity)?  
4 
2. What are the strength of association between the PIADS measure at initial (post-adoption of 
device) and follow up administrations, and the NEI-VFQ 25 at initial (post-adoption of 
device) and follow up?  
3. What is the strength of association between the PIADS and NEI-VFQ 25 at initial 
administration, and then at follow up? In other words, how does a generic impact measure 
like the PIADS compare with a vision-specific measure in sensitivity to self-reported 
functional vision?   
4. Given the time interval (2 weeks) between initial and follow up administrations, do we 
expect the relationship to change over time or remain stable for the NEI-VFQ 25 and 
PIADS?  
 
The goal of this project was to develop a conceptual framework for relating PIADS (impact) and 
NEI-VFQ 25 (functional status). The aim was to attempt to relate a functional measurement to a 
subjective one. NEI-VFQ 25 provided a functional outcome while PIADS rendered a subjective 
experience. The following has been hypothesized:  
 
1. The NEI-VFQ 25 will exhibit a stronger correlation to clinical measures than the PIADS 
will. (i.e. correlating to VA and CS) 
2. A modest correlation will exist between the PIADS measure at initial and follow up 
administration and for the NEI-VFQ 25 as well.  
3. A modest correlation will exist between the NEI-VFQ 25 and PIADS measure at initial 
administration, and at follow up.  
 
Finally, as part of a secondary hypothesis, we expected that these relationships will not change over 
time but rather remain stable given the short interval in which the measures are being repeated.  
1.3 Outcomes Research 
Outcomes research deals with the questions about which services work best, under which particular 
conditions, and for which kinds of service recipients
22
. Evaluation of measures has become 
increasingly important as a tool to aid decision makers concerning allocating resources within health 
care 
21
. There is a growing interest in using outcome measures to demonstrate the effectiveness and 
quality of rehabilitation interventions
23
, to investigate the association between age and vision loss, 
and to establish the demand for low vision rehabilitative services 
24
. The effectiveness of low vision 
rehabilitation is determined by the usefulness of the services rendered to service consumers with 
impaired vision. When the service is effective at restoring functional capability and improving 
quality of life, then the outcome is positive. However, it is important to recognize that improvements 
in functional capability do not necessarily translate to an improved quality of life. Hence, outcomes 
investigations cannot be restricted exclusively to functional and clinical status administrations. They 
5 
also must contemplate factors such as consumer satisfaction, value, quality, or cost 
14
. It is difficult to 
identify all of the interventions that legitimately contribute to a positive rehabilitation outcome. Even 
if all of these critical components could be identified, one would still need to quantify them in some 
way and then establish how they are integrated. This would depend on suitable measurement 
protocols and each intervention presents its own measurement challenges 
25
. Nevertheless, using 
benchmarks and guidelines for predicting successful outcomes is usually the best method for 
assessing low vision outcomes. Measures of patient satisfaction, vision functioning in various 
activities of daily living,  impacts on individual’s well being, and levels of understanding about the 
causal eye condition are  some of the strategies that are used to quantify successful outcomes 
26
. 
Patient outcome criteria should also include improved understanding of emotional and psychological 
adjustments to vision loss, improved ability to complete independently activities of daily living, and 




The following eight criteria have been suggested 
27, 28
 for evaluating instruments that are used to 
assess patient based outcome measures:  
 
Appropriateness:  Investigators consider match of an instrument to the specific purpose and question 
of a trial.  
Reliability: Instrument is reproducible and internally consistent, degree to which a measure is free 
from random error. 
Validity: Judging whether an instrument measures what it purports to measure.  
Responsiveness: Addresses whether an instrument is sensitive to change of importance of patients.  
Precision: Concerned with number and accuracy of distinctions made by an instrument.  
Interpretability: How meaningful are the scores from the instrument.  
Acceptability: How acceptable an instrument is for respondents to complete.  
Feasibility: Extent of effort, burden and disruption to staff and clinical care arising from use of 
instrument.   
 
Assessing such psychometric factors such as reliability and internal scale consistency should be 




where N is the number of items and r-bar is the average inter-item correlation among the items 
should be used for assessing reliability of a subscale’s internal consistency, where the acceptable 
minimum value should be >0.70, the minimum >0.6, and a poor internal consistency would be alpha 
<0.6 
30
. Many of the times these factors are not reported on and the rationale for the use of outcomes 




Using a standard taxonomy of interventions and treatments is important to provide clarity and proper 
standardization of methods to serve as a basis for measuring interventions that are used in 
conjunction with outcomes 
25
. Taxonomy is a typology that brings order and rigor to the description 
of myriad rehabilitation interventions 
25
. The purpose of a rehabilitation intervention taxonomy is to 
characterize systematically the many treatments, procedures, and interventions that are used in 
rehabilitation, taking into account their multidimensionality with respect to content, purpose, 
intensity, duration, sequence, frequency, and other characteristics
25
. Taxonomies may help to 
standardize collection on treatment intervention that will elicit a comparison of results across studies 
and across sites, such that standardization on the input side will greatly strengthen ability to make 
comparisons across an even wider range of interventions and outcomes 
25
. Thus, the need for 
integrated systems is crucial in outcomes research. 
 
When describing outcomes research, authors should define their measurement constructs and 
domains to reflect a thorough understanding of how well their conceptual model is covered 
20
. 
Measures in outcomes research that include data from both general and impaired subgroups are 
useful for comparison reasons. This ensures that there are benchmark standards to facilitate 
interpretations of scale normality, specificity, and deviance.  Researchers should only use measures 
that are known to produce data with acceptable reliability and validity. These measures should have 
evidence of content, criterion, and/or construct validity 
31
. Measures should at least satisfy the 
minimum standards and provide information on the above items. Deciding on the measures to use is 
one of the problematic aspects in planning an outcomes study of most assistive technologies 
22
. 
Without standardization of measures, clinical programming would be unorganized, unclear 
28
 and 
future researchers would find difficulty in tracking back records and reproducing results.  
 
Some surveys used in outcomes research may be insensitive to differences between people 
20
 due to 
either a floor or ceiling effect. The data may be skewed by grouping individuals at the minimum or 
maximum extremes. Floor or ceiling effects are present when 15% or more of a group of scores are 
7 
present at either extreme 
20
. Health-related quality of life measures should not be affected by such 
factors as culture, social circumstance, or impairment type, unless the instrument is designed to 
detect differences in such measures. The measures utilized in this study, which will be described 
later, are unaffected by these domains. The sample population includes a variety of cultures, socio-
economic backgrounds and visual impairments which may present a bias if the measures were 
sensitive to such factors. It is interesting to note that one study actually found that such factors 
influence one of the measures used in this study
32
.  Bias is systematic variation resulting in high or 
low results, and both random unreliability and systematic biases need to be investigated during the 
development of measures and considered when being applied 
28
. When selecting outcome measures, 
investigators should understand the general purpose of measures, the population that is being 
evaluated, the likely consequences of the administration, and any procedures that are required to 




Outcome measures are used in clinical settings when the benefits to the client outweigh the cost of 
using the measure 
33
. They may assist clinicians in determining client goals for rehabilitation which 
allows them to map out a more appropriate individual rehabilitation program than might otherwise 
be possible 
33
. Also, knowing the goals also assists the clinician and client to select an appropriate 
device, including making the decision about whether to progress to a more sophisticated device 
33
. 
Moreover, it is important to have some sort of mechanism for evaluating the success of such 
interventions at the conclusion of the service contact.
33
. Clinicians must be aware of how to evaluate 
meaningful changes in quality of life, which may be accomplished by considering the characteristics 
of the population, psychometric properties of the quality of life questionnaire, the adequacy of 
administrations, power, and so forth 
34
. This will ensure an effective strategy in obtaining the most 
clinically relevant and useful information. Many clinicians use evidence-based information to 




The order in which instruments are administered may have an effect on the quality of responses 
obtained. However one study looking at the effect of order of administration of health related quality 
of life interview instruments on responses found that the overall order did not have a large effect on 
the responses
36
. Nonetheless, the order should be kept the same for all respondents to avoid 
introducing a bias in response into the study. The study looked at two generic health-related 
instruments and one vision targeted instrument. It was assumed that administering the generic 
instrument followed by the vision targeted instrument was logical and appropriate. Others have 
8 
reported that respondents scored lower on mental health subscales when they are asked after 
responding to questions about their vision loss 
36
. Consequently, the order of surveys should be 
determined by the goals of the study and should remain consistent for the duration of the study.  
 
An uncommon method used in the administration of quality of life has been co-morbidity scores. Co-
morbidity is total burden of illness unrelated to a patient’s principal diagnosis and has been shown to 
be important in assessing severity of disease and the risk of mortality
37
. Un-weighted and weighted 
co-morbidity indexes were created for assessing co-morbidity and visual function of the LALES 
(Los Angeles Latino Eye Study), in order to model the low physical function with self-reported 
systemic co-morbidities, and illustrate the usefulness of these scores in the analysis of quality of life 




Babcock et al looked at two rehabilitation outcomes measures to examine their compatibility. FAST 
(Functional Assessment of Self-Reliance Tasks) is a clinical rating instrument and VA-13 is a self 
reporting instrument
38
. The VA-13 purports to measure functional independence while FAST 
measures functional ability 
38
. FAST serves as a clinical screen, providing clinicians with the 
administration information required to develop both treatment and discharge plans. The study 
hypothesized that respondent’s ratings should not be completely unrelated or different, and any 
inconsistencies would be explained by differences in the measurements 
38
.  Although both scales 
functioned consistently, they were found to be incompatible.  
 
Another study utilized the NEI-VFQ 25 and the SF-12. This latter instrument is a generic quality of 
life measure derived from the SF-36, contains one or more questions to measure each of the eight 
health concepts on the original SF-36 measures: physical functioning, role limitations due to physical 
health, bodily pain, general health perceptions, vitality, social functioning, role, role limitations due 
to emotional problems and mental health 
39
. The study showed that patients with worse vision had 
more difficulties in performing most vision dependent daily activities and had worse subscale scores 
than patients with less severe vision loss or those without eye diseases
39
. The SF-12/36 measure 





Other measures have been developed to specifically look at self-reports of visual function. The 
Functional Assessment Questionnaire (FAQ) was developed as a self-report of visual function and 
9 
overall well being, and the Functional Vision Performance Test (FVPT) was designed as an observer 
rated administration of visual performance 
41
. FAQ evaluated specific visual function and functional 
independence as perceived by patients, while the FVPT allocates an observer to measure an 
individual’s visual performance in standardized tasks 
41
. The study demonstrated that the 
involvement of various services in vision rehabilitation would maximize the participant’s level of 
function. An overview of low vision rehabilitation notes that several factors play a role in a 
successful rehabilitation service, such as low vision team, rehabilitative approach, rehabilitation, 
activities of daily living, travel and social or recreational activities 
42
. Other studies have also shown 
the importance of proactively utilizing all vision rehabilitation services in an attempt to maximize an 
individual’s experience at providing the best ways in which to increase function.  
 
One final study looked at the Low Vision Quality of Life Questionnaire (LVQOL) and demonstrated 
it to be a reliable and valid method for assessing vision specific quality of life 
43
. It was deemed 
acceptable for use in a clinical setting and for effectively determining the impact of low vision 
rehabilitation. A distinguishable feature of this questionnaire is that it is specifically designed for low 
vision, which may be more suitable in assessing outcomes of low vision rehabilitation than other 
measures. It was also shown to be related to functional measures of vision, such as distance acuity 
and contrast sensitivity 
43
. While the NEI-VFQ 25, which will be discussed next, is successful at 
detecting such changes, it may be interesting to compare it to the LVQOL in future research to 
determine which measure is more attune to low vision outcomes.  
1.4 NEI-VFQ (National Eye Institute Visual Function Questionnaire) 
The NEI-VFQ 25 was created by RAND with funding support from the National Eye Institute (NEI)  
in order to develop a domain that would allow individuals to report on their professed visual health
44-
47
. The NEI-VFQ 25 measures quality of life based on visual disability and how the disability affects 
well being and emotional responses. It is a measure of vision targeted health-related quality of life 
and generates a single overall visual function score that reports an individual’s perception of their 
visual functioning
30, 48
. The NEI-VFQ 25 consist of  twenty-five items, which generates the 
following twelve visual subscales: overall health, overall vision, difficulty with near vision and 
distance activities, ocular pain, driving difficulties, limitations and peripheral vision and color vision; 
social functioning, role limitations, dependency and mental health symptoms related to vision
44, 45, 46, 
47, 49, 50
. Eleven subscales constitute independent function specific measures of visual functioning, 
related specific aspects of visual function 
30
. The twelfth subscale is a single general health rating 
10 
scale, which is shown to be a very robust predictor of future health and mortality in population based 
studies
44, 48
.  The NEI-VFQ-25 is a short form version of the 51-item National Eye Institute Visual 
Function Questionnaire (NEI-VFQ), a vision specific HRQOL instrument derived from a multi-
condition focus group process 
49, 51
, which has been shown to retain much of the original content of 
the longer questionnaire 
44
. The reliability and validity of the NEI-VFQ-25 has been compared to the 
NEI-VFQ-51, and has been shown to maintain the same multi-dimensional content, reliability, and 
validity of the full length survey 
44, 49, 51
. The shorter version was created in response to a need that 
would be appropriate for research and clinical settings. Studies are ongoing to assess the reliability 
and validity of the 25-item scale in comparison to both the 51-item and previous 96-item 
questionnaire 
44
.The NEI-VFQ-25 contains twelve subscales and requires approximately ten minutes 
to complete an interview-administered format. Topics covered include difficulties reading a 
newspaper, performing activities up close, or feeling like he/she accomplishes less than he/she would 
like to because of the vision loss. The NEI-VFQ 25 has been shown to be sensitive to any low vision 
cause, and thus is a clinically valid measure 
44, 46, 50
. The measure also exhibits internal consistency 
and reliability which has been assessed using Cronbach’s alpha 
30, 52
. Item internal consistency and 
item discriminate validity could not be calculated for Peripheral Vision, Color Vision, General 
Vision, and General Health because these subscales have only one item 
30
, but overall evidence for 
validity has been examined 
44
. The 25 item questionnaire was chosen in recognition that survey 
length plays an important role in data quality and costs.  The NEI-VFQ 25 has been used in 
numerous studies, and is proven to be a valid and reliable questionnaire for participants with various 
eye conditions, and is appropriate for a broad range of individuals




The NEI-VFQ 25 has been deemed acceptable for use in other languages
30, 60, 66, 70, 75
, such 
as French, Spanish, Italian, Japanese, and Turkish. Moreover, the NEI-VFQ 25 is a responsive and 
evaluative measure that is able to detect meaningful changes in populations over time and across any 
eye condition, changes in visual acuity, in addition to changes associated with low vision 
rehabilitation services
44, 46, 47, 50, 72, 75
. NEI-VFQ 25 is a useful tool in assessing whether or not 
improved functional performance occurs as a result of an intervention in a study, as may be noted in 
the studies acknowledged previously.  
 
In previous studies, the NEI-VFQ 25 was administered pre and post intervention when horizontal 
rectus tenotomy was performed on patients with congenital nystagmus
48
. The following study 
demonstrates how NEI-VFQ 25 can be used to monitor impact of intervention on a low vision 
population. The following data were reported:  
11 






This illustrates that following an intervention, if the improvement is favorable, then the NEI-VFQ 25 
is sensitive to the difference in change and is able to pick this up. The NEI-VFQ 25 also has been 
shown to be sensitive to changes in functional status and quality of life related to the provision of 
low vision services 
76




The NEI-VFQ 25 also has been used to assess depression in older adults with visual impairments 
62
. 
Any individual who experiences an impairment resulting in a disability is likely to experience some 
level of depression. Scores were reported to be lower for depressed individuals than for those who 
were not, indicating that those who reported lower scores seemed to have more depressive symptoms 
than those who scores higher 
62
. Depression was associated with the specific NEI-VFQ 25 subscales 
that are more psychosocially oriented such as role difficulties, mental health, and dependency 
62
. 
Based on studies reported in the literature, the NEI-VFQ 25 appears to be a valid and reliable tool for 
assessing health related quality of life. 
12 
1.5 PIADS (Psychosocial Impact of Assistive Devices Scale) 
Quality of life is a subjective concept and should be based on a user’s perception of his/her own well 
being, whether or not they have full or partial functional capability. The Psychosocial Impact of 
Assistive Devices Scale (PIADS) emerged through the development of several quality of life scales. 
The PIADS evolved from empirical explorations with a pleasure-arousal dominance scale, users’ 
responses concerning how they expected devices to impact their quality of life, and the literature on 
personality research (which suggested the inclusion of constructs associated with perceived self-
efficacy and personal control) 
15, 77
. Day and Jutai developed PIADS as a measure that was 
specifically designed to assess the psychosocial impact of assistive technology, and assess the effects 
of a device on functional independence, well being, and quality of life
77, 78
. The goal was to create a 
scale that would reliably measure perceived device impact and discriminate among device categories 
and user conditions in a clinically sensible way 
15
. The term ‘psychosocial’ refers to both factors 
within the person and factors attributable to the environment that affect the psychological adjustment 
of individuals who have a disability 
77
. It is assumed that assistive technology should have some 




PIADS is a more sensitive of a scale than other measures, and is responsive to detecting clinically 
important change over time, sensitive to important variables such as the user’s clinical condition, 
device stigma, and functional feature of the device
12, 13, 15, 77, 79
. The instrument has good internal 
consistency, test-retest reliability, and construct validity 
77
. PIADS was developed due to a need for a 
measure that would properly assess impact of an assistive device, since much health related quality 
of life measures were too medically oriented and focused more on the change in health status, rather 
than the impact attributable to any particular form of intervention. The scale is based on 26 items, 
measuring a user’s perceptions on three different sub-scales: Competence, Adaptability, and Self-
esteem. Competence (12 items) refers to an individual’s perceived functional capability, 
independence, and performance
3, 15, 77, 79-81
. Example determinants within the Competence subscale 
would be adequacy, efficiency, and skillfulness. Adaptability (6 items) refers to inclination or 
motivation to participate socially and take risks
3, 15, 77, 79-81
. Example determinants within this subscale 
would be ability to participate, willingness to take chances, and ability to take advantage of 
opportunities. Finally, self-esteem (8 items) reflects on self confidence, self-esteem and emotional 
well being
3, 15, 77, 79-81
. Example determinants within this subscale would be sense of power, 
happiness, and frustration. An individual can score themselves within a range of -3 to +3. A score of 
+1 to +3 indicates a positive impact; a score of -1 to -3 indicates a negative impact, while a score of 
13 
0 indicates no perceived impact or simply neutrality. PIADS has been used in several studies that 
investigate quality of life for various assistive devices, without being specifically limited to vision 
loss
3, 12, 22, 77-86
, and has been proven as a reliable, sensible, valid, and responsive tool, with good 
clinical utility for testing psychosocial impact of assistive technology
3, 15, 22, 81, 84
. The PIADS scale 
has been proven to be internally consistent using Cronbach’s alpha, that items are homogenous but 
not redundant, and demonstrate excellent psychometric properties
22, 79, 81





The PIADS was used to investigate changes in quality of life following small fenestra stapedotomy, 
a surgical procedure to improve severe conductive hearing loss. Overall, patients experienced a 
positive impact following device intervention. The results of this study compared favorably with 
other studies in which PIADS was used to validate the use of contact lenses and eyeglasses 
80
. The 
study suggested the possibility that impact of the assistive device may in fact diminish with time 
82
. 
This is generally the case for any assistive device, and not just specific to hearing devices, that the 
effectiveness is not as dramatic as when the device is first adopted. It was also found that the 
psychosocial impact on users was stable over time in a study with electronic aids for daily living, and 
it was suggested that the reported impacts may be a blend of perceptions relating to the device and 
services rendered with it
84
. Conversely, an article on psychosocial impact of assistive technology 
devices in stroke rehabilitation illustrated a change in impact over time, rather than at first
83
, 
suggesting in fact the possibility that depending on device and condition, impact and perceived 
effectiveness may not be apparent until captured with a repeated measure.  This was also consistent 
with a study on hearing aids, implying that users are more likely to experience the expected benefit 




The research and development of the PIADS has proceeded in the best tradition of rehabilitation 
outcome measures, by first developing a measure that was sensitive and responsive to clinically 
important variations. The ability of the scale to predict abandonment and retention of assistive 
devices has prompted for further research in this field 
15
. PIADS provides clinicians with a reliable 
and economical method for assessing the role of psychosocial factors in retention or abandonment of 
an assistive device 
82
. It also may provide researchers with information that will help create better 
technologies and improved matches with the needs of users. It also may help predict how new 
assistive technologies and prototype devices will be accepted or abandoned by their users and used 
effectively in both short and long terms 
11, 12
. PIADS is not a measure of quality of life, but a measure 
14 
of the impact of an assistive device on quality of life, and is able to predict continuation or 
discontinuation of a device based on impact 
85
. It is a reliable measure that provides best results when 
used in conjunction with another measure 
12
, such as the NEI-VFQ 25.  
1.6 Assistive Technology Devices (ATD’s) 
An assistive device is any item, piece of equipment, or product system that is used to increase, 
maintain, or improve the functional capabilities of individuals with disabilities 
85
. It is any device 
that would help an individual accomplish a task that they otherwise would not be able to. Assistive 
devices (ATD’s) are considered essential for the health and well being of many people with sensory 
or physical disabilities 
81
. They are among the most widely prescribed and recommended therapies 
for these individuals and they constitute a significant proportion of health and rehabilitation costs 
15
. 
In reference to the significant cost and benefits associated, assistive technology research is now 
gaining more attention 
87
. The demand for assistive devices is significant and is expected to continue 
to grow 
14
.  Vision devices range from basic eyeglasses, magnifiers, binoculars, and telescopes to 
sophisticated electro optical devices such as closed circuit television (CCTV) systems. The purpose 
of an assistive device is to improve function and quality of life 
13, 19, 82
. Jutai defines the role of an 
assistive device as one that will promote good quality of life for the user to the extent to which it 
makes the user feel competent, confident and inclined (or motivated) to exploit life’s possibilities 
12, 
15, 78, 82
. Reported problems adapting or using assistive devices are generally attributed to a high 
degree of dissatisfaction with assistive devices
81, 82
. The increased involvement of clients in the 
rehabilitation process increases the likelihood of a good outcome 
33
. A significant proportion of low 
vision devices are abandoned within four months of adoption 
2
. These cases may indicate a failure to 
fit the device to the individual with some expectation that the individual will eventually adapt to the 
device 
15
. When the opinion of the individual is incorporated into the selection of a device, the 
likelihood that they will abandon that device is decreased 
81
. Some major problems reported with 
assistive devices are inadequate performance, failure to achieve improved function, difficulty in 
operating device, and the high cost and maintenance of the device 
12, 82, 85
. Overall, success is 





Assistive technology outcomes research is a systemic study of the impact of assistive technology 
devices on the lives of users
19
. Assistive technology outcomes encompass a variety of factors: 
facilitation of activities of daily living, changes in functional independence, user satisfaction, societal 
15 
and individual gains, and effect on participation, employment, and societal roles 
87
. Psychosocial 
factors, such as attitudes, perceptions, and behaviors, appear to play critical roles in determination of 
assistive technology device outcomes 
85
. Psychosocial impact describes the extent to which assistive 
devices affect the individual’s subjective perceptions of psychological well being and quality of life 
85
. It is important to use standardized instruments to properly evaluate those outcomes. This requires 
the use of instruments that will produce data of quality, and with verified reliability, validity, and 
responsiveness. Both the PIADS and NEI-VFQ 25 meet these standards.  
 
The use of PIADS reflects an assumption that the adoption of a device will lead to an improved 
quality of life, which may include improvement in health, happiness and advancement of society 
81
.  
Assistive technology may have an impact on psychosocial status that is somewhat independent from 
the impact on vision function. It is useful in determining whether or not this is indeed the case, and if 




Quality of life and its component feelings of competence, self efficacy, self confidence, self esteem 
are all considered to be important goals of rehabilitation. One would expect that the likelihood of 
assistive device abandonment would increase if the device failed to enhance these feelings 
89
. 
Accordingly, outcomes research provides a useful mechanism for identifying different ways to 




Some health related quality of life measures appear to be too medically oriented to focus properly on 
the importance of assistive technologies, which is not to promote good health and healing, but to 
restore functional capabilities 
13
. In these instances, the goal is to assess the impact of the device or 
intervention rather than just a change in health status. The PIADS is expressly designed to assess the 
perceived impact of an assistive device on psychosocial wellbeing, with its three subscales, 
Competence, Adaptability, and Self-esteem.  
1.7 PIADS and NEI-VFQ 25: A comparison 
The PIADS and the NEI-VFQ 25 are two measures that can be used to evaluate the impact of using 
an assistive device on an individual’s quality of life. In this study, the NEI-VFQ 25 will look at 
functional status, and PIADS will explore the impact. Quality of life is defined in the NEI-VFQ 25 
based on an individual’s functional capabilities whereas in the PIADS it is related to the perceived 
impact of an assistive device, and thus the PIADS is better equipped to measure the psychosocial 
16 
impact of an assistive device. NEI-VFQ 25 is specifically geared to visual loss, whereas the PIADS 
may be used for any device. Research has shown that PIADS is sensitive to the use of an assistive 
device across various populations and that the impact is unaffected by illness and disability 
103, 54, 90, 
55
. NEI-VFQ 25 scores are generally higher for individuals with less visual disability than for 
individuals with greater levels of vision loss 
44, 46, 50
. Both measures are sensitive in their own 
manner, but PIADS will likely be shown to be more sensitive. In general, quality of life should be 
consistent no matter how it is measured. However, it seems likely that it cannot be measured 
accurately with a single test instrument. It will be significant to examine whether or not the measures 
in question exhibit a modest correlation since they are both assessing different aspects quality of life.  
It is expected that these measures will be correlated, and some aspects of PIADS and NEI-VFQ 25 
will be more correlated that others. Even though they do measure different aspects of quality of life, 
one can still say that they should be related.  
 
It is important to establish a conceptual framework that explains how assistive technology impacts 
on quality of life and how it relates to the measures being considered. A framework also can provide 
a template for other models. It provides a useful perspective for all stakeholders (consumers, funders, 
and service providers) 
90
. Models also help us understand the functional problems upon which the 
device type is intended to impact, critical features of the device type that are putatively responsible 
for those impacts, characteristics of individuals that are affected by the model, elements and 
contingencies in the causal chain connecting procurement of the device type with likely outcomes, 




The International Classification of Functioning, Disability and Health (ICF) described two 
conceptual models for disability: 
- A medical model views disability as a feature of the person that is directly caused by the 
disease or health condition, and  




Both models can be incorporated to provide completion, since neither one seems adequate on its 




Figure 1-1 ICF Disability Model 
91 
Health condition influences several domains, body functions and structure, activity, participation, which are all 
intertwined and affected by environmental and personal factors.  
 
Disability and functioning are portrayed as outcomes of the interactions between health conditions 
and contextual factors, and functioning is identified at the level of the body, the whole person, or the 
whole person in a social context 
91
. This framework can be used to encourage research that promotes 
a common understanding among those with an interest on various perspectives in considering 
assistive technology device outcomes 
90
. CATOR assigned priority to outcomes in five areas: 
effectiveness, social significance, device satisfaction, psychological functioning, and subjective well 
being 
19
. The user’s perspective must be accounted for and the framework should facilitate 
administrations of the effect of assistive technology devices on users. Below is a conceptual 
framework that is proposed for the current study.   
18 
 
Figure 1-2 Proposed Conceptual Model Linking Vision Impairment, Device Demand, and 
Quality of life 
A change in eye condition leads to visual impairment, causing a disability, initiating a demand for services (i.e. 
Assistive Device Adoption), which will aid in restoring some functional capability, leading to a verifiable 
improvement in quality of life.  
 
The above model suggests that a change in eye condition, as measured by clinical measures, will 
likely lead to a visual impairment, thus eliciting a demand for change in function. In turn, a demand 
for change in function should therefore bring forth the adoption of a device to aid in restoring 
function, thus translating into a verifiable improvement in quality of life, which should then translate 
into a perceived increased in psychosocial impact. The purpose of the model is to show that although 
one may not necessarily be able to restore lost visual function, but by adopting a device, quality of 
life can be improve through restoring some functional status.  
19 
1.8 Research Gaps 
There are some obvious gaps in the research literature. No large scale randomized control trial needs 
have been conducted to describe quality of life in all of its significant constructs: visual function, 
clinical measures, physical function, psychosocial function, and so forth. As well, more and better 
research is needed to look at the perspective of the patient and to evaluate the most effective tools to 
meet their rehabilitation demands. Further outcomes research is warranted as the visually impaired 
aging population is constantly increasing.  
1.9 Significance of Study 
Although it may be desirable to find a single instrument for measuring quality of life changes 
associated with low vision rehabilitation, the quality of life concept is much too complicated for this 
to be viable.  This study investigated how a vision-specific measure compares with a more generic 
measure of quality of life.  On the surface, vision-specific measures would seem to enjoy a validity 
advantage. Measures like the NEI-VFQ 25 appear to address the issues most relevant to successful 
use of low vision aids such as closed-circuit television systems (CCTV).  However, the effectiveness 
of these devices at restoring lost functional capabilities may be poorly correlated with how well they 
improve psychosocial well-being.  For example, an individual with more severe vision loss may 
derive significant functional benefit from a CCTV system that allows him/her to read independently, 
but the presumed impact on quality of life may be offset by less frequent visits by friends or relatives 
who used to drop by to read to.  No single measure can successfully engage all of the issues inherent 







One hundred and twenty adult subjects (≥18yrs) were recruited after obtaining their first ever 
prescribed low vision device through the Low Vision Clinic at the University of Waterloo, School of 
Optometry. This recruitment is related to a parent research project being funded by the Canadian 
Institutes of Health Research (CIHR). Recruitment was conducted sequentially from consecutive 
appointments at the Low Vision Clinic and therefore was not selected randomly. First, their 
eligibility for the study was determined. The inclusion criteria required them to be over the age of 18, 
a new patient to the clinic, and someone who had little or no experience with low vision aids. All 
other patients were considered ineligible. The age criterion was selected to ensure subjects were 
competent and able to give personal consent with respect to the significant time commitment 
required to participate in the host CIHR study. This group was selected order to track changes that 
occur following the first adoption of a device.    
2.2 Procedures 
Prospective subjects were approached on the day of their low vision administration. They were given 
a large print information letter that described the study being conducted, as well to receiving the 
information verbally. They were invited to ask questions to obtain any additional information they 
required. If they agreed to participate, they were asked to sign a consent form confirming their 
agreement. For those patients who refused to take part, their reasons were noted and recorded in a 
database.  
 
After a person completed their low vision clinical administration, their file was reviewed and data 
collected from forms that were completed during the administration. These data include eye 
condition, living support, visual acuities (distance VA’s, Pelli-Robson Contrast Sensitivity tests), 
primary and secondary chief complaints, diagnosis, and any other limitations.   
 
Subjects were contacted approximately two weeks after their low vision appointment. The initial 
administration was conducted after verifying that subjects had received their low vision device and 
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had commenced using it. If they had not yet received their low vision devices, a subsequent contact 
time was arranged to ensure they were utilizing their new device before taking part in the first 
administration. Those who decided not to obtain a device were excluded from the study. Data 
collection was administered by telephone interview for both the PIADS and the NEI-VFQ 25. For 
the NEI-VFQ 25, standard instructions were followed and respondents were asked to answer all 
questions, taking into account their use of the assistive device. It has been shown that there is no 
statistically significant difference in results obtained from face to face and telephone interviews
89
. 
Subjects were contacted for follow-up administration two weeks after their initial administration. 
The parent CIHR study continued with the follow up administrations at bi-weekly intervals for six 
months, followed by monthly interviews over the next six months.  
 
The primary administration instruments were PIADS and NEI-VFQ 25. These data were recorded on 
data report sheets and then transferred into an SPSS database for analysis.  
2.3 Instruments 
The measures used were the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) 
and the Psychosocial Impact of Assistive Devices Scales (PIADS). Table 2 provides examples of 
items that are included in the 26-item PIADS measure. A copy of a complete PIADS questionnaire is 
included in Appendix A:   






-3 -2 -1 0 1 2 3 
Embarrassment        
Self-Confidence        
Ability to Adapt to Activities of 
Daily Living 
       
  
 
Participants were asked to score the impact that their device has had on each item; for example if 
using the device has increased, decreased, or made no change in their competence. The scoring of 
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three of the PIADS items are reversed (confusion, frustration and embarrassment). The score for 
each subscale is not the total score for that subscale. Instead, the subscale score is based on the mean 
for all the items on that subscale. This ensures that each subscale will always have a score between -
3 and +3, thereby facilitating interpretation and comparison. 
 
 The NEI-VFQ 25 was scored according to the scoring algorithm 
45
. Please see Appendix B for the 
complete questionnaire of the NEI-VFQ 25. NEI-VFQ-25 subscales are scored on a scale from 0 to 
100, with 100 indicating the highest level of function. As specified by Mangione et al, the VFQ-25 
composite score is calculated as the un-weighted average of all items excluding the general health 
subscale 
45
. All items are scored so that a high score represents better functioning. Item responses 
were adjusted for directionality (high values reflect participants with good vision or health) and were 
transformed to a scale of 0 to 100. Adjusted items belonging to a scale were averaged together to 
create a single scale score 
67
. The overall (composite) score is the mean of all responses to all 11 
domains (excluding general health) and represents a global estimate of a patient’s visual function 
48
.  
For those individuals who do not drive it was coded as missing and they did not have the driving 
subscale included in their composite score. Participants were excluded from the analysis if they had 
stopped doing the activity for reasons other than poor eyesight. 
 
The overall composite score of the NEI-VFQ was tabulated, in addition to an overall PIADS score of 
the three subscales. The composite score is best used in situations where an overall measure of vision 
targeted health-related quality of life is desired 
48
. The NEI-VFQ-25 composite (overall) score is 
calculated as the un-weighted average of all items, excluding the general health subscale. The two 
measures were not directly comparable, since the PIADS questionnaire contains 26 items, grouped 
into three-subscales, and the NEI-VFQ contains 25 items, grouped into 12 subscales.  
2.4 Data Analysis 
Data analysis was performed using SPSS version 13.00. The sample size population was chosen at 
120 subjects, and α (alpha) was set to 0.05. ß will equal 1-power. With 80% power, ß will equal 0.2. 
Failure to reject the null hypothesis will yield a type I error where the probability of error is likely in 
5% of all studies. The Null Hypothesis in this case is that the means of the data sets will be equal and 
no significant correlation would exist. The alternative hypothesis would state that they are not equal 
and that a difference does exist, thus a significant correlation is present. In a paired t-test, if the 95% 
confidence interval does not include the null hypothesis, then we can safely reject. If p < α then we 
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would have sufficient evidence to reject the null hypothesis. If p> α then we would fail to reject the 
null hypothesis. The degrees of freedom would be 119 (# of pairs-1). We made the assumption that a 
normal distribution existed for the population. The assumption was also made that the populations 
have the same variance and the samples will be independent of one another. Each subject was 
assessed individually and unaware of the answers of other subjects. The above applied to both the 
PIADS and NEI-VFQ 25.  
 
Clinical data were collected for analysis. Distance visual acuity was recorded, because it is a 
common reference for visual function 
92
. It is tested by clinicians by using standardized wall charts 
with black letters on a white background under high light levels. The visual acuity measure was 
converted from a decimal acuity to its log MAR equivalent. (Log minimum angle of resolution)  VA 
= 1/MAR and Log MAR= log (1/VA). Contrast sensitivity was recorded from Pelli Robson data in 
clinic records.  
 
Descriptive data for the PIADS and NEI-VFQ 25 at initial and follow up administrations are 
presented as medians, floor and ceiling effects, and means ± standard deviation. Floor or ceiling 
effects are identified when 15% or more of scores occur at either extreme. Graphical representations 
of these distributions are presented.  
2.4.1 Psychometric Properties of the Instruments 
Psychometric properties of the PIADS and the NEI-VFQ 25 have been verified and validated in the 
literature. The psychometrics were examined for the sample population of this study. Internal 
consistency of both measures was calculated using Cronbach’s alpha 
29
. Both measures at both time 
instances had a Cronbach’s alpha > 0.70, except the NEI-VFQ 25 at initial administration whose 
alpha value was 0.695, which is still deemed to be acceptable. Test-retest reliability analysis was 
done by calculating the inter item correlation coefficient (ICC). Responsiveness was tested by 
determining the effect size and conducting t-tests to see if there was a change between the two 
instances. When the sample size is reasonable and the t-value is greater than 1.96, the null hypothesis 
is rejected and one can conclude that a statistically significant change in the measure occurred over 
time, making the measure responsive 
93
. A significant change in score would be evidence of 
responsiveness, where effect size (ES) was calculated as the mean change in scores between first and 
second administration, divided by the standard deviation of the scale at the first administration 
46
. A 
large effect size indicates greater likelihood that the instrument as a whole or the various subscales 
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will detect progression; an effect size of 0.2 to 0.49 represents a small change, 0.5 to 0.79 a medium 
change, and an effect size > 0.8 indicates that the scale on average changed by 0.8 SDs, suggesting 
that the scale or domain is responsive
46.  
 
Please refer to Appendices C and F for ICC matrix, reliability and effect size calculations.  
 
Looking at the literature for the NEI-VFQ 25, an 80% power is attained when α= 0.05 and is two-
tailed.  ß will be equal to 0.2, which would mean that a type II error would occur in 20% of the 
studies. A two-tailed is a test that will be interpreted if the criterion for significance (alpha) falls in 
either direction.  The following table provides us with an estimate of the sample sizes needed: 
 






It is interesting to note the “number of points difference” in Table 3, which is taken from the NEI-
VFQ 25 scoring manual
45
. This refers to the anticipated differences in scores between groups. There 
is a relative difference between sample sizes need for 5 points difference and 10. In agreement with 
the sample size chosen, we will approximate number of points difference to be 10. This method is 
25 





A MANOVA (multivariate analysis of variance) test was conducted to assess whether or not the 
PIADS and NEI-VFQ 25 subscales were influenced by the type of device participants had adopted.  
 
The NEI-VFQ 25 data collected was also compared to a reference group of subjects who were eye 
disease-free. This reference group was obtained from prior published NEI-VFQ 25 data (NEI-VFQ 
25 scoring algorithm). Participants in this reference group had no evidence of underlying eye disease 
except for corrected refractive error to at least 20/25 
44, 49, 50
. T-tests conducted allowed for a 
comparison of means.  
 
A Pearson Product Moment Correlation result was used to examine the association between the 
clinical measurements (visual acuity and contrast sensitivity) to the measures administered (PIADS 
and NEI-VFQ 25), and scatter plots were constructed for visual representation. The Pearson Product 
Moment Correlation test was chosen because data appeared to be normally distributed.  To examine 
the relationship between the same measures at the different time points, a Spearman Rank 
Correlation was used to test whether a linear relationship existed. The correlations between measures 
were summarized by the Spearman correlation coefficient, because many of the measures were 
highly skewed and/or ordinal. For the secondary hypothesis, using the paired t-test, a comparison of 
means was used to determine if the relationship changed or remained stable over the short interval 
stated.  
 
The sample population of 120 was filtered to consider only the participants with Age Related 
Macular Degeneration (ARMD), and where applicable, the above analyses were repeated. This was 
done in an attempt to eliminate the variable of eye condition by limiting the sample to only subjects 
with ARMD, with the possibility that eye condition may have some influence on test scores. The 
mean scores of PIADS and NEI-VFQ 25 for this ARMD subpopulation fell within the 95% 
confidence interval of the mean scores for the overall sample population, which indicates that eye 




3.1 Overall Sample Population 
3.1.1 Demographics 
Subjects were 66% female with a mean age of 76 years (Fig3-2) and 71% had ARMD (Fig 3-1) as 
the primary diagnosis. The majority of participants were female between the ages of 76-85 (Fig 3-3). 
Devices obtained from the low vision clinic included: CCTV System (37.5%), Hand/stand 
magnifiers (25%), Rx Spectacle (20%), Telescope/Binoculars (7.5%), Field Enhancement Device 
(3.3%), Adaptive Computer Equipment (5%), and Non-Optical Device (1.7%). Refer to Fig 3-4 for 
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Figure 3-1 Distribution of Eye Conditions for 120 Subjects 




















Figure 3-2 Age and Gender Distribution for 120 Subjects 
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Figure 3-3 Device Distribution for 120 Subjects 
CCTV Systems were the most common adopted assistive technology device, followed by Hand/Stand 
Magnifiers and Rx Spectacles.  
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The average best corrected visual acuity was 0.78 ± 0.32 logMAR (log minimum angle of 
resolution), and contrast sensitivity was 1.15 log CS (log contrast sensitivity) (Table 4). On the 
logMAR scale, 0 coincides with 6/6 acuity, while 1.0 coincides with 6/60 acuity. In other words, the 
lower the logMAR score, the better the acuity performance.  Conversely, the higher the Pell Robson 
score, the greater contrast sensitivity is. Both clinical measures exhibited normal distribution (Fig 3-
5 and 3-6). 













































Figure 3-4 Distribution of Distance Visual Acuity Data for 120 Subjects 

















Figure 3-5 Distribution of Contrast Sensitivity Data for 120 Subjects  
Normal Distribution exhibited for Pelli Robson Binocular Data, with most common being 1.15 
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3.1.2 PIADS Distributions 
The distributions for PIADS and its subscales are presented in Tables 5 and 6 for both initial and 
follow up administrations. No significant floor or ceiling effects were noted. Competence exhibited 
the highest subscale mean (1.16 ± 0.77 at initial and 1.35 ±0.71 at follow up). In every instance, 
there appeared to be a positive shift between initial and follow up for each subsequent subscale and 
the overall scores (Figs 3-7,3-8,3-9,3-10,3-11,3-12,3-13,3-14). The shift to the right indicates user 
response has improved at the follow-up administration.  
Table 5 26-Item PIADS Frequency Distributions for 1
st
 Administration for 120 Subjects 
Scale N Mean ± 
Standard 
Deviation 
Median Floor n (%) Ceiling n (%) 
Competence 120 1.16  ± 0.77 1.25 6(4.8%) 6(4.8%) 
Adaptability 120 0.97 ±0.74 1.00 6(4.8%) 5(4%) 
Self-Esteem 120 0.81 ±0.66 0.81 9(7.2%) 2(1.6%) 
Overall 
PIADS 
120 0.98 ±0.66 0.94 6(4.8%) 3(2.4%) 
Note: Floor effects were calculated for those individuals with scores less than 0, while ceiling effects 
were calculated for those with scores higher than 2.5 
 
Table 6 26-Item PIADS Frequency Distributions for 2
nd
 Administration for 120 Subjects 
Scale N Mean ± 
Standard 
Deviation 
Median Floor n (%) Ceiling n(%) 
Competence 120 1.35 ±0.71 1.25 2(1.6%) 8(6.4%) 
Adaptability 120 1.10 ±0.67 1.00 2(1.6%) 7(5.6%) 
Self-Esteem 120 1.03 ±0.63 0.87 1(0.8%) 2 (1.6) 
Overall 
PIADS 









Figure 3-6  PIADS Distribution at initial administration for Competence for 120 subjects  
Data exhibited normal distribution with majority of scores being positive. 
 
Figure 3-7 PIADS Distribution at follow up administration for Competence for 120 subjects 
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Data exhibited normal distribution with majority of scores being positive 
 
Figure 3-8 PIADS Distribution at initial administration for Adaptability for 120 Subjects  
Data exhibited normal distribution with majority of scores being positive 
 
Figure 3-9 PIADS Distribution at follow up administration for Adaptability for 120 subjects 
Data exhibited normal distribution with majority of scores being positive 
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Figure 3-10 PIADS Distribution at initial administration for Self-esteem for 120 Subjects 
Data exhibited normal distribution with majority of scores being positive 
 
Figure 3-11 PIADS Distribution at follow up administration for Self-esteem for 120 Subjects 
Data exhibited normal distribution with majority of scores being positive 
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Figure 3-12 PIADS Distribution at initial administration for overall score for 120 Subjects 
Data exhibited normal distribution with majority of scores being positive 
 
Figure 3-13 PIADS Distribution at follow up administration for overall score for 120 subjects 
Data exhibited normal distribution with majority of scores being positive  
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3.1.3 Responsiveness of the PIADS 
The paired t-test was used to determine which subscales are most responsive. The overall PIADS 
score was responsive(able to detect change) (t=-3.42, p=0.001) with respect to device usage. The 
subscales of the PIADS that were most responsive to device usage were “Competence” (t=-3.12, 
p=0.002) and “Self-esteem” (t=-4.06, p<0.001). Using the effect size measure, the difference 
detected with the PIADS overall score indicated a significant increase between initial and follow up 
administrations following device usage (ES=0.79). The PIADS subscales also showed a moderate to 
large increase in scores as a result of device usage: Competence (ES=0.79), Adaptability (0.74), Self 
esteem (0.72). Responsiveness statistics for the PIADS can be seen in Table 7.  
Table 7 Responsiveness Statistics of the PIADS as a Result of Device Adoption for 120 Subjects 
PIADS Subscales Mean ± Standard 
Deviation at t1 
Mean ± 
Standard 





Competence 1.16  ± 0.77 1.35 ±0.71 -3.12, p=0.002 0.785 
Adaptability 0.97 ±0.74 1.10 ±0.67 -1.92, p=0.06 0.738 
Self-Esteem 0.81 ±0.66 1.03 ±0.63 -4.06, p<0.001 0.720 
PIADS Overall 0.98 ±0.66 1.16 ±0.60 -3.42, p=0.001 0.786 
 
3.1.4 NEI-VFQ 25 Distributions 
The distributions for NEI-VFQ 25 and its subscales are presented in Tables 8 and 9 for both initial 
and follow up administrations.  Significant floor effects are present for the driving subscale in both 
instances (89.4% at initial and 88.5% at follow up) because most participants are ineligible for a 
driver’s license in Ontario due to their visual impairment. General Health (19.2% t1, 20.8% t2), 
Ocular Pain (58.3% t1, 50.8% t2), Color Vision (52.9% t1, 52.5% t2), and Peripheral Vision (51.7% t1, 
48.3% t2) NEI-VFQ 25 subscales all demonstrate ceiling effects for both the initial and follow up 
administrations. Comparing Fig 3-15 and Fig 3-16, it can be seen there is no significant change for 
the t-tests between scores for the NEI-VFQ 25 overall composite scores between initial and follow 
up administrations.  
 
Many individuals reported their general health as “Good” (Fig 3-17). The majority also reported 
their perceived visual health as either “fair” or “poor” (Fig 3-18). The Near Activities subscale 
scores were mostly reported to be either “extreme” or “moderate” difficulty accomplishing tasks 
associated with being up close (Fig 3-19). The Distance Activities subscale shows neither floor nor 
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ceiling effects, with responses ranging from “no difficulty” to “stopped doing” (Fig 3-20). Peripheral 
vision does not appear to be a problem for the majority of the participants in the study, as can be seen 
in Fig 3-21. The subscale scores for Role Difficulties, Driving, and General Vision are the lowest 
while Ocular Pain, Color Vision, and Peripheral Vision are the highest. High scores indicated least 
difficulty while low scores indicate the most difficulty.  
Table 8 NEI-VFQ 25 Frequency Distribution for 1
ST
 Administration for 120 Subjects 
Scale N Mean ± 
Standard 
Deviation 
Median Floor n (%) Ceiling n (%) 
General Health 120 56.67 ± 28.76 50.00 4(3.3%) 23 (19.2%) 
General Vision 120 45 ± 20.46 40.00 1 (0.8%) 2 (1.7%) 
Ocular Pain 120 84.85 ± 22.69 100.00 2 (1.7%) 70(58.3%) 
Near Activities 120 49.97 ±23.37 50.00 3 (2.5%) 2 (1.7%) 
Distance 
Activities 
120 49.34 ± 22.81 50.00 2 (1.7%) 3 (2.5%) 
Social 
Functioning 
120 63.23 ± 23.61 62.5 6 (5.0%) 18 (14.4%) 
Mental Health 120 54.43 ±23.36 56.25 3 (2.5%) 4 (3.3%) 
Role Difficulties 120 39.90 ±28.13 37.5 19 (15.8%) 2 (1.7%) 
Dependency 120 58.75 ± 29.78 58.33 6 (5.0%) 19 (15.8%) 
Driving 85 5.25 ± 17.31 0.00 76 (89.4%) 1 (1.2%) 
Color Vision 120 75.63 ± 32.46 100.00 8 (6.7%) 63 (52.9%) 
Peripheral 
Vision 
120 75.21 ± 31.34 100.00 6 (5.0%) 62 (51.7%) 
NEI-VFQ 
Composite 
120 56.05 ± 14.25 56.08 0 (0.00%) 0 (0.00%) 
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Figure 3-14  Distribution of NEI-VFQ 25 results for overall composite score at initial 
administration for 120 subjects 
Data exhibited normal distribution with majority of scores being positive  
 
Figure 3-15  Distribution of NEI-VFQ 25 results for overall composite score at follow up 
administration for 120 subjects 
Data exhibited normal distribution with majority of scores being positive 
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Table 9 25-Item NEI-VFQ 25 Frequency Distributions for 2
ND






Median Floor n (%) Ceiling n(%) 
General Health 120 58.96 ± 27.84 50.00 6 (5.0%) 25 (20.8%) 
General Vision 120 47.67 ± 17.43 40.00 0 (0.00%) 0 (0.00%) 
Ocular Pain 120 82.81 ± 22.69 100.00 0 (0.00%) 61 (50.8%) 
Near Activities 120 53.30 ± 23.13 50.00 1 (0.8%) 3 (2.5%) 
Distance 
Activities 
120 49.41 ± 21.79 50.00 3 (2.5%) 3 (2.5%) 
Social 
Functioning 
120 60.00 ± 24.61 62.50 0 (0.00%) 16 (13.3%) 
Mental Health 120 55.47 ± 23.15 56.25 1 (0.8%) 3 (2.5%) 
Role Difficulties 120 40.10 ± 28.11 37.50 18 (15.0 %) 4 (3.3%) 
Dependency 120 56.88 ± 29.04 58.33 6 (5.0%) 12 (10.0%) 
Driving 87 6.13 ± 18.95 0.00 77 (88.5%) 1 (1.1%) 
Color Vision 120 76.91 ± 30.17 100.00 5 (4.2%) 62 (52.5%) 
Peripheral 
Vision 
120 75.21 ± 30.14 75.00 4 (3.3%) 58 (48.3%) 
NEI-VFQ 
Composite 
120 56.10 ± 13.22 56.06 0 (0.00%) 0 (0.00%) 
Note: Floor effects are calculated for those individuals whose score is 0, while ceiling effects are for 
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Figure 3-16 Distribution of NEI-VFQ 25 results for Overall Health at initial and follow up 
administrations for 120 subjects 
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Figure 3-17  Distribution of NEI-VFQ 25 results for Overall Vision at initial and follow up 
administration for 120 subjects 




























Ordinary Print at Initial Administration Near Activities at Initial Administration Crowded Shelf at Initial Administration
Ordinary Print at Follow-Up Administration Near Activities at Follow-Up Administration Crowded Shelf at Follow-Up Administration
 
Figure 3-18 Distribution of NEI-VFQ 25 results for Near Activities at initial and follow up 
administration for 120 subjects 
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Figure 3-19 Distribution of NEI-VFQ 25 results for Distance Activities at initial and follow up 
administration for 120 subjects 






























Peripheral Vision at Initial Administration Peripheral Vision at Follow-Up Administration
 
Figure 3-20 Distribution of NEI-VFQ 25 results for Peripheral Vision at initial and follow up 
administration for 120 subjects 
Majority of subjects had no difficulty with activities associated with Peripheral Vision 
 
Note: All other graphical representations for remaining subscales are located in Appendix E 
3.1.5 Responsiveness of the NEI-VFQ 25 
The responsiveness of the NEI-VFQ 25 was first calculated using the paired t-test. Using this 
method, none of the subscales or the composite score exhibited responsiveness. When using the 
effect size measure, all the subscales except driving, and the overall composite score showed a 
moderate to large effect size. They were: General Health (ES=0.84), General Vision (ES= 0.88), 
Ocular Pain (ES= 0.94), Near Activities (ES= 0.85), Distance Activities (ES= 0.84), Social 
Functioning (ES= 0.88), Mental Health (ES= 0.86), Role Difficulties (ES= 0.72), Dependency 
(ES=0.82), Color Vision (ES= 0.87), Peripheral Vision (ES= 0.87), and the composite score (ES= 
0.95). Although effect size deems the NEI-VFQ 25 responsive for the sample population, the paired 










Deviation at t1 
Mean ± 
Standard 
Deviation at t2 
Observed t-
value 
Effect Size (ES) 
General Health 56.67 ± 28.76 58.96 ± 27.84 -1.06, p=0.289 0.836 
General Vision 45 ± 20.46 47.67 ± 17.43 -1.78, p=0.077 0.880 
Ocular Pain 84.85 ± 22.69 82.81 ± 22.69 1.47, p=0.144 0.939 
Near Activities 49.97 ±23.37 53.30 ± 23.13 -2.13, p= 0.035 0.852 
Distance 
Activities 
49.34 ± 22.81 49.41 ± 21.79 -0.06, p=0.953 0.844 
Social 
Functioning 
63.23 ± 23.61 60.00 ± 24.61 1.23, p=0.222 0.879 
Mental Health 54.43 ±23.36 55.47 ± 23.15 -0.65 , p=0.518 0.856 
Role Difficulties 39.90 ±28.13 40.10 ± 28.11 -0.09, p=0.928 0.719 
Dependency 58.75 ± 29.78 56.88 ± 29.04 1.04, p=0.302 0.815 
Driving 5.25 ± 17.31 6.13 ± 18.95 0.17, p=0.868 0.098 
Color Vision 75.63 ± 32.46 76.91 ± 30.17 -0.78 , p=0.439 0.870 
Peripheral 
Vision 
75.21 ± 31.34 75.21 ± 30.14 0.00, p=1.00 0.871 
NEI-VFQ 
Composite 
56.05 ± 14.25 56.10 ± 13.22 -0.07, p=0.947 0.947 
 
3.1.6 PIADS and NEI-VFQ 25 as a Function of Device 
A multivariate analysis of variance (MANOVA) revealed no differences between device choices for 
PIADS or NEI-VFQ 25, or for any of their respective subscales. Alpha was calculated at 0.001, since 
34 analysis of variance tests were run to determine if there were any differences based on device 
choice, and these were adjusted by Bonferroni’s method. (See Appendix G for results of MANOVA 
calculations).  
3.1.7 NEI-VFQ 25 Comparison to a Published Reference Group  
NEI-VFQ 25 subscale and overall scores were compared with those for a published reference group. 
Significant differences were found for most subscales at initial and follow up administrations, where 
the reference group was higher in most subscales (Tables 11 and 12). Bonferonni’s method was also 
used here to adjust for multiple comparisons. With alpha set at 0.004, differences were found in 
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every subscale except for Ocular Pain at both initial and follow up administration (t=2.06878, p= 
0.039 at initial, t=1.61992, p = 0.106 at follow up).  
Table 11 Comparison of NEI-VFQ 25 Scores for Low Vision Cohort (N=120) Versus Published 
Reference Group of Eye Disease-free Patients (N=118) for 1
ST
 Administration  
NEI-VFQ-25 Scale 






LV vs. Reference (two 
tailed t-test) 
General Health 56.67 ± 28.76 69 ± 24 T= 3.59,  p = 0.000402 
General Vision 45 ± 20.46 83 ± 14 T=16.7457,  p<0.0001 
Ocular Pain 84.85 ± 22.69 90 ± 15 
T=2.06878, p= 
0.039656 
Near Activities 49.97 ±23.37 92 ± 12 T=17.4948, p<0.0001 
Distance Activities 49.34 ± 22.81 94 ± 11 T=19.274, p<0.0001 
Social Functioning 63.23 ± 23.61 99 ± 4 T=16.3593, p<0.0001 
Mental Health 54.43 ±23.36 92 ± 12 T=16.1874, p<0.0001 
Role Difficulties 39.90 ±28.13 93 ± 13 t=18.7429, p<0.0001 
Dependency 58.75 ± 29.78 99 ± 4 t=14.6718, p<0.0001 
Driving 5.25 ± 17.31 87 ± 16 t=37.8437, p<0.0001 
Color Vision 75.63 ± 32.46 98 ± 8 t=7.32644, p<0.0001 
Peripheral Vision 75.21 ± 31.34 97 ± 10 t=7.25029, p<0.0001 
NEI-VFQ Composite 56.05 ± 14.25 92 ± 7 t=24.764, p<0.0001 
 
 
Table 12 Comparison of NEI-VFQ 25 Scores for Low Vision Cohort (N=120) Versus Published 
Reference Group of Eye Disease-free Patients (N=118) for 2
nd
 Administration  
NEI-VFQ-25 Scale 
LV Cohort (mean ± 
SD) 
Reference Group 
(mean ± SD) 
44, 63
 
LV versus Reference 
(two tailed t-test) 
44 
General Health 58.96 ± 27.84 69 ± 24 t=2.98142, p=0.00317 
General Vision 47.67 ± 17.43 83 ± 14 t=17.2542, p<0.0001 
Ocular Pain 82.81 ± 22.69 90 ± 15 
t=1.61992, p = 
0.10658 
Near Activities 53.30 ± 23.13 92 ± 12 t=16.2401, p<0.0001 
Distance Activities 49.41 ± 21.79 94 ± 11 t=19.977, p<0.0001 
Social Functioning 60.00 ± 24.61 99 ± 4 t=17.1312, p<0.0001 
Mental Health 55.47 ± 23.15 92 ± 12 t=15.3191, p<0.0001 
Role Difficulties 40.10 ± 28.11 93 ± 13 t=18.6832, p<0.0001 
Dependency 56.88 ± 29.04 99 ± 4 t=15.7374, p<0.0001 
Driving 6.13 ± 18.95 87 ± 16 t=35.5941, p<0.0001 
Color Vision 76.91 ± 30.17 98 ± 8 t=7.39767, p<0.0001 
Peripheral Vision 75.21 ± 30.14 97 ± 10 t=7.51039, p<0.0001 
NEI-VFQ Composite 56.10 ± 13.22 92 ± 7 t=26.2411, p<0.0001 
 
3.1.8 PIADS Correlations with Clinical Measures: Visual Acuity and Contrast 
Sensitivity 
Table 13 presents the correlations between PIADS and visual acuity. No significant correlations 
existed and visual acuity did not play a role in PIADS scores. Figs 3-22 and 3-23 present a graphical 
representation of visual acuity versus overall PIADS score at t1 & t2. The same was the case for 
PIADS correlations with contrast sensitivity (Table 14); with Figs 3-24 and 3-25 as graphical 
representations for contrast sensitivity versus PIADS. Graphical representations of all the visual 
acuity and contrast sensitivity versus PIADS subscales can be found in Appendix H.  
Table 13 Correlations Between PIADS Subscale and Overall Items for Initial (t1) and Follow 
up Administrations (t2) with Best Corrected Visual Acuity Score N=116 
PIADS Subscale Items with 
Visual Acuity scores 
Correlation Coefficient* P-value 
PIADS Competence t1 0.196 0.033 
PIADS  Competence t2 0.067 0.467 
45 
PIADS Adaptability t1 0.187 0.041 
PIADS Adaptability t2 0.032 0.730 
PIADS Self-Esteem t1 0.152 0.098 
PIADS Self Esteem t2 0.196 0.033 
PIADS Overall t1 0.198 0.031 
PIADS Overall t2 0.107 0.245 
*Correlation is significant at the 0.05 level (2-tailed). 
 
Figure 3-21 Correlation between visual Acuity and overall PIADS score at initial 
administration. Scatter plot indicates very little correlation between PIADS and VA, n=116 
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Figure 3-22 Correlation between Visual Acuity and overall PIADS score at follow up 
administration. Scatter plot indicates very little correlation between PIADS and VA, n=116 
Table 14 Correlations between PIADS Subscale Items for Initial (t1) and Follow up (t2) 
Administrations with Pelli-Robson Contrast Sensitivity Test, n=119 
PIADS Items with Pelli- 
Robson scores 
Correlation Coefficient P-value 
PIADS Competence t1 -0.059 0.527 
PIADS  Competence t2 -0.025 0.794 
PIADS Adaptability t1 0.023 0.810 
PIADS Adaptability t2 0.008 0.928 
PIADS Self-Esteem t1 -0.042 0.654 
PIADS Self Esteem t2 -0.026 0.779 
PIADS Overall t1 -0.029 0.759 
PIADS Overall t2 -0.016 0.867 
*Correlation is significant at the 0.05 level (2-tailed), and correlation coefficient is ≥0.20. 
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Figure 3-23 Correlation between Contrast Sensitivity and overall PIADS score at initial 
administration. Scatter plot indicates very little correlation between PIADS and CS, n=116 
 
FIGURE 3-24 Correlation between Contrast Sensitivity and overall PIADS score at follow up 
administration. Scatter plot indicates very little correlation between PIADS and CS, n=116 
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3.1.9 Correlations between NEI-VFQ 25 and Clinical Measures of Visual Acuity and 
Contrast Sensitivity 
The NEI-VFQ 25 appears to correlate somewhat better than the PIADS with the clinical measures. 
Table 15 shows that NEI-VFQ 25 subscales all show modest correlations in the areas of General 
Vision at t1 (-0.218, p=0.017), Driving at t1 (-0.292, p=0.007), Peripheral Vision at t1 (0.240, p= 
0.009), Driving at t2 (-0.266, p=0.013), and Peripheral Vision at t2 (0.221, p= 0.015). Figs 3-26 and 
3-27 present a graphical representation for visual acuity versus overall NEI-VFQ 25 composite 
scores at t1 & t2. For contrast sensitivity (Table 16), there are several more correlations, but these are 
also modest at best: Near Activities at t1 (0.279, p= 0.002), Distance Activities at t1 (0.250, p=0.007), 
Driving at t1 (0.258, p= 0.019), Color Vision at t1 (0.297, p=0.001), NEI-VFQ 25 composite score at 
t1 (0.270, p=0.003), Distance Activities at t2 (0.260, p=0.005), Driving at t2 (0.319, p=0.003), Color 
Vision at t2 (0.277, p=0.003), and NEI-VFQ 25 composite score at t2 (0.284, p=0.002).  Figs 3-28 
and 3-29 also present a graphical representation for contrast sensitivity versus overall NEI-VFQ 25 
composite scores at t1 & t2.  See Appendix H for graphical representations of all the visual acuity and 
contrast sensitivity versus NEI-VFQ 25 subscales.  
Table 15 Correlations between NEI-VFQ 25 Subscale and Overall Items for Initial (t1) and 
Follow up (t2) with Best Corrected Visual Acuity Score, n=116 
NEI-VFQ 25 Items with 
Visual Acuity scores 
Correlation Coefficient P-value 
General Health  t1 -0.136 0.140 
General Vision t1 -0.218* 0.017 
Ocular Pain t1 0.054 0.558 
Near Activities t1 -0.040 0.667 
Distance Activities t1 -0.022 0.813 
Social Functioning t1 0.009 0.926 
Mental Health t1 0.050 0.586 
Role Difficulties t1 0.084 0.364 
Dependency t1 -0.054 0.563 
Driving t1 -0.292* 0.007 
Color Vision t1 -0.110 0.237 
Peripheral Vision t1 0.240* 0.009 
NEI-VFQ Composite t1 0.009 0.924 
General Health t2 0.010 0.916 
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General Vision t2 -0.171 0.063 
Ocular Pain t2 0.077 0.408 
Near Activities t2 0.025 0.786 
Distance Activities t2 -0.055 0.554 
Social Functioning t2 -0.131 0.154 
Mental Health t2 0.105 0.255 
Role Difficulties t2 -0.087 0.346 
Dependency t2 -0.035 0.707 
Driving t2 -0.266* 0.013 
Color Vision t2 -0.134 0.150 
Peripheral Vision t2 0.221* 0.015 
NEI-VFQ Composite t2 -0.044 0.631 
*Correlation is significant at the 0.05 level (2-tailed), and correlation coefficient is ≥0.20. 
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Figure 3-25 Correlation between Visual Acuity and overall NEI-VFQ 25 score at initial 




Figure 3-26 Correlation between Visual Acuity and overall NEI-VFQ 25 score at follow up 
administration. Scatter plot indicates some but little correlation between NEI-VFQ 25 and VA, 
n=116 
Table 16 Correlations between NEI-VFQ 25 Subscale and Overall Items for Initial (t1) and 
Follow up (t2) Administrations with Pelli-Robson Contrast Sensitivity n =119 
NEI –VFQ 25 Items with 
Pelli-Robson scores 
Correlation Coefficient P-value 
General Health t1 0.040 0.672 
General Vision t1 0.141 0.132 
Ocular Pain t1 0.102 0.275 
Near Activities t1 0.279* 0.002 
Distance Activities t1 0.250* 0.007 
Social Functioning t1 0.098 0.295 
Mental Health t1 -0.025 0.789 
Role Difficulties t1 0.052 0.579 
Dependency t1 0.181 0.051 
Driving t1 0.258* 0.019 
Color Vision t1 0.297* 0.001 
Peripheral Vision t1 0.022 0.811 
NEI-VFQ Composite t1 0.270* 0.003 
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General Health t2 -0.002 0.981 
General Vision t2 0.167 0.074 
Ocular Pain t2 0.098 0.295 
Near Activities t2 0.170 0.068 
Distance Activities t2 0.260* 0.005 
Social Functioning t2 0.167 0.073 
Mental Health t2 -0.046 0.625 
Role Difficulties t2 0.141 0.131 
Dependency t2 0.168 0.072 
Driving t2 0.319* 0.003 
Color Vision t2 0.277* 0.003 
Peripheral Vision t2 0.033 0.728 
NEI-VFQ Composite t2 0.284* 0.002 
*Correlation is significant at the 0.05 level (2-tailed), and correlation coefficient is ≥0.20. 
 
 
Figure 3-27 Correlation between Contrast Sensitivity and overall NEI-VFQ 25 score at initial 
administration. Scatter plot indicates modest correlation between NEI-VFQ 25 and CS, n=116 
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Figure 3-28 Correlation between Contrast Sensitivity and overall NEI-VFQ 25 score at follow 
up administration. Scatter plot indicates modest correlation between NEI-VFQ 25 and VA, 
n=116 
3.1.10 PIADS & NEI-VFQ 25 Within Measure Correlations at Initial and Follow Up 
Administrations 
Table 17 illustrates the correlations between PIADS subscales and overall scores at initial and 
follow-up administrations. Moderate to high correlations are evident for all scores, thus helping to 
validate the stability of the relationship within the measures. A graphical representation of the overall 
PIADS scores at t1 and t2 is presented (Fig 3-30). In addition, the NEI-VFQ 25 subscales and 
composite scores also exhibit moderate to high correlations (Table 18), over the test/retest interval, 
which demonstrates a stable relationship within the measure. Graphical representation of composite 
scores between t1 & t2 can been seen in Fig 3-31.  
 
Table 17  Correlation between PIADS Subscale Items at Initial and Follow up Administrations 
(i.e. t1=Initial t2=Follow up, t2-t1=2 Weeks). N=120.  
PIADS Subscale Items Correlation 
Coefficient* 
P-value 
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R Sq Linear = 0.08 
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PIADS Competence t1 with 
Competence t2 
0.593 <0.001 
PIADS Adaptability t1 with 
Adaptability t2 
0.528 <0.001 
PIADS Self-Esteem t1 with 
Self Esteem t2 
0.613 <0.001 
PIADS Overall t1 with t2 0.609 <0.001 
*Correlation is significant at the 0.05 level (2-tailed), and correlation coefficient is ≥0.20. 
 
 
Figure 3-29 Correlations of PIADS overall scores for initial and follow up administrations for 
120 subjects. Moderate correlations are present for PIADS between administrations during 
given time period (2 weeks)  
Table 18 Correlation between NEI-VFQ 25 Subscale Items at Initial and Follow up 
Administrations (i.e. t1=Initial, t2=Follow up, t2-t1=2 weeks) n=120. 
NEI-VFQ-25 Subscale Items Correlation Coefficient P-value 
General Health t1 with t2 0.670 <0.001 
General Vision t1 with t2 0.665 <0.001 
Ocular Pain t1 with t2 0.745 <0.001 
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Near Activities t1 with t2 0.737 <0.001 
Distance Activities t1 with t2 0.827 <0.001 
Social Functioning t1 with t2 0.482 <0.001 
Mental Health t1 with t2 0.740 <0.001 
Role Difficulties t1 with t2 0.591 <0.001 
Dependency t1 with t2 0.764 <0.001 
Driving t1 with t2 0.998 <0.001 
Color Vision t1 with t2 0.806 <0.001 
Peripheral Vision t1 with t2 0.783 <0.001 
NEI-VFQ Composite t1 with t2 0.841 <0.001 
*Correlation is significant at the 0.05 level (2-tailed), and correlation coefficient is ≥0.20. 
 
Figure 3-30 Correlations of NEI-VFQ 25 composite scores for initial and follow up 
administrations for 120 subjects. Moderate correlations are present for NEI-VFQ25 between 
administrations during given time period (2 weeks)  
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3.1.11 PIADS and NEI-VFQ between Measures Correlations at Initial and Follow Up 
Administrations 
The correlations between PIADS and NEI-VFQ 25 were summarized for time periods, t1 and t2.  A  
Spearman correlation coefficient was used because the measures were highly skewed and or/ordinal. 
The correlations were significant at α= 0.05, and where the correlation coefficient was ≥0.20. The 
bolded items in Tables 19 and 20 represent those that are statistically significant. Although they are 
significant statistically, the value of the correlation coefficients is moderate at best. Several weak but 
significant correlations were found between subscale items for PIADS and NEI-VFQ 25 at initial 
administration:  
 
 Vision function status in the areas of near activities (r= 0.290, p=0.001), social 
functioning (r= 0.211, p=0.022), overall composite score (r= 0.215, p=0.018) (as 
revealed by NEI-VFQ 25) and psychosocial impact on competence (as revealed by 
PIADS). 
 Vision function status in the areas of near activities (r= 0.353, p<0.001), mental 
health (r= 0.240, p=0.008), overall composite score (r= 0.233, p=0.01) (as revealed 
by NEI-VFQ 25) are correlated with adaptability (as revealed by PIADS). 
 Vision function status in the areas of near activities (r= 0.208, p=0.023) (as revealed 
by NEI-VFQ 25 ) with self-esteem (as revealed by PIADS) 
 The PIADS overall score correlated positively with near activities (r= 0.321, 
p<0.001), mental health (r= 0.200, p=0.028), role difficulties (r= 0.201, p= 0.027), 
and the NEI-VFQ 25 composite score (r= 0.226, p=0.013).  
Fig 3-32 is a plot of PIADS overall score with the NEI-VFQ 25 composite score at initial 
administration. For all other significant correlations, please refer to Appendix I 
Table 19 Correlations between NEI-VFQ 25 Subscale Items and PIADS Subscale Items at 
Initial Administration (i.e. t1=Initial) N=120. Bolded Items indicate a correlations coefficient ≥ 
0.20 
 PIADS Subscales 





















0.092 0.319 0.050 0.586 0.009 0.920 0.039 0.671 
General 
Vision 
0.057 0.539 0.143 0.119 0.165 0.072 0.138 0.132 
Ocular Pain -0.076 0.410 -0.035 0.704 -0.072 0.437 -.060 0.517 
Near 
Activities 
0.290* 0.001 0.353* 
<0.0
01 
0.208* 0.023 0.321* <0.001 
Distance 
Activities 




0.211* 0.022 0.147 0.109 0.061 0.507 0.168 0.067 
Mental 
Health 
0.101 0.272 0.240* 0.008 0.154 0.094 0.200* 0.028 
Role 
Difficulties 
0.192 0.036 0.149 0.105 0.166 0.070 0.201* 0.027 
Dependency 0.055 0.548 0.081 0.377 0.020 0.833 0.076 0.407 
Driving 0.017 0.881 -0.051 0.641 -0.063 0.569 -0.035 0.750 
Color Vision 0.118 0.175 -0.018 0.843 -0.081 0.384 0.011 0.903 
Peripheral 
Vision 
0.131 0.153 0.199 0.290 0.135 0.142 0.167 0.069 
NEI-VFQ 
Composite 
0.215* 0.018 0.233* 0.01 0.117 0.204 0.226* 0.013 
*Correlation is significant at the 0.05 level (2-tailed). 
 
Figure 3-31 Correlations of overall scores between PIADS and NEI-VFQ 25 at initial 
administration for 120 subjects. Several modest correlations are present between PIADS 
subscales and NEI-VFQ 25 subscales and overall scores.   
• Several weak but significant correlations were found between subscale items for PIADS and 
NEI-VFQ 25 at follow-up administration:  
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 Vision function status in the areas of general health (r= 0.203, p=0.026), role 
difficulties (r= 0.261, p=0.004), dependency (r= 0.212, p=0.020), overall composite 
score (r= 0.274, p=0.002) (as revealed by NEI-VFQ 25) and psychosocial impact on 
competence (as revealed by PIADS). 
 Vision function status in the areas of general health (r= 0.292, p=0.001), near 
activities (r= 0.244, p=0.007), distance activities (r= 0.259, p=0.004), mental health 
(r= 0.212, p=0.020), overall composite score (r= 0.271, p=0.003) (as revealed by 
NEI-VFQ 25) are correlated with adaptability (as revealed by PIADS). 
 Vision function status in the areas of general health (r= 0.237, p=0.009) (as revealed 
by NEI-VFQ 25 ) with self-esteem (as revealed by PIADS) 
 The PIADS overall score correlated positively with general health (r= 0.271, 
p=0.003), distance activities (r= 0.210, p=0.021), mental health (r= 0.215, p=0.018), 
role difficulties (r= 0.203, p=0.026), dependency (r= 0.218, p=0.017), and the NEI-
VFQ 25 composite score (r= 0.281, p=0.002).  
Fig 3-33 is a plot of PIADS overall score with the NEI-VFQ 25 composite score at follow up 
administration. For all other significant correlations, please refer to Appendix I.  
Table 20 Correlations between NEI-VFQ 25 Subscale Items and PIADS Subscale Items at 
Follow Up Administration (i.e. t2= Follow up) n=120. Bolded Items indicate a correlation 
coefficient ≥ 0.20 
 PIADS Subscales 





















0.203* 0.026 0.292* 0.001 0.237* 0.009 0.271* 0.003 
General 
Vision 
0.153 0.096 0.164 0.073 0.179 0.051 0.183 0.045 
Ocular Pain 0.018 0.848 0.045 0.629 -0.063 0.493 0.000 0.98 
Near 
Activities 
0.128 0.165 0.244* 0.007 0.078 0.400 0.179 0.051 
Distance 
Activities 
0.151 0.100 0.259* 0.004 0.108 0.242 0.210* 0.021 
Social 
Functioning 
0.017 0.851 0.023 .799 -0.001 0.992 0.020 0.826 
Mental 
Health 
0.187 0.041 0.212* 0.020 0.129 0.160 0.215* 0.018 
Role 
Difficulties 
0.261* 0.004 0.161 0.079 0.081 0.381 0.203* 0.026 
Dependency 0.212* 0.020 0.150 0.102 0.190 0.038 0.218* 0.017 
Driving 0.078 0.473 0.086 0.430 0.031 0.778 0.071 0.515 
Color Vision 0.081 0.385 0.057 0.537 0.060 0.517 0.082 0.379 
Peripheral 
Vision 




0.274* 0.002 0.271* 0.003 0.152 0.098 0.281** 0.002 
*Correlation is significant at the 0.05 level (2-tailed). 
 
 
Figure 3-32 Correlations of overall scores between PIADS and NEI-VFQ 25 at initial 
administration for 120 subjects. Several modest correlations are present between PIADS 
subscales and NEI-VFQ 25 subscales and overall scores.    
3.1.12 Relationship Changes Over Time for PIADS and NEI-VFQ 25 
Table 21 shows that a significant change occurs between times t1 and t2 for the PIADS subscales 
Competence (t=-3.121, p=0.002), Self-esteem (t= -4.059, p<0.001), and PIADS overall (t= -3.430 p= 
0.001). In each instance, t2 had a significant higher score, thus indicating that there is a positive 
change at the follow up administration. No Significant change was present for the Adaptability 
subscale of PIADS. It is interesting to note that there is a slight positive change for the NEI-VFQ 25 
composite score, but it is negligible (no significant status change).  
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Table 21 Paired Samples Test assessing whether or Not the Relationship between PIADS and 
NEI-VFQ 25 Measures change between t1 and t2. Bolded values indicated scores for t2 are of 
significantly higher value. In this case, α= 0.05/17 = 0.003, Known as the Bonferroni 
Correction, since 17 pairs of tests are run.   







Interval of the 




        Lower Upper       
PIADS Subscale 




0.67769 .06186 -.31555 -.07056 -3.121 119 .002 
PIADS Subscale Self-




0.59037 0.05389 -.32546 
-
0.11204 
-4.059 119 .000 
PIADS Adaptability 1-






0.0032 -1.929 119 0.056 
PIADSOverall1 - 
PIADSOverall2 
-.17940 0.57467 .05246 -.28327 -.07552 -3.420 119 .001 
VFQ Composite Score1 - 
VFQ Composite Score2 
-.04439 7.24759 .66161 
-
1.35444 
1.26567 -.067 119 .947 
Note: Appendix J includes all paired t-test conducted  
3.2 Age-related Macular Degeneration Population (ARMD) 
3.2.1 Clinical Measures: Visual Acuity and Contrast Sensitivity 
The ARMD sample subgroup was taken from the cohort of 120 participants of the overall sample. 
71% of participants had ARMD as their reported eye condition. The average best corrected visual 
acuity for the ARMD sample was 0.83 ± 0.28 logMAR (compared to 0.78 ± 0.32 logMAR for 
overall sample), and log contrast sensitivity was 1.11 (compared to 1.15 for overall sample) (See 
Table 22). Each clinical measure (VA and CS) also exhibited normal distribution for the ARMD 
sample (Figs 3-34& 3-35).  
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Table 22 Clinical Statistics for ARMD Population for Best Corrected Visual Acuity and 
Contrast Sensitivity. Log Mar Scale Used. 
 DISTANCE VA 
PELLI 
ROBSON OU 
N  84 82 
Mean .827082 1.1116 
Median .903000 1.1500 
Std. Deviation .2826708 .26878 
Variance .080 .072 
Skewdness -.217 -.589 
Std. Error of Skewdness .263 .266 
Percentiles 25 .602000 1.0000 
  50 .903000 1.1500 















Figure 3-33 Distribution of Distance Visual Acuity Data for ARMD Population  

















Figure 3-34 Distribution of Contrast Sensitivity Data for ARMD Population   
Normal Distribution exhibited for Pelli Robson Binocular Data, with most common being 1.15 
3.2.2 PIADS Distributions 
The distributions for PIADS and its subscales are presented in Tables 23 and 24for both initial and 
follow up administrations for the ARMD sample. No significant floor or ceiling effects were noted. 
Competence also exhibited the highest subscale mean (1.11 ± 0.72 at initial and 1.34 ±0.71 at follow 
up) for the ARMD sample as well. The same improvement in responses on the PIADS subscales and 
overall scores was noted at follow up administration. Every subscale had a positive shift between 
initial and follow up for each subsequent subscale and the overall scores (Figs 3-36,3-37,3-38,3-
39,3-40,3-41,3-42,3-43). The shift to the right indicates user response has improved at the follow-up 
administration. No significant differences were noted in improvement between overall sample and 





Table 23 26-Item PIADS Frequency Distributions for 1
ST
 Administration for ARMD 
Population  
Scale N Mean ± 
Standard 
Deviation 
Median Floor n (%) Ceiling n (%) 
Competence 85 1.11  ± 0.72 1.08 4(4.8%) 2(2.4%) 
Adaptability 85 0.98 ±0.74 1.00 5(5.8%) 3(3.6%) 
Self-Esteem 85 0.81 ±0.64 0.88 6(7.2%) 0(0%) 
Overall 
PIADS 
85 0.97 ±0.63 0.92 4(4.8%) 1(1.2%) 
Note: Floor effects were calculated for those individuals with scores less than 0, while ceiling effects 
were calculated for those with scores higher than 2.5 
 
Table 24 26-Item PIADS Frequency Distributions for 2
ND
 Administration for ARMD 
Population   
Scale N Mean ± 
Standard 
Deviation 
Median Floor n (%) Ceiling n(%) 
Competence 85 1.34 ±0.71 1.25 1(1.2%) 3(3.6%) 
Adaptability 85 1.08 ±0.68 0.83 1(1.2%) 4(4.8%) 
Self-Esteem 85 1.04 ±0.62 1.00 6(7.2%) 0(0%) 
Overall 
PIADS 
85 1.15 ±0.60 1.11 0 (0.0%) 0(0%) 
Note: Appendix K includes more detailed distributions.  
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Figure 3-35  PIADS Distribution at initial administration for Competence for ARMD 
Population 
Data exhibited normal distribution with majority of scores being positive 
 
Figure 3-36 PIADS Distribution at follow up administration for Competence for ARMD 
population  
Data exhibited normal distribution with majority of scores being positive 
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Figure 3-37 PIADS Distribution at initial administration for Adaptability for ARMD 
population  
Data exhibited normal distribution with majority of scores being positive 
 
Figure 3-38 PIADS Distribution at follow up administration for Adaptability for ARMD 
population  

















Std. Dev. = 0.63873
N = 85
 
Figure 3-39 PIADS Distribution at initial administration for Self-esteem for ARMD population  
Data exhibited normal distribution with majority of scores being positive 
 
Figure 3-40 PIADS Distribution at follow up administration for Self-esteem for ARMD 
population  




Figure 3-41 PIADS Distribution at initial administration for Overall score for ARMD 
population  
Data exhibited normal distribution with majority of scores being positive 
 
 
Figure 3-42 PIADS Distribution at follow up administration for Overall score for ARMD 
population  
Data exhibited normal distribution with majority of scores being positive 
 
67 
3.2.3 NEI-VFQ 25 Distributions 
The distributions for NEI-VFQ and its subscales are presented in Tables 25 and 26 for both initial 
and follow up administrations for the ARMD subgroup. For the initial and follow up administrations, 
significant floor effects were noted for the Driving subscale (91.5% at initial and 90.2% at follow 
up). The percentages were slightly higher than the overall population but this is also due to the fact 
most participants are ineligible to drive in Ontario based on their visual impairment. Ocular pain 
(63.5% t1, 54.1% t2), Color Vision (48.8% t1, 47.6% t2), and Peripheral Vision (60.0% t1, 54.1% t2) 
subscales all demonstrate ceiling effects for both the initial and follow up administrations. General 
Health is the only subscale that does not demonstrate ceiling effects, as is the case in the overall 
sample population. The subscale scores for Role Difficulties, Driving, and General Vision are the 
lowest while Ocular Pain, Color Vision, and Peripheral Vision are the highest, as is the case for the 
overall sample population as well. Comparing Figs 3-44 and 3-45, it can be seen there is no 
significant change between scores for the NEI-VFQ 25 overall composite scores between initial and 
follow up administrations.  
Table 25  25-Item NEI-VFQ 25 Frequency Distributions for 1
ST






Median Floor n (%) Ceiling n(%) 
General Health 85 52.06 ± 28.41 50.00 4(4.7%) 12(14.1%) 
General Vision 85 44 ± 19.23 40.00 0(0%) 1 (1.2%) 
Ocular Pain 85 86.23 ± 22.1 100.00 0 (0%) 54(63.5%) 
Near Activities 85 49.07 ±22.81 50.00 1 (1.2%) 2 (2.4%) 
Distance 
Activities 
85 47.89 ± 23.35 50.00 2 (2.4%) 2 (2.4%) 
Social 
Functioning 
85 63.53 ± 32.52 62.5 6 (5.0%) 13 (15.3%) 
Mental Health 85 54.48 ±25.71 56.25 2 (2.4%) 3 (3.5%) 
Role Difficulties 85 39.11 ±27.47 37.5 13 (15.3%) 1 (1.2%) 
Dependency 85 58.82 ± 31.03 58.33 5 (5.9%) 15 (17.6%) 
Driving 59 4.16 ± 16.21 0.00 54 (91.5%) 1 (1.7%) 
Color Vision 85 72.32 ± 33.39 75.00 5 (6.0%) 41 (48.8%) 
Peripheral 
Vision 
85 80.88 ± 28.78 100.00 3 (3.5%) 51 (60%) 
NEI-VFQ 
Composite 
85 56.058± 14.98 56.67 0 (0.00%) 0 (0.00%) 
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Table 26 25-Item NEI-VFQ 25 Frequency Distributions for 2
ND






Median Floor n (%) Ceiling n(%) 
General Health 85 55.88 ± 27.72 50.00 5(5.9%) 14 (16.5%) 
General Vision 85 47.06 ± 16.53 40.00 0 (0.00%) 0 (0.00%) 
Ocular Pain 85 85.00 ± 21.72 100.00 0 (0.00%) 46 (54.1%) 
Near Activities 85 52.11 ± 23.51 50.00 1 (1.2%) 2 (2.4%) 
Distance 
Activities 
85 47.35 ± 22.13 50.00 3 (3.5%) 2 (2.4%) 
Social 
Functioning 
85 56.03 ± 23.75 62.50 0 (0.00%) 9 (10.6%) 
Mental Health 85 55.66 ± 23.58  56.25 1 (01.2%) 9 (10.6%) 
Role Difficulties 85 37.06 ± 28.96 37.50 16 (18.8 %) 4 (4.7%) 
Dependency 85 56.08 ± 28.89 50.00 5 (5.9%) 10 (11.8%) 
Driving 61 5.33 ± 18.00 0.00 55 (90.2%) 1 (1.6%) 
Color Vision 85 75.30 ± 29.43 75.00 2 (2.4%) 40 (47.6%) 
Peripheral 
Vision 
85 79.71 ± 27.68 100.00 2 (2.4%) 46 (54.1%) 
NEI-VFQ 
Composite 
85 55.50 ± 13.99 55.23 0 (0.00%) 0 (0.00%) 
Note: Floor effects are calculated for those individuals whose score is 0, while ceiling effects are for 
those individuals who scored 100. Refer to Appendix L for more detailed distributions 
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Figure 3-43 Distribution of NEI-VFQ 25 results for Overall Composite score at initial 
administration for ARMD population  
Data exhibited normal distribution with majority of scores being positive 
 
Figure 3-44 Distribution of NEI-VFQ 25 results for Overall Composite score at follow up 
administration for ARMD population  
Data exhibited normal distribution with majority of scores being positive 
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3.2.4 PIADS Correlations with Clinical Measures: Visual Acuity and Contrast 
Sensitivity  
Table 27 presents the correlations between PIADS and visual acuity for the ARMD sample. Unlike 
the overall population, there are several weak but significant correlations and visual acuity appears to 
play a slight role in PIADS scores. Looking at Table 27, competence at t1 (0.262, p=0.016), self 
esteem at t1 (0.258, p=0.018), and PIADS overall at t1 (0.263, p= 0.016) all presented weak but 
modest correlations. Figs 3-46 and 3-47 present a graphical representation of visual acuity versus 
overall PIADS score at t1 & t2.  
Only one PIADS subscale correlated with contrast sensitivity (Table 28), Competence at t1 (-0.229, 
p=0.038). No valid conclusions can be drawn about PIADS and contrast sensitivity for the ARMD 
sample since only one correlation existed, it was negative and modest at best. Figs 3-48 and 3-49 are 
presented as graphical representations for contrast sensitivity versus PIADS.  Refer to Appendix M 
for statistical tests of all correlations.  
Table 27  Correlations between PIADS Subscale Items for Initial (t1) and Follow up (t2) 
Administrations with Best Corrected Visual Acuity Score, n=82 for ARMD Population  
PIADS Subscale Items 
with Visual Acuity scores 
Correlation Coefficient P-value 
PIADS Competence t1 0.262* 0.016 
PIADS  Competence t2 0.024 0.829 
PIADS Adaptability t1 0.197 0.072 
PIADS Adaptability t2 -0.103 0.350 
PIADS Self-Esteem t1 0.258* 0.018 
PIADS Self Esteem t2 0.164 0.135 
PIADS Overall t1 0.263* 0.016 
PIADS Overall t2 0.027 0.804 
*Correlation is significant at the 0.05 level (2-tailed), and correlation coefficient is ≥0.20. 
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Figure 3-45 Correlation between Visual Acuity and overall PIADS score at initial 
administration for ARMD population. Scatter plot indicates some weak correlation between 
PIADS and VA, n=116 
 
Figure 3-46 Correlation between Visual Acuity and overall PIADS score at follow up 
administration for ARMD population. Scatter plot indicates some weak correlation between 
PIADS and VA, n=116 
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Table 28 Correlations between PIADS Subscale Items for Initial (t1) and Follow up (t2) 
Administrations with Pelli-Robson Score, n=84 for ARMD Population 
PIADS Items with Pelli-
Robson scores 
Correlation Coefficient P-value 
PIADS Competence t1 -0.229* 0.038 
PIADS  Competence t2 -0.041 0.712 
PIADS Adaptability t1 -0.005 0.965 
PIADS Adaptability t2 0.061 0.584 
PIADS Self-Esteem t1 -0.193 0.083 
PIADS Self Esteem t2 -0.074 0.510 
PIADS Overall t1 -0.153 0.171 
PIADS Overall t2 -0.019 0.868 
*Correlation is significant at the 0.05 level (2-tailed), and correlation coefficient is ≥0.20. 
 
Figure 3-47 Correlation between Contrast Sensitivity and overall PIADS score at initial 
administration for ARMD population. Scatter plot indicates very little correlation between 
PIADS and CS, n=116 
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R Sq Linear = 0.023 
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Figure 3-48 Correlation between Contrast Sensitivity and overall PIADS score at follow up 
administration for ARMD population. Scatter plot indicates very little correlation between 
PIADS and CS, n=116 
3.2.5 NEI-VFQ 25 Correlations with Clinical Measures: Visual Acuity and Contrast 
Sensitivity 
The overall sample for the NEI-VFQ 25 appeared to have more correlations than the ARMD sample 
for visual acuity.  Looking at Table 29, General Health at t1 (-0.262, p=0.016) and General Vision at 
t1 (-0.248, p=0.023) are the only two subscales that are correlated (albeit a modest correlation). Figs 
3-50 and 3-51 present a graphical representation for visual acuity versus overall NEI-VFQ 25 
composite scores at t1 & t2. Correlations with contrast sensitivity (Table 30) were as follows: 
General Vision at t1 (0.238, p=0.031), Ocular Pain at t1 (0.334, 0.002), Near Activities at t1 (0.331, p= 
0.004), Distance Activities at t1 (0.234, p=0.034), NEI-VFQ 25 composite score at t1 (0.242, 
p=0.028), General Vision at t2 (0.227, p=0.040), Ocular pain at t2 (0.360, p=0.001), Near Activities at 
t2 (0.260, p=0.019), Distance Activities at t2 (0.305, p=0.005), Driving at t2 (0.298, p=0.022), and 
NEI-VFQ composite score at t2 (0.281, p=0.011).  Figs 3-52 and 3-53 also present a graphical 
representation for contrast sensitivity versus NEI-VFQ 25 composite scores at t1 & t2 for the ARMD 
sample.   
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R Sq Linear = 3.458E-4 
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Table 29 Correlations between NEI-VFQ 25 Subscales and Overall Items for Initial (t1) and 
Follow up (t2) Administrations with Best Corrected Visual Acuity Score, n=82 for ARMD 
Population 
NEI-VFQ 25 Items with Visual 
Acuity scores 
Correlation Coefficient P-value 
General Health  t1 -0.262* 0.016 
General Vision t1 -0.248* 0.023 
Ocular Pain t1 0.048 0.663 
Near Activities t1 0.003 0.976 
Distance Activities t1 -0.034 0.756 
Social Functioning t1 0.043 0.696 
Mental Health t1 0.043 0.698 
Role Difficulties t1 0.186 0.090 
Dependency t1 0.018 0.871 
Driving t1 -0.196 0.136 
Color Vision t1 -0.081 0.466 
Peripheral Vision t1 0.164 0.135 
NEI-VFQ Composite t1 0.049 0.660 
General Health t2 0.000 0.997 
General Vision t2 -0.160 0.145 
Ocular Pain t2 -0.019 0.866 
Near Activities t2 0.030 0.786 
Distance Activities t2 -0.047 0.671 
Social Functioning t2 0.007 0.952 
Mental Health t2 -0.076 0.490 
Role Difficulties t2 -0.055 0.621 
Dependency t2 0.038 0.732 
Driving t2 -0.129 0.323 
Color Vision t2 -0.049 0.662 
Peripheral Vision t2 0.198 0.071 
NEI-VFQ Composite t2 0.006 0.960 




Figure 3-49 Correlation between Visual Acuity and overall NEI-VFQ 25 score at initial 
administration for ARMD population. Scatter plot indicates very little correlation between 
NEI-VFQ 25 and VA, n=116 
76 
 
Figure 3-50 Correlation between Visual Acuity and overall NEI-VFQ 25 score at follow up 
administration for ARMD population. Scatter plot indicates very little correlation between 
NEI-VFQ 25 and VA, n=116  
Table 30 Correlations between NEI-VFQ 25 Subscale Items for Initial (t1) and Follow up (t2) 
Administrations with Pelli-Robson Contrast Sensitivity Test, n=84 for ARMD Population  
NEI –VFQ 25 Items with 
Pelli-Robson scores 
Correlation Coefficient P-value 
General Health t1 0.031 0.785 
General Vision t1 0.238* 0.031 
Ocular Pain t1 0.334* 0.002 
Near Activities t1 0.311* 0.004 
Distance Activities t1 0.234* 0.034 
Social Functioning t1 0.073 0.512 
Mental Health t1 -0.005 0.967 
Role Difficulties t1 -0.092 0.412 
Dependency t1 0.117 0.295 
Driving t1 0.197 0.137 
Color Vision t1 0.187 0,095 
Peripheral Vision t1 0.079 0.483 
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NEI-VFQ Composite t1 0.242* 0.028 
General Health t2 -0.027 0.807 
General Vision t2 0.227* 0.040 
Ocular Pain t2 0.360* 0.001 
Near Activities t2 0.260* 0.019 
Distance Activities t2 0.305* 0.005 
Social Functioning t2 0.110 0.326 
Mental Health t2 0.024 0.829 
Role Difficulties t2 0.074 0.510 
Dependency t2 0.163 0.143 
Driving t2 0.298* 0.022 
Color Vision t2 0.056 0.620 
Peripheral Vision t2 0.134 0.229 
NEI-VFQ Composite t2 0.281* 0.011 




Figure 3-51 Correlation between Contrast Sensitivity and overall NEI-VFQ 25 score at initial 
administration for ARMD population. Scatter plot indicates modest correlation between 
PIADS and CS, n=116 
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Figure 3-52 Correlation between Contrast Sensitivity and overall NEI-VFQ 25 score at follow 
up administration for ARMD population. Scatter plot indicates modest correlation between 
PIADS and CS, n=116 
3.2.6 PIADS & NEI-VFQ 25 Within Measure Correlations at Initial and Follow Up 
Administrations 
 
Table 31 shows the correlations between PIADS subscales and overall scores at initial and follow- 
up administrations for the ARMD population. Moderate correlations are seen for all scores, thus 
helping to validate the stability of the relationship within the measures. A graphical representation of 
the overall PIADS scores at t1 and t2 are presented (Fig 3-54) In addition, the NEI-VFQ 25 subscales 
and composite scores also exhibited moderate to high correlations (Table 32), over the given time 
period, also illustrating a stable relationship within the measure. Graphical representation of 
composite scores between t1 & t2 can been seen in Fig 3-55.  
Table 31 Correlation between PIADS Subscale Items at Initial and Follow up Administrations 
(i.e. t1=Initial, t2=Follow up). n=85, ARMD Population. Time between Initial and Follow up 
Administration is 2 weeks.  
PIADS Subscale Items Correlation Coefficient P-value 




PIADS Adaptability t1 with 
Adaptability t2 
0.481 <0.001 
PIADS Self-Esteem t1 with 
Self Esteem t2 
0.610 <0.001 
PIADS Overall t1 with t2 0.557 <0.001 




Figure 3-53 Correlations of PIADS overall scores for initial and follow up administrations for 
ARMD population. Moderate correlations are present for PIADS between administrations 










Table 32 Correlation between NEI-VFQ 25 Subscale Items at Initial and Follow up 
Administrations (i.e. t1=Initial, t2=Follow up) n=85, ARMD Population  
NEI-VFQ-25 Subscale Items Correlation Coefficient* P-value 
General Health t1 with t2 0.608 <0.001 
General Vision t1 with t2 0.724 <0.001 
Ocular Pain t1 with t2 0.709 <0.001 
Near Activities t1 with t2 0.744 <0.001 
Distance Activities t1 with t2 0.841 <0.001 
Social Functioning t1 with t2 0.435 <0.001 
Mental Health t1 with t2 0.690 <0.001 
Role Difficulties t1 with t2 0.569 <0.001 
Dependency t1 with t2 0.729 <0.001 
Driving t1 with t2 0.997 <0.001 
Color Vision t1 with t2 0.802 <0.001 
Peripheral Vision t1 with t2 0.760 <0.001 
NEI-VFQ Composite t1 with t2 0.858 <0.001 





Figure 3-54 Correlations of NEI-VFQ 25 composite scores for initial and follow up 
administrations for ARMD population. Moderate correlations are present for NEI-VFQ25 
between administrations during given time period (2 weeks)  
3.2.7 PIADS and NEI-VFQ between Measures Correlations at Initial and Follow-Up 
Administrations 
The correlations between PIADS and NEI-VFQ 25 are summarized for time periods, t1 and t2 for the 
ARMD sample in Tables 33 and 34. Correlations between measures were summarized by Spearman 
correlation coefficient, because the measures were highly skewed and/or ordinal. The correlations 
were significant at α= 0.05, and where the correlation was ≥ 0.20. The bolded items in represent 
correlations that are statistically significant, but these correlations are only moderate. Several weak 
but significant correlations were found between subscale items for PIADS and NEI-VFQ 25 at initial 
administration:  
 
 Vision function status in the areas of near activities (r= 0.230, p=0.035), social functioning 
(r= 0.216, p=0.047), peripheral vision (r= 0.243, p=0.025) (as revealed by NEI-VFQ 25) 
and psychosocial impact on competence (as revealed by PIADS). 
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 Vision function status in the areas of near activities (r= 0.348, p<0.001), mental health (r= 
0.267, p=0.014), peripheral vision (r= 0.273, p=0.011), overall composite score (r= 0.226, 
p=0.038) (as revealed by NEI-VFQ 25) are correlated with adaptability (as revealed by 
PIADS). 
 Vision function status in the areas of peripheral vision (r= 0.263, p=0.015) (as revealed by 
NEI-VFQ 25 ) with self-esteem (as revealed by PIADS) 
 The PIADS overall score correlated positively with near activities (r= 0.279, p=0.001), 
mental health (r= 0.225, p=0.038) and peripheral vision (r= 0.284, p=0.008). 
 
Fig 3-56 is a plot of PIADS overall score with the NEI-VFQ 25 composite score at initial 
administration. 
 
Table 33 Correlation between NEI-VFQ 25 Subscale Items and PIADS Subscale Items at 
Initial Administration (i.e. t1=initial) n=85, ARMD Population. Bolded Items Indicate a 
Correlation Coefficient ≥ 0.20 
 PIADS Subscales 

























-0.028 0.797 -0.084 0.444 -0.002 0.986 -0.079 0.474 
General 
Vision 
-0.051 0.644 0.095 0.387 0.074 0.502 0.058 0.601 
Ocular Pain -0.178 0.103 -0.072 0.514 -0.139 0.206 -0.139 0.206 
Near 
Activities 
0.230* 0.035 0.348* <0.001 0.125 0.256 0.279* 0.001 
Distance 
Activities 
0.078 0.477 0.195 0.074 0.002 0.984 0.110 0.314 
Social 
Functioning 
0.216* 0.047 0.147 0.180 0.080 0.467 0.194 0.075 
Mental 
Health 
0.144 0.190 0.267* 0.014 0.130 0.236 0.225* 0.038 
Role 
Difficulties 
0.195 0.074 0.111 0.313 0.115 0.293 0.170 0.120 
Dependency 0.016 0.882 0.005 0.966 -0.089 0.419 0.009 0.934 
Driving -0.051 0.702 -0.015 0.908 -0.140 0.291 -0.081 0.540 
Color Vision 0.043 0.697 -0.047 0.670 -0.141 0.200 -0.039 0.724 
Peripheral 
Vision 




0.177 0.105 0.226* 0.038 0.069 0.529 0.200 0.067 
*Correlation is significant at the 0.05 level (2-tailed). 
 
 
Figure 3-55 Correlations of overall scores between PIADS and NEI-VFQ 25 at initial 
administration for ARMD population. Several modest correlations are present between PIADS 
subscales and NEI-VFQ 25 subscales and overall scores.   
Several weak but significant correlations were found between subscale items for PIADS and NEI-
VFQ 25 at follow-up administration:  
 Vision function status in the areas of general health (r= 0.250, p=0.021), mental health (r= 
0.229, p=0.035), role difficulties (r= 0.253, p=0.019), dependency (r= 0.302, p=0.005), 
overall composite score (r= 0.304, p=0.005) (as revealed by NEI-VFQ 25) and psychosocial 
impact on competence (as revealed by PIADS). 
 Vision function status in the areas of general health (r= 0.300, p=0.005), general vision (r= 
0.298, p=0.006), near activities (r= 0.311, p=0.004), distance activities (r= 0.348, p=0.001), 
mental health (r= 0.315, p=0.003), dependency (r= 0.290, p=0.007), overall composite score 
(r= 0.351, p=0.001) (as revealed by NEI-VFQ 25) are correlated with adaptability (as 
revealed by PIADS). 
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 Vision function status in the areas of general health (r= 0.336, p=0.002), general vision (r= 
0.262, p=0.016), distance activities (r= 0.241, p=0.026), dependency (r= 0.261, p=0.016), 
overall composite score (r= 0.275, p=0.011) (as revealed by NEI-VFQ 25 ) with self-esteem 
(as revealed by PIADS) 
 The PIADS overall score correlated positively with general health (r= 0.328, p=0.002), 
general vision (r= 0.280, p=0.009), near activities (r= 0.234, p=0.031), distance activities (r= 
0.311, p=0.004), mental health (r= 0.288, p=0.007), role difficulties (r= 0.210, p=0.054), 
dependency (r= 0.333, p=0.002), and the NEI-VFQ 25 composite score (r= 0.359, p=0.001).  
 
Fig 3-57 is a plot of PIADS overall score with the NEI-VFQ 25 composite score at follow up 
administration.  
 
Table 34 Correlation between NEI-VFQ 25 Subscale Items and PIADS Subscale Items at 
Follow up Administration (i.e. t2= follow-up). n=85, ARMD Population. Bolded Items Indicate 
a Correlation Coefficient ≥ 0.20 
 PIADS Subscales 

























0.204 0.061 0.298* 0.006 0.262* 0.016 0.280* 
0.009 
Ocular Pain -0.070 0.522 -0.033 0.766 -0.168 0.125 -0.106 0.334 
Near 
Activities 
















0.253* 0.019 0.168 0.123 0.143 0.192 0.210* 
0.054 
Dependency 0.302* 0.005 0.290* 0.007 0.261* 0.016 0.333* 0.002 
Driving 0.175 0.178 0.178 0.171 0.075 0.566 0.169 0.194 
Color Vision 0.067 0.546 0.064 0.562 0.093 0.402 0.095 0.390 
Peripheral 
Vision 




0.304* 0.005 0.351* 0.001 0.275* 0.011 0.359* 
0.001 
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*Correlation is significant at the 0.05 level (2-tailed). 
 
 
Figure 3-56 Correlations of overall scores between PIADS and NEI-VFQ 25 at follow up 
administration for ARMD population. Several modest correlations are present between PIADS 
subscales and NEI-VFQ 25 subscales and overall scores.   
Note: Appendix N includes all detailed correlation tests conducted for both measures.  
3.2.8 Relationship Changes Over Time for PIADS and NEI-VFQ 25  
Table 35 illustrates a significant change is present between times t1 and t2 for the PIADS subscales 
competence (t=-2.998, p=0.004), self-esteem (t= -3.590, p= 0.001), and PIADS overall (t= -2.891, p= 
0.005). In each instance, t2 had a significant higher score, thus indicating that there was a positive 
change at the follow up administration. Negative values denote the follow up administration was 
more positive. No significant changes were present for the Adaptability subscale of PIADS or for 
any of the NEI-VFQ 25 subscale or composite scores.  
 
Table 35 Paired Samples Test assessing whether or not the Relationship between the PIADS 
and NEI-VFQ 25 measures change between t1 and t2. Bolded Values indicate scores for t2 are of 
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Significantly Higher Value. In this case, α= 0.05/17 = 0.003, known as the Bonferroni 
correction, since 17 pairs of tests were run.   








Interval of the 
Difference  t df  
 Sig. (2-
tailed)  
        Lower Upper       
PIADS Subscale 
Competence1 - PIADS 
Subscale Competence2 





Esteem1 - PIADS 
Subscale Self-Esteem2 

















VFQ Composite Score1 - 
VFQ Composite Score2 
.58073 7.44811 .80786 -1.02579 2.18725 .719 84 .474 
Note: Refer to Appendix O for complete list of 17 paired t-tests that were conducted. 
3.3 Overall Comparison of Sample Population versus ARMD Population 
Comparison of the PIADS and NEI-VFQ 25 subscales and overall scores of the ARMD population 
to the overall sample of 120 participants revealed no significant differences. The means of the 
subscales and overall score fall within the 95% Confidence Intervals of the overall population means 
of the subscales and overall score. For the NEI-VFQ 25, no significant differences were found either, 
except for the General Health subscales at both the initial and follow up administrations, where the 
mean scores for these two were just shy of the lower bound of the 95% Confidence Interval. This 
may imply condition plays a role in perceived health. However the scores were just outside the 
interval and further investigation is required to resolve this. It is interesting to note that PIADS 
correlated more strongly with the clinical measures for the ARMD population, whereas there were 
no significant correlations present for the overall sample. In the case of the NEI-VFQ 25, the overall 
sample appeared to correlate better with visual acuity than the ARMD sample, but contrast 
sensitivity correlations were not very different between the samples.  
 
Significant differences were not detected for the correlations for PIADS between t1 and t2, as was the 
case for the NEI-VFQ 25 subscales and composite scores. For the correlations between measures at 
initial administration, no major differences were detected either as the correlations still remained 
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weak but modest at best for the ARMD sample like the overall population. At the follow up 
administration, several more correlations between PIADS and NEI-VFQ 25 were apparent for the 
ARMD sample than the overall population. However, all the correlations between the measures 
remained relatively weak, falling in the range between 0.2-0.4. When it came to assessing the 
relationship over time, the ARMD sample exhibited the same pattern as did the overall population, 
with only significant differences being noted for the competence, self-esteem, and PIADS overall 
scores. Overall, the ARMD population did not illustrate any distinctive difference from the overall 
sample population which encompassed various eye conditions.  
 
Refer to Appendix P for results for Confidence Intervals.  
3.4 Results Summary 
The results of this study are consistent with our previously stated hypotheses. NEI-VFQ 25 
correlated more strongly to clinical measures than the PIADS.  The measures showed stability, as 
indicated by the moderate correlations for the time interval. PIADS was shown to be a more 
responsive measure, able to detect change within the 2 week time interval. Finally, modest 






The ever-increasing prevalence/incidence of low vision in North America is associated with dramatic 
increases in the need for assistive technology device rehabilitation to meet the demands of those who 
wish to improve their quality of life despite functional vision loss. 
 
Both PIADS and NEI-VFQ 25 are reliable and valid self-reported outcome measures that are 
relevant for low vision rehabilitation settings. The NEI-VFQ 25 is used to assess the functional 
vision status of vision loss on the individual’s performance of activities that contribute to their 
quality of life. The PIADS assesses the impact of specific assistive devices on psychosocial factors 
that contribute to quality of life. The PIADS provides a useful administration tool because the 
perceived impact of assistive device interventions is measured relatively independently from the 
device user’s functional condition.  
 
For PIADS, there were no significant changes between the overall population and the ARMD 
population. The study showed PIADS as a reliable tool that is responsive in detecting change as a 
result of device adoption. 
 
The NEI-VFQ 25 was originally developed to assess visual function in those with ocular disease. 
Establishing benchmarks standards, however, is important in comparing a diseased population to one 
without any ocular disease 
30
. There is a significant difference between our low vision cohort and the 
reference group, which confirms that visual function does have an effect on the measures. Significant 
differences are present for most subscales and the NEI-VFQ 25 composite scores at initial and 
follow-up administration. This is consistent with other studies that have compared a diseased cohort 
with a reference group and found that the diseased cohort demonstrates a greater degree of self-
reported visual dysfunction 
44, 51
. It is interesting to note though that the NEI-VFQ 25 was not 
designed to incorporate the impact of type of correction for refractive error on functioning and well 
being 
68
. Comparing the overall sample with a published low vision sample 
44
, reveals no differences 
in General Health and Ocular Pain subscales. General Vision, Near Activities, Distance Activities, 
Peripheral Vision, Color Vision, Role Difficulties, Dependency, Social Functioning, and Mental 
89 
Health are all significantly higher at both time intervals for the study sample. Driving and Role 
Difficulties were the only subscales that had lower subscale scores for the study population. The 
higher subscale scores of the study population may be attributable to the device intervention, since 
the published low vision sample did not receive any form of intervention. The overall study 
population exhibited a ceiling effect for the General Health subscale, while the ARMD sample did 
not. This may suggest that persons with ARMD view their quality of life more negatively than other 
samples. It is interesting to note that when comparing the ARMD sample population to a published 
ARMD sample 
44
, the only subscale with a higher score is Peripheral Vision, and Ocular Pain shows 
no significant difference. Even a study on patients with uveitis reported NEI-VFQ 25 scores lower 
than the referenced ARMD population 
73
. Ceiling effects for both study samples were noted for the 
Ocular Pain, Color Vision, and Peripheral Vision subscales. ARMD is characterized by painless loss 
of the central field of vision, so one might expect it would have little impact on Peripheral Vision 
and Ocular Pain subscales. It is interesting that NEI-VFQ 25 scores for the ARMD subjects with 
assistive devices are lower than those of the published sample. Another study showed patients with 
age-related maculopathy who presented for low vision rehabilitation services have lower NEI-VFQ 
25 scores than those who did not 
72
. Further investigation into this matter is warranted. Mangione et 
al 
44
 present distributions for other ocular conditions as well.  
 
Peripheral vision does not appear to be an issue for the participants in this study. As stated 
previously, 71% of the study participants have ARMD, which rarely interferes with peripheral 
vision. At both initial and follow-up administrations, a substantial ceiling effect was noted (51.7% 
and 48.3% t1 and t2, respectively). A study on quality of life in patients with glaucoma indicated that 
subjects rated peripheral vision loss as less important than other activities associated with central 
vision and outdoor mobility 
7
. Other studies also show that individuals are mainly concerned with 




Moreover, the Driving subscale experienced significant floor effects for both overall and ARMD 
samples, at both administrations. This is likely because most subjects have quit driving and have no 
reasonable expectation that they will be able to resume driving due to the current vision requirements 
for driving in Ontario. This is noteworthy because others have reported an association between 





One of the items in the distance activities subscales asks users to rate their difficulty going down 
steps or stairs in dim light or at night. Studies of quality of life in patients with glaucoma study found 
‘darkness or glare’ to be the chief complaint among the study cohort 
7
. Furthermore, it was found 
that although glaucoma is characterized by central and peripheral vision loss, it is concerns of central 
vision that are most important to the patients even where the peripheral field loss is only rated as 
mild 
7
.  With our subjects, Peripheral Vision does not appear to be the primary complaint since the 
distribution of scores is normal and not skewed   
 
PIADS subscale and overall scores did not show any significant effects across device categories with 
the MANOVA test. These results are consistent with an investigation of the psychosocial impact of 
hearing aids 
78
. The NEI-VFQ 25 subscales also did not show any significant effects across device 
categories with the MANOVA test. Since there is no gold standard for comparing vision-specific 
quality of life measures or even health related quality of life measures, it is important to evaluate 
these data alongside clinical measures such as visual acuity and contrast sensitivity 
24
. No significant 
correlations are present between the PIADS subscales and overall score for visual acuity and contrast 
sensitivity with respect to the overall sample. This finding is consistent with the results of a study 
involving closed circuit television systems (CCTVs) which found no statistically significant 
correlations between PIADS scores and visual acuity 
3
. The ARMD sample did have a few 
significant yet modest correlations between visual acuity and the PIADS subscales of Competence at 
t1 (0.262, p=0.016), Self esteem at t1 (0.258, p=0.018), and PIADS overall at t1 (0.263, p= 0.016). 
These data are presented in Table 27. Only the PIADS subscale of competence at t1 (-0.229, p=0.038) 
is correlated with contrast sensitivity (See Table 28). Consistent with other studies 
63
, it is possible 
that a health related quality of life measure that includes emotional or psychological dimensions, 
such as the PIADS, might detect effects from a study population that are independent of visual acuity  
 
Previous studies confirm the NEI-VFQ 25 to be a reliable and valid tool for clinical research seeking 
to assess vision related related quality of life 
36, 54
. NEI-VFQ 25 has been shown to be sensitive to 
different levels of visual acuity 
44, 47, 50, 71
.The weak correlations show that the NEI-VFQ 25 is not 
directly affected by the severity of a participant’s eye disease, suggesting that the measure is able to 
provide reproducible and valid data when used across multiple eye conditions 
36
. However, in 
another study it was noted that such subscales as General Health, General Vision, Near Vision, 
Distance Vision, and Peripheral Vision are generally worse for subjects with severe ARMD 
87
. A 
study on the quality of life with visual acuity loss from diabetic retinopathy and age related macular 
91 
degeneration reports that the degree of visual acuity loss rather than the underlying disease causing 
the visual acuity loss is primarily responsible for the reduction in quality of life 
94
. In an ARMD 
study, participants with better visual function had higher scores on all the NEI-VFQ 25 subscales, 
especially in the subscales of general vision, near vision, and distance vision 
59
, whereas those in an 
age-related maculopathy study reported lower scores with greater visual acuity impairment 
72
. The 
clinical expectation is that there is an inverse relation between increasing severity of ARMD and 
visual function and quality of life 
74
. The NEI-VFQ 25 has been shown to be sensitive to differences 
in visual acuity 
52
, and is most responsive when visual acuity loss is binocular 
46
. This was also the 
case in another study, where strong correlations of NEI-VFQ 25 composite scores with binocular 
visual acuity were noted 
49
. Strong associations were also reported between best-corrected visual 
acuity and the NEI-VFQ 25 composite and subscale scores associated with central vision in a study 
with people with Diabetes Mellitus 1 
71
. Such data presented here and in previous studies, 
54
 may 
provide additional insight into the application of the NEI-VFQ 25 in a clinical setting to offer 
information about an individual’s health, and further to the objective clinical measurements that are 
normally conducted.  
 
It can be seen that the NEI-VFQ 25 correlates more strongly to visual acuity and contrast sensitivity 
data than the PIADS. This serves as an indicator that a user’s rating of a task or perceived impact 
cannot be accurately predicted by the type or severity of vision loss. This finding is consistent with 
other studies 
7
.  Although the correlations are moderate, the NEI-VFQ 25 seems to be influenced by 
visual function as measured by acuity.  It appears that visual acuity does influence some aspects of 
quality of life, on a more functional level. Significant associations using the NEI-VFQ 25 have been 
found between self-reported morbidity limitation and poor visual acuity and contrast sensitivity tests 
92
. Other studies also confirm that visual acuity is associated with decreased quality of life and that 
self reported decrement in quality of life was present even with modest visual loss 
32
. It can be 
assumed that the level of decrease is associated with the level of visual impairment, since the greater 
the visual loss, the greater decrease in quality of life. In accordance with other studies, the NEI-VFQ 
25 has been shown to be sensitive to visual acuity 
58, 67
. Weak to modest correlations of visual 
measures with NEI-VFQ 25 in this study may be due to the restricted range of visual function of 
participants, as was noted in another study 
59
. The driving subscale for the overall sample 
experienced modest correlations with visual acuity and contrast sensitivity, whereas there were none 
for the ARMD sample. Other studies have shown that the driving subscale is responsive to changes 
in visual acuity 
47
. As well, other measures such as activities of daily living scale have also been 
92 
shown to be sensitive to clinical measures 
95
. It is important to assess the association between visual 
acuity and the measures because visual acuity is widely recognized as a major determinant in vision-
related quality of life, so much so that ophthalmologists rely primarily on visual acuity to plan 
patient management 
59
. Overall, the NEI-VFQ 25 has been shown to discriminate between different 




Both PIADS and NEI-VFQ 25 for the overall and ARMD population exhibited significant 
correlations within the measures, thus illustrating the stability within the measures and that scores 
will be similar between administrations. The research indicates that there although there were several 
significant correlations between the two outcome measures, they were relatively weak to modest 
(range r= 0.20 to 0.353, p<0.05 at initial administration and r =0.203 to 0.292, p <0.05 at follow up 
administration). I was able to safely reject the null hypothesis since there was a significant difference 
and the p-values were less than α. However, the fact that the correlations were not strong confirms 
that the NEI-VFQ 25 and PIADS are relatively independent measures and are attuned to different 
quality of life constructs. On some level they do look at similar domains or otherwise they would not 
have correlated at all. Speculation into what the domains might be can simply be traced back to the 
subscales that had the highest correlations and were present for both initial and follow up 
administrations. As an example, Adaptability (PIADS) with Mental Health (NEI-VFQ 25) correlated 
at both time instances. What’s interesting to note is that some subscales of one measure correlated 
with the other at the first time interval but didn’t at the second. The possibility that the range of the 
scales is restricted warrants for suppression and the low correlations. Further research needs to be 
conducted to explore this relationship. 
 
Significant change over the time period was present for some PIADS subscales but none of the NEI-
VFQ 25 subscales. A change in function (NEI-VFQ 25) should not be expected between initial and 
follow up administrations but should only be expected to change after initial device adoption but 
won’t continue to change afterwards. This is an implication for future research to be conducted in the 
administration of function change pre and post device adoption. On the other hand, perceived impact 
(PIADS) will change positively because suddenly an individual is able to perform activities they 
couldn’t do before, and as a consequence, they will start to feel better and continue to feel better 
about themselves because it is providing a positive impact. This is consistent with the significant 
change that is present (Tables 21 and 35) with PIADS between initial and follow up administrations. 
93 
As a result, it appears there is greater opportunity for detecting change through PIADS as it appears 
to be a more responsive scale when looking at device adoption.  
 
4.1 Limitations 
Normally, it can be assumed that we are sampling randomly from the population. However, because 
of the inclusion/exclusion criteria specified and the source of the sample, this was not the case. The 
selected population was patients of the Low Vision Clinic, which may have posed some bias. There 
exists other low vision populations but due to economic and cost limitations, they may not come for 
an evaluation which they have to pay for, or may be seeking other services, and therefore we were 
not accessible to these. In addition to introduction of a sample bias, we also introduced an age bias 
by limiting our sample to those over the age of 18. The reason for this is to obtain more precise and 
accurate data by ensuring a competent and mature population base.  
 
4.2 Research Shortcomings 
Since we did not randomly sample, we cannot estimate how likely our findings can be generalized to 
the populations with the ocular conditions of those in our study. It should be noted that this type of 
research makes it extremely difficult to ensure random selection due to the nature of the data 
collection and the need for reasonable sample sizes. In the future if the study is to be reproduced, 
subjects should be administered the NEI-VFQ 25 prior to device adoption and then post in order to 
track any robust change that the device may have made. This is currently being investigated for 
future research in this area.  
 
4.3 Conclusion 
The results of this study are consistent with our hypothesis that subjective reports of changes in 
functional status following device acquisition (NEI-VFQ 25 results) will be somewhat correlated 
with self- reported changes in psychosocial status (PIADS results). As was predicted, NEI-VFQ 25 
correlated more strongly to clinical measures than the PIADS. The measures showed stability, as 
indicated by the moderate correlations for the time interval. PIADS was shown to be a more 
responsive measure, able to detect change within the 2 week time interval. These two instruments 
evaluate different but complementary aspects of quality of life. When used in tandem, it is believed 
94 
they provide much greater insight into the impact of device intervention than simply looking at 
changes in functional status. As well, by incorporating self reports of visual functioning and health 
related quality of life into clinical studies, it may be possible to demonstrate the negative effects of 
visual impairment on everyday activities that are not reflected in a clinical measure endpoint such as 
visual acuity 
63
.  Due to the dynamic nature of quality of life, these relationships are expected to 
change over time as people adapt to their newly acquired low vision devices. The longer term data 
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Client Name:         male   female 
(Last name, then first name)      
Diagnosis:      Date of Birth:   ______  
          Month/day/year 
The form is being filled out at  (choose one)  1.  home   2.  a clinic   3.  other (describe):________ 
The form is being filled out by (choose one)  1.  the client, without any help     2.  the client, with 
help from  the caregiver (e.g., client showed or told caregiver what answers to give)     3.  the 
caregiver on behalf of the  client, without any direction from the client     4.  other (describe): _____           
Each word or phrase below describes how using an assistive device may affect a user.  Some might seem 
unusual but it is important that you answer every one of the 26 items.  So, for each word or phrase, put an "X" 
in the appropriate box to show how you are affected by using the ___________________________ (device 
name). 
 
  Decreases  -3 -2 -1 0 1 2 3 Increases 
1)  competence          
2)  happiness          
3)  independence          
4)  adequacy          
5)  confusion          
6)  efficiency          
7)  self-esteem          
8)  productivity          
9)  security                   
10)  frustration          
  
11)  usefulness          
12)  self-confidence                  
13)  expertise          
14)  skillfulness          
15)  well-being          
16)  capability          
17)  quality of life          
18)  performance          
19)  sense of power          
20)  sense of control                  
21)  embarrassment                  
22)  willingness to take chances        
23)  ability to participate         
24)  eagerness to try new things        
25)  ability to adapt to the         
  
 activities of daily living     
26) ability to take advantage                 
 of opportunities        
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The covariance matrix is calculated and used in the analysis.
 
 






















































1.000 .217 .224 .052 -.076 -.163 .126 .082 -.018 .080 .014 -.054
.217 1.000 .238 .265 .216 .055 .192 .319 .267 .260 .098 -.190
.224 .238 1.000 .201 .134 -.049 .070 .274 .044 -.012 .183 .029
.052 .265 .201 1.000 .436 .230 .352 .111 .358 .096 .170 .210
-.076 .216 .134 .436 1.000 .527 .368 .303 .392 .243 .295 .099
-.163 .055 -.049 .230 .527 1.000 .223 .205 .320 .089 .247 -.013
.126 .192 .070 .352 .368 .223 1.000 .373 .345 -.082 .150 .024
.082 .319 .274 .111 .303 .205 .373 1.000 .225 -.082 .350 -.102
-.018 .267 .044 .358 .392 .320 .345 .225 1.000 .315 .319 .031
.080 .260 -.012 .096 .243 .089 -.082 -.082 .315 1.000 .187 .032
.014 .098 .183 .170 .295 .247 .150 .350 .319 .187 1.000 .124


































































































Items N of Items
 
Inter-Item Correlation Matrix
1.000 .243 .203 .030 .075 .157 .150 .216 .111 -.055 .050 -.051
.243 1.000 .198 .135 .254 .263 .351 .357 .352 .088 .115 -.104
.203 .198 1.000 .012 .007 -.128 .088 .220 -.006 -.103 .033 .151
.030 .135 .012 1.000 .436 .181 .372 .189 .396 .121 .290 .331
.075 .254 .007 .436 1.000 .356 .289 .323 .458 .312 .142 .166
.157 .263 -.128 .181 .356 1.000 .250 .399 .305 .273 .224 -.089
.150 .351 .088 .372 .289 .250 1.000 .364 .426 .118 .131 -.007
.216 .357 .220 .189 .323 .399 .364 1.000 .357 .251 .168 .052
.111 .352 -.006 .396 .458 .305 .426 .357 1.000 .301 .353 .056
-.055 .088 -.103 .121 .312 .273 .118 .251 .301 1.000 .185 .162
.050 .115 .033 .290 .142 .224 .131 .168 .353 .185 1.000 .230





















































































N  120 120 120 120 120 120 120 120 
Mean 1.1611 .9764 .8146 .9840 1.3542 1.1028 1.0333 1.1634 
Median 1.2500 1.0000 .8125 .9444 1.2500 1.0000 .8750 1.1181 
Std. Deviation .77354 .73948 .66441 .65886 .71075 .69686 .63340 .60271 
Variance .598 .547 .441 .434 .505 .486 .401 .363 
Skewness -.244 .255 .332 .112 .076 .554 .416 .323 
Std. Error of Skewness .221 .221 .221 .221 .221 .221 .221 .221 
Minimum -1.33 -1.00 -.50 -.82 -.50 -.33 -.13 .08 
Maximum 2.92 3.00 2.63 2.81 2.92 3.00 2.50 2.50 
Percentiles 25 .6667 .5000 .2500 .5451 .8333 .5417 .5000 .6840 
  50 1.2500 1.0000 .8125 .9444 1.2500 1.0000 .8750 1.1181 




































Pain or Discomfor at Initial Assessment Pain Limiting Activities at Initial Assessment
Pain or Discomfort at Follow-Up Assessment Pain Limiting Activities at Follow-Up Assessment  




























Faces at Initial Assessment Going out at Initial Assessment Faces at Follow-Up Assessment Going out at Follow-Up Assessment  






























Worry about sight at Initial Assessment Frustrated at Initial Assessment Less Control at Initial Assessment
Embarassment at Initial Assessment Worry about sight at Follow-Up Assessment Frustrated at Follow-Up Assessment
Less Control at Follow-Up Assessment Embarassment at Follow-Up Assessment  































Accomplish Less at Initial Assessment Limitations at Initial Assessment
Accomplish Less at Follow-Up Assessment Limitations at Follow-Up Assessment  






























Stay Home at Initial Assessment Reliance at Initial Assessment Help at Initial Assessment
Stay Home at Follow-Up Assessment Reliance at Follow-Up Assessment Help at Follow-Up Assessment
 




























Driving at Initial Assessment Driving Night at Initial Assessment
Driving Difficult Conditions at Initial Assessment Driving at Follow-Up Assessment
Driving Night at Follow-Up Assessment Driving Difficult Conditions at Follow-Up Assessment
 




























Recognizing Colours at Initial Assessment Recognizing Colours at Follow-Up Assessment
 

















Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average


























Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average
























Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average
























Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average




























Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average



























Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average


























Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average




























Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average

























Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average


























Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average

























Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average



























Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average


























Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average






















Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average



























Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average


























Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average
























Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average





































Tests of Between-Subjects Effects
2.612
a
5 .522 .882 .497
4.119
b
5 .824 1.821 .119
1.391
c
5 .278 .562 .729
2.306d 5 .461 1.077 .380
2.318
e
5 .464 .945 .457
3.022
f
5 .604 1.404 .233
1.918
g
5 .384 1.033 .405
2.182h 5 .436 1.296 .275
4486.671
i
5 897.334 1.052 .394
2380.502
j
5 476.100 1.089 .373
781.322
k
5 156.264 .271 .928
2424.312
l
5 484.862 1.056 .391
1855.424
m
5 371.085 .752 .587
5063.284
n
5 1012.657 1.212 .312
108.957
o
5 21.791 .032 .999
5852.823
p
5 1170.565 1.663 .154
6919.134
q
5 1383.827 1.548 .186
874.515r 5 174.903 .536 .749
4342.070
s
5 868.414 .894 .490
8281.362
t
5 1656.272 1.804 .122
1001.427u 5 200.285 1.208 .314
7556.116
v
5 1511.223 2.298 .054
845.878
w
5 169.176 .523 .758
1824.352
x
5 364.870 .660 .655
2777.191
y
5 555.438 1.266 .288
1113.330z 5 222.666 .472 .796
6084.117aa 5 1216.823 2.184 .065
951.447bb 5 190.289 .365 .871
6475.869cc 5 1295.174 1.896 .105
5601.108dd 5 1120.222 1.315 .267
528.798bb 5 105.760 .368 .869
4645.497e 5 929.099 .944 .458
8625.112ee 5 1725.022 1.961 .094
1088.491ff 5 217.698 1.448 .217
44.541 1 44.541 75.212 .000
34.424 1 34.424 76.088 .000
21.413 1 21.413 43.287 .000
32.751 1 32.751 76.484 .000
47.350 1 47.350 96.473 .000
32.898 1 32.898 76.414 .000
28.922 1 28.922 77.882 .000
35.979 1 35.979 106.843 .000
121407.794 1 121407.794 142.294 .000
71421.031 1 71421.031 163.427 .000
213222.094 1 213222.094 369.706 .000
83258.114 1 83258.114 181.408 .000
85110.872 1 85110.872 172.544 .000
143773.980 1 143773.980 172.146 .000
96309.844 1 96309.844 142.907 .000
51331.804 1 51331.804 72.941 .000
135207.218 1 135207.218 151.222 .000
1123.243 1 1123.243 3.441 .068
195334.232 1 195334.232 201.105 .000
134806.991 1 134806.991 146.837 .000
97554.885 1 97554.885 588.494 .000
131877.575 1 131877.575 200.543 .000
82477.922 1 82477.922 255.007 .000
188662.926 1 188662.926 341.018 .000
104439.685 1 104439.685 238.129 .000
79348.519 1 79348.519 168.161 .000
131318.384 1 131318.384 235.745 .000
88080.873 1 88080.873 168.831 .000
50182.097 1 50182.097 73.456 .000
107897.960 1 107897.960 126.621 .000
1025.789 1 1025.789 3.565 .063
191488.434 1 191488.434 194.583 .000
141485.023 1 141485.023 160.844 .000
94630.333 1 94630.333 629.438 .000
2.612 5 .522 .882 .497




























































































































Clinical Measures, Correlations and Graphs for Overall Sample 
Population 
Correlations
1 -.368** -.059 .023 -.042 -.029 -.025 .008 -.026 -.016 .040 .141 .102 .279** .250** .098 -.025 .052
.000 .527 .810 .654 .759 .794 .928 .779 .867 .672 .132 .275 .002 .007 .295 .789 .579
116 115 116 116 116 116 116 116 116 116 116 116 116 116 116 116 116 116
-.368** 1 .196* .187* .152 .198* .067 .032 .196* .107 -.136 -.218* .054 -.040 -.022 .009 .050 .084
.000 .033 .041 .098 .031 .467 .730 .033 .245 .140 .017 .558 .667 .813 .926 .586 .364
115 119 119 119 119 119 119 119 119 119 119 119 119 119 119 119 119 119
-.059 .196* 1 .770** .731** .925** .586** .407** .430** .538** .100 .125 -.032 .308** .185* .168 .111 .206*
.527 .033 .000 .000 .000 .000 .000 .000 .000 .277 .174 .726 .001 .043 .067 .229 .024
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
.023 .187* .770** 1 .700** .911** .439** .502** .383** .500** .070 .152 -.007 .350** .182* .081 .217* .148
.810 .041 .000 .000 .000 .000 .000 .000 .000 .447 .097 .939 .000 .047 .381 .017 .108
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
-.042 .152 .731** .700** 1 .884** .518** .409** .587** .567** .020 .185* -.015 .192* .026 .012 .149 .169
.654 .098 .000 .000 .000 .000 .000 .000 .000 .829 .043 .873 .036 .781 .899 .106 .065
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
-.029 .198* .925** .911** .884** 1 .567** .485** .509** .588** .072 .168 -.020 .316** .149 .100 .174 .192*
.759 .031 .000 .000 .000 .000 .000 .000 .000 .434 .067 .826 .000 .104 .278 .057 .035
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
-.025 .067 .586** .439** .518** .567** 1 .692** .771** .930** .106 .145 .045 .079 .120 -.010 .013 .197*
.794 .467 .000 .000 .000 .000 .000 .000 .000 .248 .114 .626 .394 .192 .914 .885 .031
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
.008 .032 .407** .502** .409** .485** .692** 1 .563** .855** .285** .276** .106 .198* .189* -.040 .126 .047
.928 .730 .000 .000 .000 .000 .000 .000 .000 .002 .002 .250 .030 .039 .661 .170 .609
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
-.026 .196* .430** .383** .587** .509** .771** .563** 1 .870** .024 .139 .007 .001 .080 -.052 .000 .145
.779 .033 .000 .000 .000 .000 .000 .000 .000 .797 .129 .943 .992 .387 .572 .998 .114
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
-.016 .107 .538** .500** .567** .588** .930** .855** .870** 1 .160 .212* .061 .107 .148 -.038 .054 .146
.867 .245 .000 .000 .000 .000 .000 .000 .000 .081 .020 .510 .243 .107 .682 .560 .111
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
.040 -.136 .100 .070 .020 .072 .106 .285** .024 .160 1 .179 .134 .124 .029 -.080 .024 .022
.672 .140 .277 .447 .829 .434 .248 .002 .797 .081 .051 .144 .177 .750 .382 .795 .809
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
.141 -.218* .125 .152 .185* .168 .145 .276** .139 .212* .179 1 .236** .244** .231* .067 .232* .209*
.132 .017 .174 .097 .043 .067 .114 .002 .129 .020 .051 .009 .007 .011 .465 .011 .022
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
.102 .054 -.032 -.007 -.015 -.020 .045 .106 .007 .061 .134 .236** 1 .174 .142 -.017 .078 .194*
.275 .558 .726 .939 .873 .826 .626 .250 .943 .510 .144 .009 .058 .121 .856 .397 .033
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
.279** -.040 .308** .350** .192* .316** .079 .198* .001 .107 .124 .244** .174 1 .474** .268** .268** .156
.002 .667 .001 .000 .036 .000 .394 .030 .992 .243 .177 .007 .058 .000 .003 .003 .089
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
.250** -.022 .185* .182* .026 .149 .120 .189* .080 .148 .029 .231* .142 .474** 1 .571** .323** .344**
.007 .813 .043 .047 .781 .104 .192 .039 .387 .107 .750 .011 .121 .000 .000 .000 .000
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
.098 .009 .168 .081 .012 .100 -.010 -.040 -.052 -.038 -.080 .067 -.017 .268** .571** 1 .289** .302**
.295 .926 .067 .381 .899 .278 .914 .661 .572 .682 .382 .465 .856 .003 .000 .001 .001
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
-.025 .050 .111 .217* .149 .174 .013 .126 .000 .054 .024 .232* .078 .268** .323** .289** 1 .420**
.789 .586 .229 .017 .106 .057 .885 .170 .998 .560 .795 .011 .397 .003 .000 .001 .000
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
.052 .084 .206* .148 .169 .192* .197* .047 .145 .146 .022 .209* .194* .156 .344** .302** .420** 1
.579 .364 .024 .108 .065 .035 .031 .609 .114 .111 .809 .022 .033 .089 .000 .001 .000
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
.181 -.054 .075 .055 -.007 .047 .081 .101 .086 .101 -.056 .298** .074 .362** .392** .325** .432** .313**
.051 .563 .415 .554 .938 .607 .381 .273 .353 .275 .540 .001 .421 .000 .000 .000 .000 .000
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
.258* -.292** -.061 -.143 -.142 -.124 .093 .080 .043 .082 .081 .262* -.014 .099 .243* .084 -.085 -.085
.019 .007 .578 .190 .196 .258 .395 .467 .699 .455 .462 .015 .895 .367 .025 .444 .438 .440
83 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
.297** -.110 .163 .021 -.020 .065 .056 .042 -.004 .037 .069 .117 .153 .269** .329** .275** .158 .360**
.001 .237 .077 .820 .825 .485 .544 .649 .967 .689 .456 .207 .096 .003 .000 .002 .087 .000
115 118 119 119 119 119 119 119 119 119 119 119 119 119 119 119 119 119
.022 .240** .095 .171 .107 .137 .071 .094 -.023 .056 -.112 -.192* .089 .243** .154 .114 .131 .056
.811 .009 .300 .062 .247 .135 .439 .309 .804 .543 .222 .036 .335 .008 .092 .215 .154 .543
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
.270** .009 .252** .236** .126 .229* .159 .203* .080 .169 .030 .387** .345** .580** .684** .582** .574** .597**
.003 .924 .005 .009 .171 .012 .083 .026 .384 .065 .743 .000 .000 .000 .000 .000 .000 .000
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
-.002 .010 .177 .199* .144 .192* .216* .306** .266** .296** .653** .186* .207* .140 .193* -.047 -.040 .147
.981 .916 .053 .029 .115 .035 .018 .001 .003 .001 .000 .042 .024 .126 .035 .613 .665 .110
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
.167 -.171 .116 .151 .193* .167 .163 .214* .194* .214* .182* .636** .237** .290** .279** .088 .243** .241**
.074 .063 .205 .100 .035 .069 .075 .019 .034 .019 .046 .000 .009 .001 .002 .342 .007 .008
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
.098 .077 -.087 -.024 -.103 -.078 .049 .075 .003 .049 .101 .114 .776** .120 .127 .033 .056 .102
.295 .408 .346 .791 .261 .398 .595 .415 .976 .594 .274 .214 .000 .191 .168 .722 .545 .267
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
.170 .025 .222* .335** .122 .253** .144 .220* .106 .178 .115 .219* .122 .728** .436** .237** .253** .024
.068 .786 .015 .000 .183 .005 .117 .016 .251 .051 .210 .016 .184 .000 .000 .009 .005 .794
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
.260** -.055 .124 .172 .065 .135 .144 .242** .107 .187* .027 .253** .089 .454** .833** .454** .265** .262**
.005 .554 .176 .061 .479 .142 .116 .008 .246 .040 .767 .005 .333 .000 .000 .000 .003 .004
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
.167 -.131 .190* .135 .138 .171 .036 .081 .023 .054 .142 .246** .041 .243** .405** .440** .268** .396**
.073 .154 .038 .141 .132 .061 .696 .376 .802 .561 .121 .007 .659 .007 .000 .000 .003 .000
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
-.046 .105 .056 .126 .123 .110 .221* .251** .138 .232* .101 .164 .196* .209* .335** .165 .741** .370**
.625 .255 .542 .171 .180 .230 .015 .006 .132 .011 .274 .074 .032 .022 .000 .072 .000 .000
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
.141 -.087 .163 .086 .105 .131 .265** .178 .116 .214* .235** .149 .223* .060 .238** .136 .281** .597**
.131 .346 .076 .353 .255 .154 .003 .051 .207 .019 .010 .105 .014 .514 .009 .138 .002 .000
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
.168 -.035 .125 .138 .082 .128 .225* .165 .203* .223* .016 .206* .031 .340** .372** .290** .349** .346**
.072 .707 .172 .133 .370 .162 .013 .071 .026 .014 .863 .024 .737 .000 .000 .001 .000 .000
116 119 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120
.319** -.266* .014 -.051 -.008 -.015 .025 .048 -.006 .026 .047 .204 -.007 .145 .282** .110 .035 .005
.003 .013 .896 .638 .945 .890 .815 .657 .958 .813 .665 .058 .951 .182 .008 .309 .746 .965
84 87 87 87 87 87 87 87 87 87 87 87 87 87 87 87 87 87
.277** -.134 .230* .079 .091 .150 .079 .068 .088 .088 .083 .012 .113 .295** .246** .276** .159 .295**
.003 .150 .012 .394 .325 .104 .392 .467 .343 .342 .373 .899 .225 .001 .007 .002 .086 .001
114 117 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118
.033 .221* .108 .146 .068 .120 .062 .066 -.003 .049 -.099 -.022 .184* .263** .218* .133 .119 -.004
.728 .015 .240 .111 .464 .193 .502 .476 .973 .599 .284 .810 .045 .004 .017 .147 .195 .968


























































































































































































































































































































































































































































R Sq Linear = 6.96E-4
 
100.0080.0060.0040.0020.000.00














R Sq Linear = 0.018
 
100.0080.0060.0040.0020.000.00














R Sq Linear = 0.047


















R Sq Linear = 0.003
 
100.0080.0060.0040.0020.000.00














R Sq Linear = 0.002
 
100.0080.0060.0040.0020.000.00














R Sq Linear = 4.804E-4
 
200.00150.00100.0050.000.00














R Sq Linear = 7.364E-5
 
100.0080.0060.0040.0020.000.00














R Sq Linear = 0.003
 
100.0080.0060.0040.0020.000.00




















































R Sq Linear = 0.086
 
100.0080.0060.0040.0020.000.00














R Sq Linear = 0.012
 
100.0080.0060.0040.0020.000.00














R Sq Linear = 0.058
 
100.0080.0060.0040.0020.000.00














R Sq Linear = 9.476E-5
 
80.0070.0060.0050.0040.0030.0020.00
































R Sq Linear = 0.006
 
100.0080.0060.0040.0020.000.00






















































































































































R Sq Linear = 0.049
 
100.0080.0060.0040.0020.000.00



















R Sq Linear = 0.002
100.0080.0060.0040.0020.00










































R Sq Linear = 0.01
 
100.0080.0060.0040.0020.000.00



















R Sq Linear = 0.078
 
100.0080.0060.0040.0020.000.00



















R Sq Linear = 0.063
 
200.00150.00100.0050.000.00



















R Sq Linear = 0.01
R Sq Linear = 0.01
 
100.0080.0060.0040.0020.000.00



















R Sq Linear = 6.312E-4
 
100.0080.0060.0040.0020.000.00
































































R Sq Linear = 0.066
 
100.0080.0060.0040.0020.000.00



















R Sq Linear = 0.088
 
100.0080.0060.0040.0020.000.00



















R Sq Linear = 5.038E-4
 
100.0080.0060.0040.0020.000.00



















R Sq Linear = 5.127E-6
 
80.0070.0060.0050.0040.0030.0020.00










































R Sq Linear = 0.01
 
100.0080.0060.0040.0020.000.00








































































































































































































Statistical Tests for Correlations of PIADS and NEI-VFQ Measures 
for Overall Sample Population 
PIADS Initial and Follow up Administration Correlations 
Correlations
1.000 .757** .705** .916** .593** .435** .452** .564**
. .000 .000 .000 .000 .000 .000 .000
120 120 120 120 120 120 120 120
.757** 1.000 .686** .906** .444** .528** .392** .517**
.000 . .000 .000 .000 .000 .000 .000
120 120 120 120 120 120 120 120
.705** .686** 1.000 .869** .508** .422** .613** .572**
.000 .000 . .000 .000 .000 .000 .000
120 120 120 120 120 120 120 120
.916** .906** .869** 1.000 .569** .514** .531** .609**
.000 .000 .000 . .000 .000 .000 .000
120 120 120 120 120 120 120 120
.593** .444** .508** .569** 1.000 .713** .764** .933**
.000 .000 .000 .000 . .000 .000 .000
120 120 120 120 120 120 120 120
.435** .528** .422** .514** .713** 1.000 .576** .857**
.000 .000 .000 .000 .000 . .000 .000
120 120 120 120 120 120 120 120
.452** .392** .613** .531** .764** .576** 1.000 .866**
.000 .000 .000 .000 .000 .000 . .000
120 120 120 120 120 120 120 120
.564** .517** .572** .609** .933** .857** .866** 1.000
.000 .000 .000 .000 .000 .000 .000 .














































































NEI-VFQ 25 Initial and Follow Up Administration Correlations 
148 
Correlations
1.000 .186* .092 .153 .038 -.049 .019 .014 -.050 .119 .049 -.088 .045 .670** .185* .082 .146
. .042 .317 .096 .677 .595 .840 .876 .584 .280 .595 .338 .625 .000 .044 .371 .112
120 120 120 120 120 120 120 120 120 85 119 120 120 120 120 120 120
.186* 1.000 .228* .271** .216* .125 .231* .174 .303** .281** .092 -.170 .396** .181* .665** .137 .254
.042 . .012 .003 .018 .173 .011 .057 .001 .009 .319 .064 .000 .048 .000 .135 .005
120 120 120 120 120 120 120 120 120 85 119 120 120 120 120 120 120
.092 .228* 1.000 .237** .151 .089 .082 .159 .078 .033 .148 .146 .384** .167 .229* .745** .177
.317 .012 . .009 .099 .336 .370 .083 .398 .762 .108 .112 .000 .068 .012 .000 .053
120 120 120 120 120 120 120 120 120 85 119 120 120 120 120 120 120
.153 .271** .237** 1.000 .471** .364** .266** .177 .359** .107 .271** .243** .585** .146 .285** .185* .737
.096 .003 .009 . .000 .000 .003 .053 .000 .331 .003 .007 .000 .112 .002 .043 .000
120 120 120 120 120 120 120 120 120 85 119 120 120 120 120 120 120
.038 .216* .151 .471** 1.000 .629** .292** .309** .395** .273* .329** .178 .640** .179* .270** .109 .416
.677 .018 .099 .000 . .000 .001 .001 .000 .012 .000 .052 .000 .050 .003 .238 .000
120 120 120 120 120 120 120 120 120 85 119 120 120 120 120 120 120
-.049 .125 .089 .364** .629** 1.000 .294** .372** .338** .083 .330** .239** .664** -.001 .102 .102 .298
.595 .173 .336 .000 .000 . .001 .000 .000 .451 .000 .009 .000 .988 .269 .269 .001
120 120 120 120 120 120 120 120 120 85 119 120 120 120 120 120 120
.019 .231* .082 .266** .292** .294** 1.000 .414** .413** -.057 .173 .113 .561** -.015 .259** .071 .260
.840 .011 .370 .003 .001 .001 . .000 .000 .603 .060 .219 .000 .871 .004 .439 .004
120 120 120 120 120 120 120 120 120 85 119 120 120 120 120 120 120
.014 .174 .159 .177 .309** .372** .414** 1.000 .300** -.072 .385** .092 .603** .142 .236** .062 .032
.876 .057 .083 .053 .001 .000 .000 . .001 .514 .000 .315 .000 .123 .009 .502 .731
120 120 120 120 120 120 120 120 120 85 119 120 120 120 120 120 120
-.050 .303** .078 .359** .395** .338** .413** .300** 1.000 .368** .332** .065 .627** -.031 .346** .015 .319
.584 .001 .398 .000 .000 .000 .000 .001 . .001 .000 .478 .000 .734 .000 .867 .000
120 120 120 120 120 120 120 120 120 85 119 120 120 120 120 120 120
.119 .281** .033 .107 .273* .083 -.057 -.072 .368** 1.000 .139 -.023 .304** .024 .167 -.106 .026
.280 .009 .762 .331 .012 .451 .603 .514 .001 . .206 .835 .005 .829 .126 .336 .811
85 85 85 85 85 85 85 85 85 85 84 85 85 85 85 85
.049 .092 .148 .271** .329** .330** .173 .385** .332** .139 1.000 .199* .602** -.053 .151 .068 .215
.595 .319 .108 .003 .000 .000 .060 .000 .000 .206 . .030 .000 .569 .100 .460 .019
119 119 119 119 119 119 119 119 119 84 119 119 119 119 119 119 119
-.088 -.170 .146 .243** .178 .239** .113 .092 .065 -.023 .199* 1.000 .370** -.023 -.085 .202* .158
.338 .064 .112 .007 .052 .009 .219 .315 .478 .835 .030 . .000 .805 .357 .027 .085
120 120 120 120 120 120 120 120 120 85 119 120 120 120 120 120 120
.045 .396** .384** .585** .640** .664** .561** .603** .627** .304** .602** .370** 1.000 .070 .398** .265** .440
.625 .000 .000 .000 .000 .000 .000 .000 .000 .005 .000 .000 . .450 .000 .003 .000
120 120 120 120 120 120 120 120 120 85 119 120 120 120 120 120 120
.670** .181* .167 .146 .179* -.001 -.015 .142 -.031 .024 -.053 -.023 .070 1.000 .302** .013 .143
.000 .048 .068 .112 .050 .988 .871 .123 .734 .829 .569 .805 .450 . .001 .887 .120
120 120 120 120 120 120 120 120 120 85 119 120 120 120 120 120 120
.185* .665** .229* .285** .270** .102 .259** .236** .346** .167 .151 -.085 .398** .302** 1.000 .175 .237
.044 .000 .012 .002 .003 .269 .004 .009 .000 .126 .100 .357 .000 .001 . .055 .009
120 120 120 120 120 120 120 120 120 85 119 120 120 120 120 120 120
.082 .137 .745** .185* .109 .102 .071 .062 .015 -.106 .068 .202* .265** .013 .175 1.000 .113
.371 .135 .000 .043 .238 .269 .439 .502 .867 .336 .460 .027 .003 .887 .055 . .221
120 120 120 120 120 120 120 120 120 85 119 120 120 120 120 120 120
.146 .254** .177 .737** .416** .298** .260** .032 .319** .026 .215* .158 .440** .143 .237** .113 1.000
.112 .005 .053 .000 .000 .001 .004 .731 .000 .811 .019 .085 .000 .120 .009 .221
120 120 120 120 120 120 120 120 120 85 119 120 120 120 120 120 120
.047 .250** .092 .453** .827** .481** .233* .214* .291** .245* .268** .074 .516** .171 .214* -.006 .483
.608 .006 .317 .000 .000 .000 .010 .019 .001 .024 .003 .423 .000 .062 .019 .952 .000
120 120 120 120 120 120 120 120 120 85 119 120 120 120 120 120 120
.134 .249** .030 .242** .367** .482** .256** .371** .380** .220* .326** .009 .486** .203* .214* -.139 .206
.144 .006 .743 .008 .000 .000 .005 .000 .000 .043 .000 .924 .000 .026 .019 .130 .024
120 120 120 120 120 120 120 120 120 85 119 120 120 120 120 120 120
.103 .159 .177 .212* .305** .180* .740** .380** .355** .074 .185* .164 .516** .131 .222* .059 .221
.263 .082 .053 .020 .001 .049 .000 .000 .000 .504 .044 .074 .000 .155 .015 .523 .015
120 120 120 120 120 120 120 120 120 85 119 120 120 120 120 120 120
.242** .157 .197* .087 .214* .212* .279** .591** .201* .171 .351** .142 .462** .159 .216* .100 .058
.008 .087 .031 .345 .019 .020 .002 .000 .027 .117 .000 .121 .000 .083 .018 .275 .531
120 120 120 120 120 120 120 120 120 85 119 120 120 120 120 120 120
.026 .230* .052 .340** .366** .296** .324** .342** .764** .273* .344** .091 .564** .065 .348** .030 .330
.778 .011 .576 .000 .000 .001 .000 .000 .000 .011 .000 .326 .000 .483 .000 .746 .000
120 120 120 120 120 120 120 120 120 85 119 120 120 120 120 120 120
.103 .274* .028 .124 .285** .108 .002 -.015 .380** .998** .146 .000 .311** -.012 .151 -.072 .051
.343 .010 .799 .253 .007 .319 .988 .893 .000 .000 .180 .998 .003 .914 .162 .509 .638
87 87 87 87 87 87 87 87 87 81 86 87 87 87 87 87
.096 .010 .078 .314** .262** .339** .171 .319** .329** .128 .806** .221* .531** .022 .128 .070 .266
.302 .918 .399 .001 .004 .000 .063 .000 .000 .246 .000 .016 .000 .815 .166 .449 .004
118 118 118 118 118 118 118 118 118 84 118 118 118 118 118 118 118
-.058 -.020 .256** .258** .229* .226* .092 .020 .165 .121 .211* .783** .364** -.009 -.087 .238** .275
.529 .826 .005 .004 .012 .013 .318 .830 .072 .270 .021 .000 .000 .926 .347 .009 .002
120 120 120 120 120 120 120 120 120 85 119 120 120 120 120 120 120
.134 .357** .377** .495** .528** .447** .442** .482** .565** .331** .555** .332** .843** .169 .428** .269** .495
.145 .000 .000 .000 .000 .000 .000 .000 .000 .002 .000 .000 .000 .065 .000 .003 .000







































































































































































Correlation is significant at the 0.05 level (2-tailed).*. 
Correlation is significant at the 0.01 level (2-tailed).**. 
 
PIADS and NEI-VFQ at Initial Administration 
149 
Correlations
1.000 .757** .705**.916** .092 .057 -.076 .290** .132 .211* .101 .192* .055 .017 .118 .131 .215*
. .000 .000 .000 .319 .539 .410 .001 .152 .020 .272 .036 .548 .881 .202 .153 .018
120 120 120 120 120 120 120 120 120 120 120 120 120 85 119 120 120
.757**1.000 .686**.906** .050 .143 -.035 .353** .163 .151 .240** .149 .081 -.051 -.029 .199* .233*
.000 . .000 .000 .586 .119 .704 .000 .075 .100 .008 .105 .377 .641 .755 .029 .010
120 120 120 120 120 120 120 120 120 120 120 120 120 85 119 120 120
.705** .686**1.000 .869** .009 .165 -.072 .208* .014 .057 .154 .166 .020 -.063 -.081 .135 .117
.000 .000 . .000 .920 .072 .437 .023 .882 .537 .094 .070 .833 .569 .379 .142 .204
120 120 120 120 120 120 120 120 120 120 120 120 120 85 119 120 120
.916** .906** .869**1.000 .039 .138 -.060 .321** .118 .168 .200* .201* .076 -.035 .011 .167 .226*
.000 .000 .000 . .671 .132 .517 .000 .198 .067 .028 .027 .407 .750 .903 .069 .013
120 120 120 120 120 120 120 120 120 120 120 120 120 85 119 120 120
.092 .050 .009 .039 1.000 .186* .092 .153 .038 -.049 .019 .014 -.050 .119 .049 -.088 .045
.319 .586 .920 .671 . .042 .317 .096 .677 .595 .840 .876 .584 .280 .595 .338 .625
120 120 120 120 120 120 120 120 120 120 120 120 120 85 119 120 120
.057 .143 .165 .138 .186* 1.000 .228* .271** .216* .125 .231* .174 .303** .281** .092 -.170 .396**
.539 .119 .072 .132 .042 . .012 .003 .018 .173 .011 .057 .001 .009 .319 .064 .000
120 120 120 120 120 120 120 120 120 120 120 120 120 85 119 120 120
-.076 -.035 -.072-.060 .092 .228* 1.000 .237** .151 .089 .082 .159 .078 .033 .148 .146 .384**
.410 .704 .437 .517 .317 .012 . .009 .099 .336 .370 .083 .398 .762 .108 .112 .000
120 120 120 120 120 120 120 120 120 120 120 120 120 85 119 120 120
.290** .353** .208*.321** .153 .271** .237**1.000 .471** .364** .266** .177 .359** .107 .271** .243** .585**
.001 .000 .023 .000 .096 .003 .009 . .000 .000 .003 .053 .000 .331 .003 .007 .000
120 120 120 120 120 120 120 120 120 120 120 120 120 85 119 120 120
.132 .163 .014 .118 .038 .216* .151 .471**1.000 .629** .292** .309** .395** .273* .329** .178 .640**
.152 .075 .882 .198 .677 .018 .099 .000 . .000 .001 .001 .000 .012 .000 .052 .000
120 120 120 120 120 120 120 120 120 120 120 120 120 85 119 120 120
.211* .151 .057 .168 -.049 .125 .089 .364** .629**1.000 .294** .372** .338** .083 .330** .239** .664**
.020 .100 .537 .067 .595 .173 .336 .000 .000 . .001 .000 .000 .451 .000 .009 .000
120 120 120 120 120 120 120 120 120 120 120 120 120 85 119 120 120
.101 .240** .154 .200* .019 .231* .082 .266** .292** .294**1.000 .414** .413**-.057 .173 .113 .561**
.272 .008 .094 .028 .840 .011 .370 .003 .001 .001 . .000 .000 .603 .060 .219 .000
120 120 120 120 120 120 120 120 120 120 120 120 120 85 119 120 120
.192* .149 .166 .201* .014 .174 .159 .177 .309** .372** .414**1.000 .300**-.072 .385** .092 .603**
.036 .105 .070 .027 .876 .057 .083 .053 .001 .000 .000 . .001 .514 .000 .315 .000
120 120 120 120 120 120 120 120 120 120 120 120 120 85 119 120 120
.055 .081 .020 .076 -.050 .303** .078 .359** .395** .338** .413** .300**1.000 .368** .332** .065 .627**
.548 .377 .833 .407 .584 .001 .398 .000 .000 .000 .000 .001 . .001 .000 .478 .000
120 120 120 120 120 120 120 120 120 120 120 120 120 85 119 120 120
.017 -.051 -.063-.035 .119 .281** .033 .107 .273* .083 -.057 -.072 .368**1.000 .139 -.023 .304**
.881 .641 .569 .750 .280 .009 .762 .331 .012 .451 .603 .514 .001 . .206 .835 .005
85 85 85 85 85 85 85 85 85 85 85 85 85 85 84 85 85
.118 -.029 -.081 .011 .049 .092 .148 .271** .329** .330** .173 .385** .332** .139 1.000 .199* .602**
.202 .755 .379 .903 .595 .319 .108 .003 .000 .000 .060 .000 .000 .206 . .030 .000
119 119 119 119 119 119 119 119 119 119 119 119 119 84 119 119 119
.131 .199* .135 .167 -.088 -.170 .146 .243** .178 .239** .113 .092 .065 -.023 .199* 1.000 .370**
.153 .029 .142 .069 .338 .064 .112 .007 .052 .009 .219 .315 .478 .835 .030 . .000
120 120 120 120 120 120 120 120 120 120 120 120 120 85 119 120 120
.215* .233* .117 .226* .045 .396** .384** .585** .640** .664** .561** .603** .627** .304** .602** .370**1.000
.018 .010 .204 .013 .625 .000 .000 .000 .000 .000 .000 .000 .000 .005 .000 .000 .



































































VFQ Subscale Dis ance
Activities1





























































Correlation is significant at the 0.01 level (2-tailed).**. 
Correlation is significant at the 0.05 level (2-tailed).*. 
 
 
PIADS and NEI-VFQ 25 at Follow Up Administration 
150 
Correlations
1.000 .713** .764**.933** .203* .153 .018 .128 .151 .017 .187* .261** .212* .078 .081 .087 .274**
. .000 .000 .000 .026 .096 .848 .165 .100 .851 .041 .004 .020 .473 .385 .344 .002
120 120 120 120 120 120 120 120 120 120 120 120 120 87 118 120 120
.713**1.000 .576**.857** .292** .164 .045 .244** .259** .023 .212* .161 .150 .086 .057 .074 .271**
.000 . .000 .000 .001 .073 .629 .007 .004 .799 .020 .079 .102 .430 .537 .422 .003
120 120 120 120 120 120 120 120 120 120 120 120 120 87 118 120 120
.764** .576**1.000 .866** .237** .179 -.063 .078 .108 -.001 .129 .081 .190* .031 .060 .005 .152
.000 .000 . .000 .009 .051 .493 .400 .242 .992 .160 .381 .038 .778 .517 .959 .098
120 120 120 120 120 120 120 120 120 120 120 120 120 87 118 120 120
.933** .857** .866**1.000 .271** .183* .000 .179 .210* .020 .215* .203* .218* .071 .082 .076 .281**
.000 .000 .000 . .003 .045 .998 .051 .021 .826 .018 .026 .017 .515 .379 .408 .002
120 120 120 120 120 120 120 120 120 120 120 120 120 87 118 120 120
.203* .292** .237**.271**1.000 .302** .013 .143 .171 .203* .131 .159 .065 -.012 .022 -.009 .169
.026 .001 .009 .003 . .001 .887 .120 .062 .026 .155 .083 .483 .914 .815 .926 .065
120 120 120 120 120 120 120 120 120 120 120 120 120 87 118 120 120
.153 .164 .179 .183* .302**1.000 .175 .237** .214* .214* .222* .216* .348** .151 .128 -.087 .428**
.096 .073 .051 .045 .001 . .055 .009 .019 .019 .015 .018 .000 .162 .166 .347 .000
120 120 120 120 120 120 120 120 120 120 120 120 120 87 118 120 120
.018 .045 -.063 .000 .013 .175 1.000 .113 -.006 -.139 .059 .100 .030 -.072 .070 .238** .269**
.848 .629 .493 .998 .887 .055 . .221 .952 .130 .523 .275 .746 .509 .449 .009 .003
120 120 120 120 120 120 120 120 120 120 120 120 120 87 118 120 120
.128 .244** .078 .179 .143 .237** .113 1.000 .483** .206* .221* .058 .330** .051 .266** .275** .495**
.165 .007 .400 .051 .120 .009 .221 . .000 .024 .015 .531 .000 .638 .004 .002 .000
120 120 120 120 120 120 120 120 120 120 120 120 120 87 118 120 120
.151 .259** .108 .210* .171 .214* -.006 .483**1.000 .379** .264** .236** .359** .265* .188* .217* .531**
.100 .004 .242 .021 .062 .019 .952 .000 . .000 .004 .009 .000 .013 .042 .017 .000
120 120 120 120 120 120 120 120 120 120 120 120 120 87 118 120 120
.017 .023 -.001 .020 .203* .214* -.139 .206* .379**1.000 .321** .416** .355** .235* .280** .048 .560**
.851 .799 .992 .826 .026 .019 .130 .024 .000 . .000 .000 .000 .028 .002 .601 .000
120 120 120 120 120 120 120 120 120 120 120 120 120 87 118 120 120
.187* .212* .129 .215* .131 .222* .059 .221* .264** .321**1.000 .372** .427** .107 .118 .097 .544**
.041 .020 .160 .018 .155 .015 .523 .015 .004 .000 . .000 .000 .324 .201 .292 .000
120 120 120 120 120 120 120 120 120 120 120 120 120 87 118 120 120
.261** .161 .081 .203* .159 .216* .100 .058 .236** .416** .372**1.000 .295** .214* .249** .138 .602**
.004 .079 .381 .026 .083 .018 .275 .531 .009 .000 .000 . .001 .047 .007 .133 .000
120 120 120 120 120 120 120 120 120 120 120 120 120 87 118 120 120
.212* .150 .190* .218* .065 .348** .030 .330** .359** .355** .427** .295**1.000 .307**.343** .125 .673**
.020 .102 .038 .017 .483 .000 .746 .000 .000 .000 .000 .001 . .004 .000 .175 .000
120 120 120 120 120 120 120 120 120 120 120 120 120 87 118 120 120
.078 .086 .031 .071 -.012 .151 -.072 .051 .265* .235* .107 .214* .307**1.000 .158 .120 .365**
.473 .430 .778 .515 .914 .162 .509 .638 .013 .028 .324 .047 .004 . .147 .270 .001
87 87 87 87 87 87 87 87 87 87 87 87 87 87 86 87 87
.081 .057 .060 .082 .022 .128 .070 .266** .188* .280** .118 .249** .343** .1581.000 .207* .567**
.385 .537 .517 .379 .815 .166 .449 .004 .042 .002 .201 .007 .000 .147 . .025 .000
118 118 118 118 118 118 118 118 118 118 118 118 118 86 118 118 118
.087 .074 .005 .076 -.009 -.087 .238** .275** .217* .048 .097 .138 .125 .120 .207*1.000 .413**
.344 .422 .959 .408 .926 .347 .009 .002 .017 .601 .292 .133 .175 .270 .025 . .000
120 120 120 120 120 120 120 120 120 120 120 120 120 87 118 120 120
.274** .271** .152 .281** .169 .428** .269** .495** .531** .560** .544** .602** .673** .365**.567** .413**1.000
.002 .003 .098 .002 .065 .000 .003 .000 .000 .000 .000 .000 .000 .001 .000 .000 .
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Correlation is significant at the 0.01 level (2-tailed).**. 




Change in Time for PIADS and NEI-VFQ 25 for Overall Sample 
Population 
Paired Samples Test
-.19306 .67769 .06186 -.31555 -.07056 -3.121 119 .002
-.12639 .71759 .06551 -.25610 .00332 -1.929 119 .056
-.21875 .59037 .05389 -.32546 -.11204 -4.059 119 .000
-.17940 .57467 .05246 -.28327 -.07552 -3.420 119 .001
-2.29167 23.59404 2.15383 -6.55647 1.97314 -1.064 119 .289
-2.66667 16.38473 1.49571 -5.62833 .29500 -1.783 119 .077
2.04167 15.19821 1.38740 -.70553 4.78886 1.472 119 .144
-3.33333 17.16346 1.56680 -6.43576 -.23091 -2.127 119 .035
-.06944 12.90750 1.17829 -2.40257 2.26368 -.059 119 .953
3.22917 28.82940 2.63175 -1.98196 8.44030 1.227 119 .222
-1.04167 17.59080 1.60581 -4.22134 2.13800 -.649 119 .518
-.20833 25.26037 2.30595 -4.77434 4.35767 -.090 119 .928
1.87500 19.81658 1.80900 -1.70700 5.45700 1.036 119 .302
.15432 8.34490 .92721 -1.69089 1.99953 .166 80 .868
-1.48305 20.74787 1.91000 -5.26570 2.29960 -.776 117 .439
.00000 20.24015 1.84766 -3.65856 3.65856 .000 119 1.000































































































PIADS Frequency Distributions for ARMD Sample 
Statistics
85 85 85 85 85 85 85 85
289 289 289 289 289 289 289 289
1.1137 .9804 .8118 .9686 1.3402 1.0804 1.03971.1534
1.0833 1.0000 .8750 .9167 1.2500 .8333 1.00001.1111
.71684 .73886 .63873.63138 .70737 .68120 .62387.59867
.514 .546 .408 .399 .500 .464 .389 .358
.096 .453 .099 .278 .197 .679 .413 .349
.261 .261 .261 .261 .261 .261 .261 .261
.5417 .4167 .2500 .5556 .8333 .5000 .6250 .7153
1.0833 1.0000 .8750 .9167 1.2500 .8333 1.00001.1111







































NEI-VFQ 25 Frequency Distributions for ARMD Sample 
Statistics
85 85 85 85 85 85 85 85 85 59 84 85 85 85 85 85 85 85 85 85 85 85 61 84
289 289 289 289 289 289 289289 289 315290289 289289 289 289 289 289289 289289 289 313290
52.058844.000086.235349.068647.892263.529454.485339.117658.82354.166772.321480.882456.084555.882447.058885.000052.10784 .35296.029455.661837.05886.07845.327975.2976
50.00004 .00001 .00005 .00005 .000062.500056.250037.500058.3333.000075.0000100.000056.666750.00004 .00001 .00005 .00005 .000062.500056.250037.50005 .0000. 0075.0000
28.4028619.223002.1857122.8070723.3466532.5166925.7081927.4667231.0303916.2114633.3875228.7764014.9758327.7228716.5344921.7192623.5142522.1307123. 493523. 759528. 606129.8914518.0041729.42574
806.723369.524492.206520.162545.0661057.335660.911754.421962.885262.8111 4.727828.081224.276768.557273.389471.726552.920489.7685 4.032555.825838.717893.499324.15086 .874
.234.409-1.580.104.1301.042-.218.169-.2274.583-.857-1.436.000.000.032-1.539.121.124.172 -.258.456-.0923.797-.932
.261.261.261.261.261.261.261.261.261 .311.263.261.261.261.261.261.261.261.261 .261.261.261 .306.263
25.00002 .000075.000033.3333.33337.500037.500012.500033.3333.000050.000075. 00045.871250.00004 .000075.000033.3333.33337.500037.500012.500033.3333.00005 .0000
50.00004 .00001 .00005 .00005 .000062.500056.250037.500058.3333.000075.0000100.000056.666750.00004 .00001 .00005 .00005 .000062.500056.250037.50005 .0000. 0075.0000










































































































Clinical Measures and Correlations for ARMD Sample Population 
Correlations
1 -.269* -.229* -.005 -.193 -.153 -.041 .061 -.074 -.019 .031 .238* .334** .311** .234* .073 -.005 -.092
.015 .038 .965 .083 .171 .712 .584 .510 .868 .785 .031 .002 .004 .034 .512 .967 .412
82 81 82 82 82 82 82 82 82 82 82 82 82 82 82 82 82 82
-.269* 1 .262* .197 .258* .263* .024 -.103 .164 .027 -.262* -.248* .048 .003 -.034 .043 .043 .186
.015 .016 .072 .018 .016 .829 .350 .135 .804 .016 .023 .663 .976 .756 .696 .698 .090
81 84 84 84 84 84 84 84 84 84 84 84 84 84 84 84 84 84
-.229* .262* 1 .781** .704** .921** .522** .322** .420** .474** -.007 -.023 -.136 .222* .143 .148 .137 .188
.038 .016 .000 .000 .000 .000 .003 .000 .000 .951 .832 .216 .041 .190 .176 .213 .084
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
-.005 .197 .781** 1 .686** .917** .409** .468** .394** .475** -.048 .081 -.046 .333** .219* .089 .236* .116
.965 .072 .000 .000 .000 .000 .000 .000 .000 .665 .461 .674 .002 .044 .420 .030 .288
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
-.193 .258* .704** .686** 1 .871** .469** .377** .570** .526** -.017 .038 -.083 .102 .022 .000 .109 .089
.083 .018 .000 .000 .000 .000 .000 .000 .000 .875 .731 .452 .353 .841 .996 .322 .420
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
-.153 .263* .921** .917** .871** 1 .515** .431** .505** .542** -.027 .036 -.097 .249* .147 .091 .180 .147
.171 .016 .000 .000 .000 .000 .000 .000 .000 .806 .747 .376 .022 .178 .409 .099 .181
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
-.041 .024 .522** .409** .469** .515** 1 .671** .799** .926** .067 .103 .000 .047 .127 -.075 -.024 .137
.712 .829 .000 .000 .000 .000 .000 .000 .000 .541 .348 .997 .672 .246 .497 .831 .212
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
.061 -.103 .322** .468** .377** .431** .671** 1 .612** .856** .243* .287** .049 .201 .204 -.082 .163 -.008
.584 .350 .003 .000 .000 .000 .000 .000 .000 .025 .008 .653 .065 .061 .455 .135 .939
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
-.074 .164 .420** .394** .570** .505** .799** .612** 1 .894** -.024 .121 .000 .012 .169 -.019 -.014 .109
.510 .135 .000 .000 .000 .000 .000 .000 .000 .831 .272 .997 .912 .122 .860 .902 .320
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
-.019 .027 .474** .475** .526** .542** .926** .856** .894** 1 .110 .191 .018 .099 .186 -.067 .048 .089
.868 .804 .000 .000 .000 .000 .000 .000 .000 .315 .079 .867 .368 .088 .540 .663 .420
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
.031 -.262* -.007 -.048 -.017 -.027 .067 .243* -.024 .110 1 .181 .155 .126 .003 -.091 .122 .000
.785 .016 .951 .665 .875 .806 .541 .025 .831 .315 .097 .156 .252 .979 .408 .265 .997
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
.238* -.248* -.023 .081 .038 .036 .103 .287** .121 .191 .181 1 .276* .307** .309** .055 .334** .258*
.031 .023 .832 .461 .731 .747 .348 .008 .272 .079 .097 .011 .004 .004 .616 .002 .017
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
.334** .048 -.136 -.046 -.083 -.097 .000 .049 .000 .018 .155 .276* 1 .297** .228* -.032 .199 .254*
.002 .663 .216 .674 .452 .376 .997 .653 .997 .867 .156 .011 .006 .036 .773 .068 .019
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
.311** .003 .222* .333** .102 .249* .047 .201 .012 .099 .126 .307** .297** 1 .465** .216* .280** .190
.004 .976 .041 .002 .353 .022 .672 .065 .912 .368 .252 .004 .006 .000 .047 .009 .081
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
.234* -.034 .143 .219* .022 .147 .127 .204 .169 .186 .003 .309** .228* .465** 1 .554** .350** .359**
.034 .756 .190 .044 .841 .178 .246 .061 .122 .088 .979 .004 .036 .000 .000 .001 .001
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
.073 .043 .148 .089 .000 .091 -.075 -.082 -.019 -.067 -.091 .055 -.032 .216* .554** 1 .313** .306**
.512 .696 .176 .420 .996 .409 .497 .455 .860 .540 .408 .616 .773 .047 .000 .004 .004
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
-.005 .043 .137 .236* .109 .180 -.024 .163 -.014 .048 .122 .334** .199 .280** .350** .313** 1 .473**
.967 .698 .213 .030 .322 .099 .831 .135 .902 .663 .265 .002 .068 .009 .001 .004 .000
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
-.092 .186 .188 .116 .089 .147 .137 -.008 .109 .089 .000 .258* .254* .190 .359** .306** .473** 1
.412 .090 .084 .288 .420 .181 .212 .939 .320 .420 .997 .017 .019 .081 .001 .004 .000
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
.117 .018 -.016 -.046 -.126 -.066 .114 .156 .119 .146 -.046 .333** .202 .294** .318** .314** .443** .337**
.295 .871 .885 .678 .250 .546 .299 .154 .276 .184 .675 .002 .064 .006 .003 .003 .000 .002
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
.197 -.196 -.139 -.126 -.234 -.181 .230 .210 .143 .223 .280* .309* .168 .136 .198 .051 .004 -.004
.137 .136 .295 .341 .074 .171 .080 .111 .279 .089 .032 .017 .203 .304 .134 .699 .974 .974
58 59 59 59 59 59 59 59 59 59 59 59 59 59 59 59 59 59
.187 -.081 .027 -.042 -.122 -.047 .015 .028 .028 .026 .030 .122 .242* .197 .270* .272* .182 .352**
.095 .466 .807 .705 .270 .668 .891 .802 .797 .811 .789 .270 .027 .072 .013 .012 .097 .001
81 83 84 84 84 84 84 84 84 84 84 84 84 84 84 84 84 84
.079 .164 .182 .218* .237* .234* .182 .115 .180 .178 -.015 -.118 .133 .237* .144 .069 .173 .200
.483 .135 .095 .045 .029 .031 .096 .296 .100 .104 .892 .281 .225 .029 .188 .530 .114 .067
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
.242* .049 .173 .208 .055 .165 .129 .194 .146 .175 .053 .452** .452** .561** .653** .557** .632** .644**
.028 .660 .114 .056 .618 .131 .241 .074 .183 .109 .630 .000 .000 .000 .000 .000 .000 .000
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
-.027 .000 .169 .153 .194 .189 .298** .340** .356** .370** .599** .212 .246* .207 .249* -.015 .070 .139
.807 .997 .121 .161 .076 .083 .006 .001 .001 .000 .000 .051 .023 .057 .021 .891 .527 .205
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
.227* -.160 .013 .122 .099 .086 .221* .347** .258* .309** .184 .689** .283** .228* .309** .069 .320** .191
.040 .145 .902 .266 .367 .433 .042 .001 .017 .004 .092 .000 .009 .036 .004 .528 .003 .080
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
.360** -.019 -.111 -.028 -.136 -.099 -.016 .002 -.063 -.027 .093 .188 .743** .274* .244* .054 .160 .141
.001 .866 .310 .800 .214 .368 .886 .985 .569 .805 .398 .085 .000 .011 .025 .625 .143 .198
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
.260* .030 .154 .341** .123 .233* .181 .290** .199 .250* .083 .284** .186 .731** .445** .210 .262* .127
.019 .786 .158 .001 .261 .032 .097 .007 .068 .021 .453 .008 .089 .000 .000 .053 .015 .246
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
.305** -.047 .090 .208 .073 .140 .204 .326** .233* .285** .038 .293** .144 .477** .840** .450** .262* .287**
.005 .671 .414 .057 .506 .202 .061 .002 .032 .008 .727 .006 .190 .000 .000 .000 .015 .008
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
.110 .007 .184 .145 .159 .180 .054 .146 .138 .124 .130 .292** .099 .199 .368** .435** .296** .441**
.326 .952 .093 .184 .146 .100 .626 .182 .208 .256 .235 .007 .369 .067 .001 .000 .006 .000
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
.024 .076 .117 .188 .172 .175 .261* .326** .220* .303** .216* .307** .376** .235* .357** .125 .696** .401**
.829 .490 .286 .085 .116 .108 .016 .002 .043 .005 .047 .004 .000 .031 .001 .256 .000 .000
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
.074 -.055 .036 .017 .048 .037 .245* .189 .171 .227* .232* .180 .230* .047 .183 .083 .290** .567**
.510 .621 .740 .877 .664 .740 .024 .083 .118 .036 .033 .100 .035 .668 .094 .448 .007 .000
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
.163 .038 .088 .106 .010 .078 .303** .279** .256* .314** .032 .202 .163 .291** .324** .274* .301** .367**
.143 .732 .425 .335 .928 .479 .005 .010 .018 .003 .772 .063 .137 .007 .002 .011 .005 .001
82 84 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85
.298* -.129 -.011 -.006 -.038 -.020 .127 .171 .069 .139 .227 .223 .148 .191 .274* .100 .167 .128
.022 .323 .932 .963 .771 .881 .330 .189 .595 .285 .079 .085 .254 .141 .033 .443 .198 .327
59 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61
.056 -.049 .137 .039 .007 .069 .042 .056 .098 .072 .062 .008 .183 .193 .197 .311** .222* .325**
.620 .662 .214 .722 .950 .530 .703 .612 .374 .514 .576 .940 .095 .079 .072 .004 .042 .003
81 83 84 84 84 84 84 84 84 84 84 84 84 84 84 84 84 84
.134 .198 .151 .189 .183 .193 .154 .098 .155 .152 -.041 .076 .196 .306** .248* .119 .252* .269*
.229 .071 .167 .083 .093 .077 .159 .372 .157 .166 .710 .489 .072 .004 .022 .280 .020 .013
























































































































































































































Statistical Tests for Correlations of PIADS and NEI-VFQ Measures 
for ARMD Sample Population 
PIADS Correlations at Initial and Follow up Administrations 
Correlations
1.000 .753** .679** .911** .535** .330** .430** .492**
. .000 .000 .000 .000 .002 .000 .000
85 85 85 85 85 85 85 85
.753** 1.000 .642** .903** .381** .481** .377** .470**
.000 . .000 .000 .000 .000 .000 .000
85 85 85 85 85 85 85 85
.679** .642** 1.000 .843** .473** .406** .610** .550**
.000 .000 . .000 .000 .000 .000 .000
85 85 85 85 85 85 85 85
.911** .903** .843** 1.000 .508** .448** .520** .557**
.000 .000 .000 . .000 .000 .000 .000
85 85 85 85 85 85 85 85
.535** .381** .473** .508** 1.000 .681** .767** .917**
.000 .000 .000 .000 . .000 .000 .000
85 85 85 85 85 85 85 85
.330** .481** .406** .448** .681** 1.000 .616** .856**
.002 .000 .000 .000 .000 . .000 .000
85 85 85 85 85 85 85 85
.430** .377** .610** .520** .767** .616** 1.000 .883**
.000 .000 .000 .000 .000 .000 . .000
85 85 85 85 85 85 85 85
.492** .470** .550** .557** .917** .856** .883** 1.000
.000 .000 .000 .000 .000 .000 .000 .












































































NEI-VFQ 25 Correlations at Initial and Follow up Administrations 
156 
Correlations
1.000 .215* .104 .158 .013 -.077 .114 -.003 -.041 .318* .002 -.038 .080 .608** .190 .054 .081
. .048 .345 .149 .905 .482 .300 .980 .707 .014 .986 .728 .469 .000 .081 .622 .460
85 85 85 85 85 85 85 85 85 59 84 85 85 85 85 85
.215* 1.000 .256* .308** .255* .120 .339** .225* .324** .283* .119 -.087 .460** .215* .724** .200 .295
.048 . .018 .004 .018 .275 .001 .038 .002 .030 .283 .428 .000 .048 .000 .067 .006
85 85 85 85 85 85 85 85 85 59 84 85 85 85 85 85
.104 .256* 1.000 .370** .234* .089 .204 .221* .194 .165 .222* .163 .511** .180 .255* .709** .235
.345 .018 . .000 .031 .418 .061 .042 .075 .213 .042 .136 .000 .099 .018 .000 .030
85 85 85 85 85 85 85 85 85 59 84 85 85 85 85 85
.158 .308** .370** 1.000 .462** .302** .285** .218* .293** .146 .209 .262* .574** .206 .236* .374** .744
.149 .004 .000 . .000 .005 .008 .045 .006 .269 .056 .015 .000 .058 .030 .000 .000
85 85 85 85 85 85 85 85 85 59 84 85 85 85 85 85
.013 .255* .234* .462** 1.000 .614** .319** .329** .329** .190 .256* .223* .597** .238* .303** .231* .420
.905 .018 .031 .000 . .000 .003 .002 .002 .149 .019 .040 .000 .028 .005 .033 .000
85 85 85 85 85 85 85 85 85 59 84 85 85 85 85 85
-.077 .120 .089 .302** .614** 1.000 .332** .388** .330** .015 .309** .260* .639** .033 .085 .157 .262
.482 .275 .418 .005 .000 . .002 .000 .002 .911 .004 .016 .000 .763 .438 .152 .015
85 85 85 85 85 85 85 85 85 59 84 85 85 85 85 85
.114 .339** .204 .285** .319** .332** 1.000 .465** .436** .108 .203 .169 .622** .098 .338** .185 .271
.300 .001 .061 .008 .003 .002 . .000 .000 .415 .064 .122 .000 .371 .002 .091 .012
85 85 85 85 85 85 85 85 85 59 84 85 85 85 85 85
-.003 .225* .221* .218* .329** .388** .465** 1.000 .330** .004 .377** .267* .648** .154 .198 .088 .135
.980 .038 .042 .045 .002 .000 .000 . .002 .973 .000 .013 .000 .160 .070 .425 .217
85 85 85 85 85 85 85 85 85 59 84 85 85 85 85 85
-.041 .324** .194 .293** .329** .330** .436** .330** 1.000 .399** .340** .093 .630** -.012 .345** .181 .297
.707 .002 .075 .006 .002 .002 .000 .002 . .002 .002 .397 .000 .917 .001 .098 .006
85 85 85 85 85 85 85 85 85 59 84 85 85 85 85 85
.318* .283* .165 .146 .190 .015 .108 .004 .399** 1.000 .168 .072 .344** .076 .298* .078 .128
.014 .030 .213 .269 .149 .911 .415 .973 .002 . .208 .587 .008 .569 .022 .556 .335
59 59 59 59 59 59 59 59 59 59 58 59 59 59 59 59
.002 .119 .222* .209 .256* .309** .203 .377** .340** .168 1.000 .229* .585** -.073 .118 .195 .204
.986 .283 .042 .056 .019 .004 .064 .000 .002 .208 . .036 .000 .507 .286 .075 .063
84 84 84 84 84 84 84 84 84 58 84 84 84 84 84 84
-.038 -.087 .163 .262* .223* .260* .169 .267* .093 .072 .229* 1.000 .412** .092 -.041 .259* .133
.728 .428 .136 .015 .040 .016 .122 .013 .397 .587 .036 . .000 .405 .709 .017 .224
85 85 85 85 85 85 85 85 85 59 84 85 85 85 85 85
.080 .460** .511** .574** .597** .639** .622** .648** .630** .344** .585** .412** 1.000 .145 .430** .429** .462
.469 .000 .000 .000 .000 .000 .000 .000 .000 .008 .000 .000 . .185 .000 .000 .000
85 85 85 85 85 85 85 85 85 59 84 85 85 85 85 85
.608** .215* .180 .206 .238* .033 .098 .154 -.012 .076 -.073 .092 .145 1.000 .345** -.040 .135
.000 .048 .099 .058 .028 .763 .371 .160 .917 .569 .507 .405 .185 . .001 .717 .217
85 85 85 85 85 85 85 85 85 59 84 85 85 85 85 85
.190 .724** .255* .236* .303** .085 .338** .198 .345** .298* .118 -.041 .430** .345** 1.000 .221* .252
.081 .000 .018 .030 .005 .438 .002 .070 .001 .022 .286 .709 .000 .001 . .042 .020
85 85 85 85 85 85 85 85 85 59 84 85 85 85 85 85
.054 .200 .709** .374** .231* .157 .185 .088 .181 .078 .195 .259* .429** -.040 .221* 1.000 .194
.622 .067 .000 .000 .033 .152 .091 .425 .098 .556 .075 .017 .000 .717 .042 . .075
85 85 85 85 85 85 85 85 85 59 84 85 85 85 85 85
.081 .295** .235* .744** .420** .262* .271* .135 .297** .128 .204 .133 .462** .135 .252* .194 1.000
.460 .006 .030 .000 .000 .015 .012 .217 .006 .335 .063 .224 .000 .217 .020 .075
85 85 85 85 85 85 85 85 85 59 84 85 85 85 85 85
.056 .261* .142 .471** .841** .478** .232* .250* .244* .229 .226* .123 .500** .224* .243* .050 .476
.608 .016 .196 .000 .000 .000 .033 .021 .024 .081 .038 .261 .000 .039 .025 .652 .000
85 85 85 85 85 85 85 85 85 59 84 85 85 85 85 85
.128 .280** .076 .181 .310** .435** .287** .419** .356** .245 .325** .115 .503** .208 .245* -.045 .135
.243 .010 .489 .097 .004 .000 .008 .000 .001 .062 .003 .294 .000 .056 .024 .681 .218
85 85 85 85 85 85 85 85 85 59 84 85 85 85 85 85
.231* .314** .351** .239* .311** .129 .690** .399** .390** .349** .206 .210 .563** .308** .359** .158 .256
.033 .003 .001 .028 .004 .238 .000 .000 .000 .007 .060 .054 .000 .004 .001 .148 .018
85 85 85 85 85 85 85 85 85 59 84 85 85 85 85 85
.251* .206 .204 .077 .157 .152 .302** .569** .216* .293* .278* .312** .458** .134 .230* .123 -.002
.020 .058 .061 .484 .152 .164 .005 .000 .047 .024 .011 .004 .000 .222 .035 .263 .982
85 85 85 85 85 85 85 85 85 59 84 85 85 85 85 85
.034 .252* .153 .304** .318** .267* .281** .364** .729** .332* .355** .193 .580** .107 .348** .201 .338
.755 .020 .163 .005 .003 .013 .009 .001 .000 .010 .001 .077 .000 .328 .001 .065 .002
85 85 85 85 85 85 85 85 85 59 84 85 85 85 85 85
.280* .283* .147 .163 .227 .070 .179 .085 .408** .997** .180 .100 .363** .018 .238 .114 .164
.029 .027 .257 .209 .078 .592 .167 .515 .001 .000 .168 .442 .004 .889 .065 .384 .207
61 61 61 61 61 61 61 61 61 56 60 61 61 61 61 61
.056 .020 .123 .233* .200 .363** .246* .344** .329** .083 .802** .270* .534** .004 .058 .165 .278
.615 .855 .263 .033 .069 .001 .024 .001 .002 .533 .000 .013 .000 .969 .603 .133 .011
84 84 84 84 84 84 84 84 84 58 84 84 84 84 84 84
-.033 .058 .247* .278** .273* .231* .221* .264* .221* .184 .254* .760** .439** .092 .006 .248* .210
.765 .597 .023 .010 .011 .034 .042 .015 .042 .164 .019 .000 .000 .400 .960 .022 .054
85 85 85 85 85 85 85 85 85 59 84 85 85 85 85 85
.137 .419** .454** .456** .479** .394** .498** .550** .575** .424** .539** .404** .858** .197 .477** .387** .454
.211 .000 .000 .000 .000 .000 .000 .000 .000 .001 .000 .000 .000 .070 .000 .000 .000
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Correlation is significant at the 0.05 level (2-tailed).*. 
Correlation is significant at the 0.01 level (2-tailed).**. 
 
 
PIADS and NEI-VFQ 25 at Initial Administration 
157 
Correlations
1.000 .753** .679**.911** -.028 -.051 -.178 .230* .078 .216* .144 .195 .016 -.051 .043 .243* .177
. .000 .000 .000 .797 .644 .103 .035 .477 .047 .190 .074 .882 .702 .697 .025 .105
85 85 85 85 85 85 85 85 85 85 85 85 85 59 84 85 85
.753**1.000 .642**.903** -.084 .095 -.072 .348** .195 .180 .267* .111 .005 -.015 -.047 .273* .226*
.000 . .000 .000 .444 .387 .514 .001 .074 .098 .014 .313 .966 .908 .670 .011 .038
85 85 85 85 85 85 85 85 85 85 85 85 85 59 84 85 85
.679** .642**1.000 .843** -.002 .074 -.139 .125 .002 .080 .130 .115 -.089 -.140 -.141 .263* .069
.000 .000 . .000 .986 .502 .206 .256 .984 .467 .236 .293 .419 .291 .200 .015 .529
85 85 85 85 85 85 85 85 85 85 85 85 85 59 84 85 85
.911** .903** .843**1.000 -.079 .058 -.139 .279** .110 .194 .225* .170 .009 -.081 -.039 .284** .200
.000 .000 .000 . .474 .601 .206 .010 .314 .075 .038 .120 .934 .540 .724 .008 .067
85 85 85 85 85 85 85 85 85 85 85 85 85 59 84 85 85
-.028 -.084 -.002 -.079 1.000 .215* .104 .158 .013 -.077 .114 -.003 -.041 .318* .002 -.038 .080
.797 .444 .986 .474 . .048 .345 .149 .905 .482 .300 .980 .707 .014 .986 .728 .469
85 85 85 85 85 85 85 85 85 85 85 85 85 59 84 85 85
-.051 .095 .074 .058 .215* 1.000 .256* .308** .255* .120 .339** .225* .324** .283* .119 -.087 .460**
.644 .387 .502 .601 .048 . .018 .004 .018 .275 .001 .038 .002 .030 .283 .428 .000
85 85 85 85 85 85 85 85 85 85 85 85 85 59 84 85 85
-.178 -.072 -.139 -.139 .104 .256* 1.000 .370** .234* .089 .204 .221* .194 .165 .222* .163 .511**
.103 .514 .206 .206 .345 .018 . .000 .031 .418 .061 .042 .075 .213 .042 .136 .000
85 85 85 85 85 85 85 85 85 85 85 85 85 59 84 85 85
.230* .348** .125 .279** .158 .308** .370**1.000 .462** .302** .285** .218* .293** .146 .209 .262* .574**
.035 .001 .256 .010 .149 .004 .000 . .000 .005 .008 .045 .006 .269 .056 .015 .000
85 85 85 85 85 85 85 85 85 85 85 85 85 59 84 85 85
.078 .195 .002 .110 .013 .255* .234* .462**1.000 .614** .319** .329** .329** .190 .256* .223* .597**
.477 .074 .984 .314 .905 .018 .031 .000 . .000 .003 .002 .002 .149 .019 .040 .000
85 85 85 85 85 85 85 85 85 85 85 85 85 59 84 85 85
.216* .180 .080 .194 -.077 .120 .089 .302** .614**1.000 .332** .388** .330** .015 .309** .260* .639**
.047 .098 .467 .075 .482 .275 .418 .005 .000 . .002 .000 .002 .911 .004 .016 .000
85 85 85 85 85 85 85 85 85 85 85 85 85 59 84 85 85
.144 .267* .130 .225* .114 .339** .204 .285** .319** .332**1.000 .465** .436** .108 .203 .169 .622**
.190 .014 .236 .038 .300 .001 .061 .008 .003 .002 . .000 .000 .415 .064 .122 .000
85 85 85 85 85 85 85 85 85 85 85 85 85 59 84 85 85
.195 .111 .115 .170 -.003 .225* .221* .218* .329** .388** .465**1.000 .330** .004 .377** .267* .648**
.074 .313 .293 .120 .980 .038 .042 .045 .002 .000 .000 . .002 .973 .000 .013 .000
85 85 85 85 85 85 85 85 85 85 85 85 85 59 84 85 85
.016 .005 -.089 .009 -.041 .324** .194 .293** .329** .330** .436** .330**1.000 .399** .340** .093 .630**
.882 .966 .419 .934 .707 .002 .075 .006 .002 .002 .000 .002 . .002 .002 .397 .000
85 85 85 85 85 85 85 85 85 85 85 85 85 59 84 85 85
-.051 -.015 -.140 -.081 .318* .283* .165 .146 .190 .015 .108 .004 .399**1.000 .168 .072 .344**
.702 .908 .291 .540 .014 .030 .213 .269 .149 .911 .415 .973 .002 . .208 .587 .008
59 59 59 59 59 59 59 59 59 59 59 59 59 59 58 59 59
.043 -.047 -.141 -.039 .002 .119 .222* .209 .256* .309** .203 .377** .340** .168 1.000 .229* .585**
.697 .670 .200 .724 .986 .283 .042 .056 .019 .004 .064 .000 .002 .208 . .036 .000
84 84 84 84 84 84 84 84 84 84 84 84 84 58 84 84 84
.243* .273* .263* .284** -.038 -.087 .163 .262* .223* .260* .169 .267* .093 .072 .229* 1.000 .412**
.025 .011 .015 .008 .728 .428 .136 .015 .040 .016 .122 .013 .397 .587 .036 . .000
85 85 85 85 85 85 85 85 85 85 85 85 85 59 84 85 85
.177 .226* .069 .200 .080 .460** .511** .574** .597** .639** .622** .648** .630** .344** .585** .412**1.000
.105 .038 .529 .067 .469 .000 .000 .000 .000 .000 .000 .000 .000 .008 .000 .000 .


































































































































Correlation is significant at the 0.01 level (2-tailed).**. 
Correlation is significant at the 0.05 level (2-tailed).*. 
 
 




1.000 .681** .767**.917** .250* .204 -.070 .146 .207 .049 .229* .253* .302** .175 .067 .171 .304**
. .000 .000 .000 .021 .061 .522 .184 .057 .658 .035 .019 .005 .178 .546 .118 .005
85 85 85 85 85 85 85 85 85 85 85 85 85 61 84 85 85
.681** 1.000 .616**.856** .300** .298** -.033 .311** .348** .090 .315** .168 .290** .178 .064 .114 .351**
.000 . .000 .000 .005 .006 .766 .004 .001 .411 .003 .123 .007 .171 .562 .300 .001
85 85 85 85 85 85 85 85 85 85 85 85 85 61 84 85 85
.767** .616** 1.000 .883** .336** .262* -.168 .170 .241* .119 .195 .143 .261* .075 .093 .134 .275*
.000 .000 . .000 .002 .016 .125 .119 .026 .280 .074 .192 .016 .566 .402 .223 .011
85 85 85 85 85 85 85 85 85 85 85 85 85 61 84 85 85
.917** .856** .883**1.000 .328** .280** -.106 .234* .311** .095 .288** .210 .333** .169 .095 .175 .359**
.000 .000 .000 . .002 .009 .334 .031 .004 .385 .007 .054 .002 .194 .390 .110 .001
85 85 85 85 85 85 85 85 85 85 85 85 85 61 84 85 85
.250* .300** .336**.328** 1.000 .345** -.040 .135 .224* .208 .308** .134 .107 .018 .004 .092 .197
.021 .005 .002 .002 . .001 .717 .217 .039 .056 .004 .222 .328 .889 .969 .400 .070
85 85 85 85 85 85 85 85 85 85 85 85 85 61 84 85 85
.204 .298** .262* .280** .345** 1.000 .221* .252* .243* .245* .359** .230* .348** .238 .058 .006 .477**
.061 .006 .016 .009 .001 . .042 .020 .025 .024 .001 .035 .001 .065 .603 .960 .000
85 85 85 85 85 85 85 85 85 85 85 85 85 61 84 85 85
-.070 -.033 -.168 -.106 -.040 .221* 1.000 .194 .050 -.045 .158 .123 .201 .114 .165 .248* .387**
.522 .766 .125 .334 .717 .042 . .075 .652 .681 .148 .263 .065 .384 .133 .022 .000
85 85 85 85 85 85 85 85 85 85 85 85 85 61 84 85 85
.146 .311** .170 .234* .135 .252* .194 1.000 .476** .135 .256* -.002 .338** .164 .278* .210 .454**
.184 .004 .119 .031 .217 .020 .075 . .000 .218 .018 .982 .002 .207 .011 .054 .000
85 85 85 85 85 85 85 85 85 85 85 85 85 61 84 85 85
.207 .348** .241* .311** .224* .243* .050 .476** 1.000 .308** .285** .178 .350** .277* .161 .255* .479**
.057 .001 .026 .004 .039 .025 .652 .000 . .004 .008 .103 .001 .031 .144 .019 .000
85 85 85 85 85 85 85 85 85 85 85 85 85 61 84 85 85
.049 .090 .119 .095 .208 .245* -.045 .135 .308** 1.000 .347** .447** .275* .279* .307** .143 .551**
.658 .411 .280 .385 .056 .024 .681 .218 .004 . .001 .000 .011 .029 .005 .192 .000
85 85 85 85 85 85 85 85 85 85 85 85 85 61 84 85 85
.229* .315** .195 .288** .308** .359** .158 .256* .285** .347**1.000 .427** .429** .365** .216* .234* .638**
.035 .003 .074 .007 .004 .001 .148 .018 .008 .001 . .000 .000 .004 .048 .031 .000
85 85 85 85 85 85 85 85 85 85 85 85 85 61 84 85 85
.253* .168 .143 .210 .134 .230* .123 -.002 .178 .447** .427**1.000 .312** .346** .215* .277* .610**
.019 .123 .192 .054 .222 .035 .263 .982 .103 .000 .000 . .004 .006 .050 .010 .000
85 85 85 85 85 85 85 85 85 85 85 85 85 61 84 85 85
.302** .290** .261* .333** .107 .348** .201 .338** .350** .275* .429** .312** 1.000 .374** .375** .211 .707**
.005 .007 .016 .002 .328 .001 .065 .002 .001 .011 .000 .004 . .003 .000 .052 .000
85 85 85 85 85 85 85 85 85 85 85 85 85 61 84 85 85
.175 .178 .075 .169 .018 .238 .114 .164 .277* .279* .365** .346** .374**1.000 .123 .191 .462**
.178 .171 .566 .194 .889 .065 .384 .207 .031 .029 .004 .006 .003 . .348 .140 .000
61 61 61 61 61 61 61 61 61 61 61 61 61 61 60 61 61
.067 .064 .093 .095 .004 .058 .165 .278* .161 .307** .216* .215* .375** .123 1.000 .223* .569**
.546 .562 .402 .390 .969 .603 .133 .011 .144 .005 .048 .050 .000 .348 . .041 .000
84 84 84 84 84 84 84 84 84 84 84 84 84 60 84 84 84
.171 .114 .134 .175 .092 .006 .248* .210 .255* .143 .234* .277* .211 .191 .223* 1.000 .461**
.118 .300 .223 .110 .400 .960 .022 .054 .019 .192 .031 .010 .052 .140 .041 . .000
85 85 85 85 85 85 85 85 85 85 85 85 85 61 84 85 85
.304** .351** .275* .359** .197 .477** .387** .454** .479** .551** .638** .610** .707** .462** .569** .461**1.000
.005 .001 .011 .001 .070 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .
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Correlation is significant at the 0.01 level (2-tailed).**. 




Relationship Change over time for PIADS and NEI-VFQ 25 for 
ARMD Sample 
Paired Samples Test
-.22647 .69634 .07553 -.37667 -.07627 -2.998 84 .004
-.10000 .73427 .07964 -.25838 .05838 -1.256 84 .213
-.22794 .58541 .06350 -.35421 -.10167 -3.590 84 .001
-.18480 .58938 .06393 -.31193 -.05768 -2.891 84 .005
-3.82353 25.15011 2.72791 -9.24828 1.60122 -1.402 84 .165
-3.05882 14.31146 1.55230 -6.14573 .02809 -1.971 84 .052
1.23529 15.74359 1.70763 -2.16052 4.63111 .723 84 .471
-3.03922 17.00291 1.84422 -6.70666 .62823 -1.648 84 .103
.53922 12.91936 1.40130 -2.24743 3.32586 .385 84 .701
7.50000 30.81241 3.34208 .85392 14.14608 2.244 84 .027
-1.17647 19.32391 2.09597 -5.34454 2.99160 -.561 84 .576
2.05882 26.29440 2.85203 -3.61275 7.73039 .722 84 .472
2.74510 21.76064 2.36027 -1.94856 7.43876 1.163 84 .248
-2.97619 21.74772 2.37287 -7.69573 1.74335 -1.254 83 .213
1.17647 18.05493 1.95833 -2.71789 5.07083 .601 84 .550
.58073 7.44811 .80786 -1.02579 2.18725 .719 84 .474






























































































Example of 95% Confidence Intervals for Comparison of ARMD 
Population to Overall Sample 
Descriptives
1.1615 .08572
.9908
1.3321
1.1551
1.0833
.588
.76667
-.67
2.92
3.58
1.00
.034 .269
-.385 .532
.9708 .07713
.8173
1.1244
.9537
.9167
.476
.68988
-.33
3.00
3.33
1.00
.362 .269
-.156 .532
.8063 .07754
.6519
.9606
.7795
.7500
.481
.69352
-.50
2.63
3.13
1.00
.468 .269
-.201 .532
.9795 .07334
.8335
1.1255
.9645
.9167
.430
.65597
-.22
2.81
3.03
.98
.302 .269
-.335 .532
1.3052 .07819
1.1496
1.4608
1.3113
1.2500
.489
.69935
-.50
2.83
3.33
.92
.055 .269
-.350 .532
1.0729 .07429
.9250
1.2208
1.0463
.9167
.442
.66447
-.33
2.67
3.00
1.00
.545 .269
-.151 .532
.9828 .06820
.8471
1.1186
.9705
.8125
.372
.61002
-.13
2.25
2.38
.97
.503 .269
-.798 .532
1.1203 .06548
.9900
1.2507
1.1098
1.0972
.343
.58571
.08
2.35
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurtosis
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurtosis
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurtosis
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurtosis
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurtosis
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurtosis
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurtosis
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
PIADS Subscale
Competence1
PIADS Subscale
Adaptability1
PIADS Subscale
Self-Esteem1
PIADSOverall1
PIADS Subscale
Competence2
PIADS Subscale
Adaptability2
PIADS Subscale
Self-Esteem2
PIADSOverall2
Statistic Std. Error
 
